Edge_Source,Edge_Target,Edge_Type,Unnamed: 0.3,Unnamed: 0.2,Unnamed: 0.1,Unnamed: 0,pmid,exposure,outcome,direction,significance,effect_measure,value,ci_lower,ci_upper,exposure_umls_name,exposure_umls_id,exposure_tui,exposure_source,outcome_umls_name,outcome_umls_id,outcome_tui,outcome_source,study_design,number_of_participants,original,base_concept,exposure_direction
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,7383,7383,7383,7383,34537830,evolocumab,cerebrovascular events,decrease,positive,HR,0.77,0.65,0.92,evolocumab,C3529352,"T116, T121, T129",api,Transient cerebrovascular events,C0852396,T047,api,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,8896,8896,8896,8896,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,8898,8898,8898,8898,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,9436,9436,9436,9436,31121022,alirocumab,myocardial infarction,decrease,positive,HR,0.85,0.77,0.95,alirocumab,C3491162,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,10102,10102,10102,10102,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.82,0.71,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,10103,10103,10103,10103,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.85,0.77,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,10104,10104,10104,10104,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",not found,negative,HR,0.89,0.76,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,10636,10636,10636,10636,31707788,alirocumab,ischemic stroke,decrease,positive,HR,0.73,0.57,0.93,alirocumab,C3491162,"T116, T121, T129",api,Ischemic stroke,C0948008,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,10649,10649,10649,10649,31707788,alirocumab,hemorrhagic stroke,not found,negative,HR,0.83,0.42,1.65,alirocumab,C3491162,"T116, T121, T129",api,Hemorrhagic Stroke,C5234922,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,12369,12369,12369,12369,29626068,evolocumab,major vascular events,decrease,positive,HR,0.8,0.71,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,12370,12370,12370,12370,29626068,evolocumab,major vascular events,decrease,positive,HR,0.82,0.72,0.93,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,12371,12371,12371,12371,29626068,evolocumab,major vascular events,decrease,positive,HR,0.79,0.69,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,12372,12372,12372,12372,29626068,evolocumab,major vascular events,not found,negative,HR,0.95,0.85,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,12373,12373,12373,12373,29626068,evolocumab,major vascular events,not found,negative,HR,0.92,0.84,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,12374,12374,12374,12374,29626068,evolocumab,major vascular events,not found,negative,HR,0.93,0.85,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,17303,17303,17303,17303,25773607,evolocumab,cardiovascular events,decrease,positive,HR,0.47,0.28,0.78,evolocumab,C3529352,"T116, T121, T129",api,Cardiovascular event,C1320716,T033,api,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,23244,23244,23244,23244,22104547,darbepoetin alfa,stroke,increase,positive,HR,1.9,1.4,2.7,darbepoetin alfa,C0937950,"T116, T121",api,Stroke (heart beat),C5977286,T033,api,RCT,1,darbepoetin alfa,darbepoetin alfa,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,23245,23245,23245,23245,22104547,darbepoetin alfa,stroke,increase,positive,OR,2.1,1.5,2.9,darbepoetin alfa,C0937950,"T116, T121",api,Stroke (heart beat),C5977286,T033,api,RCT,1,darbepoetin alfa,darbepoetin alfa,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,31749,31749,31749,31749,12021219,abciximab,myocardial infarction,decrease,positive,RR,0.68,0.53,0.87,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,33469,33469,33469,33469,10341274,abciximab,myocardial infarction,decrease,positive,OR,0.23,0.12,0.49,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,33726,33726,33726,33726,10636365,abciximab,death or large myocardial infarction,decrease,positive,HR,0.46,0.32,0.67,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,scispacy,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,34349,34349,34349,34349,9164316,abciximab,myocardial infarction,decrease,positive,RR,0.29,0.1,0.84,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,34350,34350,34350,34350,9164316,abciximab,myocardial infarction,decrease,positive,RR,0.47,0.26,0.84,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,89133,89133,89133,89133,28245350,tocilizumab,cardiovascular events,not found,negative,HR,0.84,0.56,1.26,tocilizumab,C1609165,T116|T121|T129,cohort_kg,cardiovascular event,C1320716,T033,cohort_kg,OS,1,tocilizumab,tocilizumab,increased
Antineoplastic And Biologic Therapies,Stroke,Risk Factor,124840,124840,124840,124840,32781110,bevacizumab,acute cerebrovascular disease,not found,negative,HR,1.04,0.78,1.38,bevacizumab,C0796392,T116|T121|T129,cohort_kg,Acute cerebrovascular disease,C0810006,T047,cohort_kg,OS,1,bevacizumab,bevacizumab,increased
Antiviral Medications,Influenza Vaccine,Determinant,33389,33389,33389,33389,10536125,oseltamivir,influenza-like illness,decrease,positive,RR,0.26,0.12,0.47,oseltamivir,C0874161,"T109, T121",api,Influenza-like illness,C0521839,T047,api,RCT,1,oseltamivir,oseltamivir,increased
Antiviral Medications,Influenza Vaccine,Determinant,33397,33397,33397,33397,10536125,oseltamivir,culture-proved influenza,decrease,positive,RR,0.13,0.04,0.35,oseltamivir,C0874161,"T109, T121",api,Influenza,C0021400,T047,scispacy,RCT,1,oseltamivir,oseltamivir,increased
Antiviral Medications,Stroke,Risk Factor,23451,23451,23451,23451,21427402,abacavir,myocardial infarction,not found,negative,HR,0.7,0.2,2.4,abacavir,C0663655,"T114, T121",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abacavir,abacavir,increased
Antiviral Medications,Stroke,Risk Factor,23454,23454,23454,23454,21427402,abacavir,myocardial infarction,not found,negative,HR,0.6,0.3,1.4,abacavir,C0663655,"T114, T121",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abacavir,abacavir,increased
Antiviral Medications,Stroke,Risk Factor,108631,108631,108631,108631,25595744,HIV,myocardial infarction,not found,negative,IRR,1.01,0.41,2.54,HIV,C0019682,T005,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,HIV,HIV,increased
Antiviral Medications,Stroke,Risk Factor,108632,108632,108632,108632,25595744,HIV,myocardial infarction,increase,positive,IRR,1.78,0.75,4.24,HIV,C0019682,T005,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,HIV,HIV,increased
Antiviral Medications,Stroke,Risk Factor,121823,121823,121823,121823,31828320,atazanavir,myocardial infarction,not found,negative,OR,1.54,0.87,2.73,atazanavir,C1145759,T109|T121,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,atazanavir,atazanavir,increased
Medication Use,Stroke,Risk Factor,30955,30955,30955,30955,14643116,ximelagatran,stroke or systemic embolism,decrease,positive,RR,0.71,0.48,1.065,ximelagatran,C0966370,"T109, T121",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,ximelagatran,ximelagatran,increased
Pregnancy-Related Infections And Complications,Stroke,Risk Factor,26414,26414,26414,26414,18997197,vitamin E,hemorrhagic stroke,increase,positive,HR,1.74,1.04,2.91,vitamin E,C0042874,"T109, T121, T127",api,Hemorrhagic Stroke,C5234922,T047,api,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Stroke,Risk Factor,29628,29628,29628,29628,15998891,vitamin E,myocardial infarction,not found,negative,RR,1.01,0.82,1.23,vitamin E,C0042874,"T109, T121, T127",api,Myocardial Infarction,C0027051,T047,api,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Stroke,Risk Factor,29629,29629,29629,29629,15998891,vitamin E,stroke,not found,negative,RR,0.98,0.82,1.17,vitamin E,C0042874,"T109, T121, T127",api,Stroke (heart beat),C5977286,T033,api,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Stroke,Risk Factor,46114,46114,46114,46114,10383366,vitamin E,ischemic stroke,not found,negative,relative risk,1.18,0.77,1.82,vitamin E,C0042874,T109|T121|T127,cohort_kg,Ischemic stroke,C0948008,T047,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Stroke,Risk Factor,48926,48926,48926,48926,11380744,vitamin E,cardiovascular events,decrease,positive,RR,0.16,0.04,0.55,vitamin E,C0042874,T109|T121|T127,cohort_kg,cardiovascular event,C1320716,T033,cohort_kg,OS,1,vitamin E,vitamin,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,7383,7383,7383,7383,34537830,evolocumab,cerebrovascular events,decrease,positive,HR,0.77,0.65,0.92,evolocumab,C3529352,"T116, T121, T129",api,Transient cerebrovascular events,C0852396,T047,api,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,8896,8896,8896,8896,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,8898,8898,8898,8898,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,9436,9436,9436,9436,31121022,alirocumab,myocardial infarction,decrease,positive,HR,0.85,0.77,0.95,alirocumab,C3491162,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,10102,10102,10102,10102,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.82,0.71,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,10103,10103,10103,10103,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.85,0.77,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,10104,10104,10104,10104,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",not found,negative,HR,0.89,0.76,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,10636,10636,10636,10636,31707788,alirocumab,ischemic stroke,decrease,positive,HR,0.73,0.57,0.93,alirocumab,C3491162,"T116, T121, T129",api,Ischemic stroke,C0948008,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,10649,10649,10649,10649,31707788,alirocumab,hemorrhagic stroke,not found,negative,HR,0.83,0.42,1.65,alirocumab,C3491162,"T116, T121, T129",api,Hemorrhagic Stroke,C5234922,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,12369,12369,12369,12369,29626068,evolocumab,major vascular events,decrease,positive,HR,0.8,0.71,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,12370,12370,12370,12370,29626068,evolocumab,major vascular events,decrease,positive,HR,0.82,0.72,0.93,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,12371,12371,12371,12371,29626068,evolocumab,major vascular events,decrease,positive,HR,0.79,0.69,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,12372,12372,12372,12372,29626068,evolocumab,major vascular events,not found,negative,HR,0.95,0.85,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,12373,12373,12373,12373,29626068,evolocumab,major vascular events,not found,negative,HR,0.92,0.84,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,12374,12374,12374,12374,29626068,evolocumab,major vascular events,not found,negative,HR,0.93,0.85,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,17303,17303,17303,17303,25773607,evolocumab,cardiovascular events,decrease,positive,HR,0.47,0.28,0.78,evolocumab,C3529352,"T116, T121, T129",api,Cardiovascular event,C1320716,T033,api,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,23244,23244,23244,23244,22104547,darbepoetin alfa,stroke,increase,positive,HR,1.9,1.4,2.7,darbepoetin alfa,C0937950,"T116, T121",api,Stroke (heart beat),C5977286,T033,api,RCT,1,darbepoetin alfa,darbepoetin alfa,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,23245,23245,23245,23245,22104547,darbepoetin alfa,stroke,increase,positive,OR,2.1,1.5,2.9,darbepoetin alfa,C0937950,"T116, T121",api,Stroke (heart beat),C5977286,T033,api,RCT,1,darbepoetin alfa,darbepoetin alfa,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,31749,31749,31749,31749,12021219,abciximab,myocardial infarction,decrease,positive,RR,0.68,0.53,0.87,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,33469,33469,33469,33469,10341274,abciximab,myocardial infarction,decrease,positive,OR,0.23,0.12,0.49,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,33726,33726,33726,33726,10636365,abciximab,death or large myocardial infarction,decrease,positive,HR,0.46,0.32,0.67,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,scispacy,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,34349,34349,34349,34349,9164316,abciximab,myocardial infarction,decrease,positive,RR,0.29,0.1,0.84,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,34350,34350,34350,34350,9164316,abciximab,myocardial infarction,decrease,positive,RR,0.47,0.26,0.84,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,89133,89133,89133,89133,28245350,tocilizumab,cardiovascular events,not found,negative,HR,0.84,0.56,1.26,tocilizumab,C1609165,T116|T121|T129,cohort_kg,cardiovascular event,C1320716,T033,cohort_kg,OS,1,tocilizumab,tocilizumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke,Risk Factor,124840,124840,124840,124840,32781110,bevacizumab,acute cerebrovascular disease,not found,negative,HR,1.04,0.78,1.38,bevacizumab,C0796392,T116|T121|T129,cohort_kg,Acute cerebrovascular disease,C0810006,T047,cohort_kg,OS,1,bevacizumab,bevacizumab,increased
Abnormal Biomarker Levels,Stroke,Risk Factor,51306,51306,51306,51306,12397047,parathyroid hormone,myocardial infarction,increase,positive,OR,1.6,1.1,2.3,parathyroid hormone,C0030520,T116|T121|T125,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,parathyroid hormone,parathyroid hormone,increased
C-Reactive Protein Level,Stroke,Risk Factor,52588,52588,52588,52588,12821545,C-reactive protein,ischemic stroke,increase,positive,HR,1.19,0.92,1.53,C-reactive protein,C0006560,T116|T129,cohort_kg,Ischemic stroke,C0948008,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Stroke,Risk Factor,52589,52589,52589,52589,12821545,C-reactive protein,ischemic stroke,not found,negative,HR,1.05,0.81,1.37,C-reactive protein,C0006560,T116|T129,cohort_kg,Ischemic stroke,C0948008,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Stroke,Risk Factor,54293,54293,54293,54293,15047644,C-reactive protein,cardiovascular events,increase,positive,relative risk,1.51,1.29,5.32,C-reactive protein,C0006560,T116|T129,cohort_kg,cardiovascular event,C1320716,T033,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Stroke,Risk Factor,55054,55054,55054,55054,15262834,C-reactive protein,cardiovascular disease events,increase,positive,HR,1.9,1.2,2.9,C-reactive protein,C0006560,T116|T129,cohort_kg,cardiovascular event,C1320716,T033,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Stroke,Risk Factor,83829,83829,83829,83829,15983245,C-reactive protein,myocardial infarction,increase,positive,odds ratio,2.2,1.3,3.6,C-reactive protein,C0006560,T116|T129,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
Atrial Fibrillation,Diabetes Mellitus,Peer Interaction,38033,38033,38033,38033,37022971,heart rate,type 2 diabetes,increase,positive,HR,1.2,1.09,1.33,heart rate,C0018810,T201,api,"Diabetes Mellitus, Non-Insulin-Dependent",C0011860,T047,api,MR,1,heart rate,heart rate,increased
Atrial Fibrillation,Diabetes Mellitus,Peer Interaction,38034,38034,38034,38034,37022971,heart rate,type 2 diabetes,increase,positive,HR,1.54,1.08,2.06,heart rate,C0018810,T201,api,"Diabetes Mellitus, Non-Insulin-Dependent",C0011860,T047,api,MR,1,heart rate,heart rate,increased
Atrial Fibrillation,Diabetes Mellitus,Peer Interaction,38035,38035,38035,38035,37022971,heart rate,type 2 diabetes,increase,positive,HR,1.15,1.01,1.31,heart rate,C0018810,T201,api,"Diabetes Mellitus, Non-Insulin-Dependent",C0011860,T047,api,MR,1,heart rate,heart rate,increased
Atrial Fibrillation,Diabetes Mellitus,Peer Interaction,52242,52242,52242,52242,12695289,heart rate,type 2 diabetes,increase,positive,RR,1.6,1.33,1.92,heart rate,C0018810,T201,cohort_kg,Type 2 diabetes (Adult onset),C3842544,T047,cohort_kg,OS,1,heart rate,heart rate,increased
Atrial Fibrillation,Diabetes Mellitus,Peer Interaction,123312,123312,123312,123312,32300048,heart rate,diabetes,increase,positive,HR,1.41,1.21,1.65,heart rate,C0018810,T201,cohort_kg,Diabetes,C0011847,T047,cohort_kg,OS,1,heart rate,heart rate,increased
Atrial Fibrillation,Heart Failure,Peer Interaction,23613,23613,23613,23613,20801495,heart rate,cardiovascular death or hospital admission for worsening heart failure,increase,positive,HR,2.34,1.84,2.98,heart rate,C0018810,T201,api,Heart failure,C0018801,T047,scispacy,RCT,1,heart rate,heart rate,increased
Atrial Fibrillation,Heart Failure,Peer Interaction,23614,23614,23614,23614,20801495,heart rate,cardiovascular death or hospital admission for worsening heart failure,decrease,positive,HR,0.95,0.85,1.06,heart rate,C0018810,T201,api,Heart failure,C0018801,T047,scispacy,RCT,1,heart rate,heart rate,increased
Alcohol Use Disorder,Chronic Kidney Disease,Peer Interaction,58453,58453,58453,58453,16775042,heavy drinking,chronic kidney disease,not found,negative,OR,1.99,0.99,4.01,heavy drinking,C0687132,T048,cohort_kg,Chronic Kidney Diseases,C1561643,T047,cohort_kg,OS,1,heavy drinking,drinking,increased
Alcohol Use Disorder,Dementia,Peer Interaction,91451,91451,91451,91451,28934596,methamphetamine,clinical worsening or death,increase,positive,HR,2.04,1.28,3.25,methamphetamine,C0025611,T109|T121|T131,cohort_kg,Clinical Deterioration,C4505323,T032,cohort_kg,OS,1,methamphetamine,methamphetamine,increased
Alcohol Use Disorder,Chronic Respiratory Disease,Peer Interaction,58453,58453,58453,58453,16775042,heavy drinking,chronic kidney disease,not found,negative,OR,1.99,0.99,4.01,heavy drinking,C0687132,T048,cohort_kg,Chronic Kidney Diseases,C1561643,T047,cohort_kg,OS,1,heavy drinking,drinking,increased
Alcohol Use Disorder,Infection,Peer Interaction,53218,53218,53218,53218,14515302,heavy alcohol consumption,all-site nosocomial infection,increase,positive,OR,2.51,1.06,5.96,heavy drinking,C0687132,T048,cohort_kg,Nosocomial condition,C0481388,T037,cohort_kg,OS,1,heavy alcohol consumption,alcohol consumption,increased
Antineoplastic And Biologic Therapies,Diabetes Mellitus,Peer Interaction,1358,1358,1358,1358,39913634,alirocumab,new-onset type 2 diabetes,not found,negative,OR,0.998,0.86,1.158,alirocumab,C3491162,"T116, T121, T129",api,"Diabetes Mellitus, Non-Insulin-Dependent",C0011860,T047,scispacy,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Biologic Therapies,Heart Failure,Peer Interaction,7081,7081,7081,7081,33332779,tocilizumab,clinical failure,decrease,positive,HR,0.55,0.33,0.93,tocilizumab,C1609165,"T116, T121, T129",api,Clinical Failure,C3640841,T033,api,RCT,1,tocilizumab,tocilizumab,increased
Antineoplastic And Biologic Therapies,Heart Failure,Peer Interaction,21580,21580,21580,21580,22578446,bevacizumab,arteriothrombotic event or heart failure,decrease,positive,OR,0.23,0.05,1.07,bevacizumab,C0796392,"T116, T121, T129",api,Heart failure,C0018801,T047,scispacy,RCT,1,bevacizumab,bevacizumab,increased
Antineoplastic And Biologic Therapies,Stroke Or Transient Ischemic Attack,Peer Interaction,7383,7383,7383,7383,34537830,evolocumab,cerebrovascular events,decrease,positive,HR,0.77,0.65,0.92,evolocumab,C3529352,"T116, T121, T129",api,Transient cerebrovascular events,C0852396,T047,api,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke Or Transient Ischemic Attack,Peer Interaction,8896,8896,8896,8896,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke Or Transient Ischemic Attack,Peer Interaction,8898,8898,8898,8898,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke Or Transient Ischemic Attack,Peer Interaction,10102,10102,10102,10102,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.82,0.71,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke Or Transient Ischemic Attack,Peer Interaction,10103,10103,10103,10103,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.85,0.77,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke Or Transient Ischemic Attack,Peer Interaction,10104,10104,10104,10104,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",not found,negative,HR,0.89,0.76,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke Or Transient Ischemic Attack,Peer Interaction,10636,10636,10636,10636,31707788,alirocumab,ischemic stroke,decrease,positive,HR,0.73,0.57,0.93,alirocumab,C3491162,"T116, T121, T129",api,Ischemic stroke,C0948008,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Biologic Therapies,Stroke Or Transient Ischemic Attack,Peer Interaction,10649,10649,10649,10649,31707788,alirocumab,hemorrhagic stroke,not found,negative,HR,0.83,0.42,1.65,alirocumab,C3491162,"T116, T121, T129",api,Hemorrhagic Stroke,C5234922,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Biologic Therapies,Stroke Or Transient Ischemic Attack,Peer Interaction,12369,12369,12369,12369,29626068,evolocumab,major vascular events,decrease,positive,HR,0.8,0.71,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke Or Transient Ischemic Attack,Peer Interaction,12370,12370,12370,12370,29626068,evolocumab,major vascular events,decrease,positive,HR,0.82,0.72,0.93,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke Or Transient Ischemic Attack,Peer Interaction,12371,12371,12371,12371,29626068,evolocumab,major vascular events,decrease,positive,HR,0.79,0.69,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke Or Transient Ischemic Attack,Peer Interaction,12372,12372,12372,12372,29626068,evolocumab,major vascular events,not found,negative,HR,0.95,0.85,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke Or Transient Ischemic Attack,Peer Interaction,12373,12373,12373,12373,29626068,evolocumab,major vascular events,not found,negative,HR,0.92,0.84,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke Or Transient Ischemic Attack,Peer Interaction,12374,12374,12374,12374,29626068,evolocumab,major vascular events,not found,negative,HR,0.93,0.85,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Stroke Or Transient Ischemic Attack,Peer Interaction,124840,124840,124840,124840,32781110,bevacizumab,acute cerebrovascular disease,not found,negative,HR,1.04,0.78,1.38,bevacizumab,C0796392,T116|T121|T129,cohort_kg,Acute cerebrovascular disease,C0810006,T047,cohort_kg,OS,1,bevacizumab,bevacizumab,increased
Antineoplastic And Biologic Therapies,Arteritis And Arteriosclerosis Disorders,Peer Interaction,11282,11282,11282,11282,30403574,alirocumab,"composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization",decrease,positive,HR,0.85,0.78,0.93,alirocumab,C3491162,"T116, T121, T129",api,Coronary Arteriosclerosis,C0010054,T047,scispacy,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Biologic Therapies,Coronary Stent Status And Complications,Peer Interaction,8901,8901,8901,8901,31707849,evolocumab,major coronary events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Coronary artery stent (device),C0687568,T074,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Coronary Stent Status And Complications,Peer Interaction,8902,8902,8902,8902,31707849,evolocumab,major coronary events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Coronary artery stent (device),C0687568,T074,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Coronary Artery Disease,Peer Interaction,9436,9436,9436,9436,31121022,alirocumab,myocardial infarction,decrease,positive,HR,0.85,0.77,0.95,alirocumab,C3491162,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Biologic Therapies,Coronary Artery Disease,Peer Interaction,11282,11282,11282,11282,30403574,alirocumab,"composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization",decrease,positive,HR,0.85,0.78,0.93,alirocumab,C3491162,"T116, T121, T129",api,Coronary Arteriosclerosis,C0010054,T047,scispacy,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Biologic Therapies,Coronary Artery Disease,Peer Interaction,31749,31749,31749,31749,12021219,abciximab,myocardial infarction,decrease,positive,RR,0.68,0.53,0.87,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Coronary Artery Disease,Peer Interaction,33469,33469,33469,33469,10341274,abciximab,myocardial infarction,decrease,positive,OR,0.23,0.12,0.49,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Coronary Artery Disease,Peer Interaction,33726,33726,33726,33726,10636365,abciximab,death or large myocardial infarction,decrease,positive,HR,0.46,0.32,0.67,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,scispacy,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Coronary Artery Disease,Peer Interaction,34349,34349,34349,34349,9164316,abciximab,myocardial infarction,decrease,positive,RR,0.29,0.1,0.84,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Coronary Artery Disease,Peer Interaction,34350,34350,34350,34350,9164316,abciximab,myocardial infarction,decrease,positive,RR,0.47,0.26,0.84,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Malignant Neoplasm With Metastasis,Peer Interaction,89013,89013,89013,89013,28193515,infliximab,malignancy,not found,negative,SIR,1.69,0.46,4.32,infliximab,C0666743,T116|T121|T129,cohort_kg,malignant disease,C0442867,T047,cohort_kg,OS,1,infliximab,infliximab,increased
Antineoplastic And Biologic Therapies,Gastrointestinal Diseases,Peer Interaction,19044,19044,19044,19044,24637999,bevacizumab,GI adverse events,increase,positive,OR,2.15,1.05,4.4,bevacizumab,C0796392,"T116, T121, T129",api,gastroenterology (field),C0017163,T091,scispacy,RCT,1,bevacizumab,bevacizumab,increased
Antineoplastic And Biologic Therapies,Clinical Monitoring And Surveillance,Peer Interaction,7043,7043,7043,7043,33472855,tocilizumab,clinical status,not found,negative,OR,1.54,0.66,3.66,tocilizumab,C1609165,"T116, T121, T129",api,Clinical status,C0449440,T201,api,RCT,1,tocilizumab,tocilizumab,increased
Antineoplastic And Biologic Therapies,General Health Status,Peer Interaction,7043,7043,7043,7043,33472855,tocilizumab,clinical status,not found,negative,OR,1.54,0.66,3.66,tocilizumab,C1609165,"T116, T121, T129",api,Clinical status,C0449440,T201,api,RCT,1,tocilizumab,tocilizumab,increased
Antineoplastic And Biologic Therapies,Quality Of Life,Peer Interaction,19968,19968,19968,19968,23821759,bevacizumab,survival,decrease,positive,HR,0.52,0.29,0.94,bevacizumab,C0796392,"T116, T121, T129",api,survival aspects,C0220921,T169,api,RCT,1,bevacizumab,bevacizumab,increased
Antineoplastic And Biologic Therapies,Quality Of Life,Peer Interaction,19969,19969,19969,19969,23821759,bevacizumab,survival,not found,negative,HR,1.03,0.84,1.27,bevacizumab,C0796392,"T116, T121, T129",api,survival aspects,C0220921,T169,api,RCT,1,bevacizumab,bevacizumab,increased
Antineoplastic And Biologic Therapies,Quality Of Life,Peer Interaction,28824,28824,28824,28824,16481637,etanercept,asthma-related quality-of-life score,increase,positive,not found,0.85,0.16,1.54,etanercept,C0717758,"T116, T121",api,Perceived quality of life,C0518214,T033,scispacy,RCT,1,etanercept,etanercept,increased
Antineoplastic And Biologic Therapies,Health-Related Quality Of Life,Peer Interaction,28824,28824,28824,28824,16481637,etanercept,asthma-related quality-of-life score,increase,positive,not found,0.85,0.16,1.54,etanercept,C0717758,"T116, T121",api,Perceived quality of life,C0518214,T033,scispacy,RCT,1,etanercept,etanercept,increased
Antineoplastic And Biologic Therapies,Liver Disease,Peer Interaction,80397,80397,80397,80397,23419359,infliximab,drug-induced liver injury,increase,positive,incidence rate,675.0,184.0,718.0,infliximab,C0666743,T116|T121|T129,cohort_kg,Drug-Induced Liver Disease,C0860207,T047,cohort_kg,OS,1,infliximab,infliximab,increased
Antineoplastic And Biologic Therapies,Inflammatory Disorder,Peer Interaction,3684,3684,3684,3684,35961761,secukinumab,disease flare,decrease,positive,HR,0.28,0.13,0.63,secukinumab,C3179547,"T116, T121, T129",api,Autoimmune Diseases,C0004364,T047,api,RCT,1,secukinumab,secukinumab,increased
Antineoplastic And Biologic Therapies,Functional Dependence,Peer Interaction,11550,11550,11550,11550,29545067,natalizumab,sustained disability progression,not found,negative,OR,0.86,0.66,1.13,natalizumab,C1172734,"T116, T121, T129",api,Disability,C0231170,T033,scispacy,RCT,1,natalizumab,natalizumab,increased
Antineoplastic And Biologic Therapies,Functional Dependence,Peer Interaction,28521,28521,28521,28521,16510744,natalizumab,sustained progression of disability,decrease,positive,HR,0.58,0.43,0.77,natalizumab,C1172734,"T116, T121, T129",api,Disability,C0231170,T033,scispacy,RCT,1,natalizumab,natalizumab,increased
Antineoplastic And Biologic Therapies,Medication Use And Adherence,Peer Interaction,115798,115798,115798,115798,29981385,etanercept,adherence,increase,positive,OR,1.77,1.63,1.92,etanercept,C0717758,T116|T121,cohort_kg,Adherence (attribute),C1510802,T169,cohort_kg,OS,1,etanercept,etanercept,increased
Antineoplastic And Biologic Therapies,Medication Use And Adherence,Peer Interaction,115799,115799,115799,115799,29981385,ustekinumab,adherence,increase,positive,OR,2.54,2.24,2.87,ustekinumab,C1608841,T116|T121|T129,cohort_kg,Adherence (attribute),C1510802,T169,cohort_kg,OS,1,ustekinumab,ustekinumab,increased
Antineoplastic And Biologic Therapies,Depression,Peer Interaction,10801,10801,10801,10801,31066887,infliximab,depressive symptoms,not found,negative,RR,1.09,0.8,1.5,infliximab,C0666743,"T116, T121, T129",api,Depressive Symptoms,C0086132,T048,api,RCT,1,infliximab,infliximab,increased
Antineoplastic And Biologic Therapies,Allergic And Hypersensitivity Disorders,Peer Interaction,3684,3684,3684,3684,35961761,secukinumab,disease flare,decrease,positive,HR,0.28,0.13,0.63,secukinumab,C3179547,"T116, T121, T129",api,Autoimmune Diseases,C0004364,T047,api,RCT,1,secukinumab,secukinumab,increased
Antineoplastic And Biologic Therapies,Tuberculosis,Peer Interaction,76952,76952,76952,76952,22523429,etanercept,nontuberculous mycobacterial disease,increase,positive,rate,35.0,1.0,69.0,etanercept,C0717758,T116|T121,cohort_kg,Nontuberculous mycobacterial infections,C5543174,T047,cohort_kg,OS,1,etanercept,etanercept,increased
Antineoplastic And Biologic Therapies,Tuberculosis,Peer Interaction,76953,76953,76953,76953,22523429,etanercept,tuberculosis,increase,positive,rate,17.0,0.0,41.0,etanercept,C0717758,T116|T121,cohort_kg,Tuberculosis,C0041296,T047,cohort_kg,OS,1,etanercept,etanercept,increased
Antineoplastic And Biologic Therapies,Tuberculosis,Peer Interaction,76954,76954,76954,76954,22523429,infliximab,nontuberculous mycobacterial disease,increase,positive,rate,116.0,30.0,203.0,infliximab,C0666743,T116|T121|T129,cohort_kg,Nontuberculous mycobacterial infections,C5543174,T047,cohort_kg,OS,1,infliximab,infliximab,increased
Antineoplastic And Biologic Therapies,Tuberculosis,Peer Interaction,76955,76955,76955,76955,22523429,infliximab,tuberculosis,increase,positive,rate,83.0,10.0,156.0,infliximab,C0666743,T116|T121|T129,cohort_kg,Tuberculosis,C0041296,T047,cohort_kg,OS,1,infliximab,infliximab,increased
Antineoplastic And Biologic Therapies,Tuberculosis,Peer Interaction,114117,114117,114117,114117,24608401,infliximab,tuberculosis,not found,negative,HR,2.7,0.7,10.9,infliximab,C0666743,T116|T121|T129,cohort_kg,Tuberculosis,C0041296,T047,cohort_kg,OS,1,infliximab,infliximab,increased
Antineoplastic And Biologic Therapies,Tuberculosis,Peer Interaction,114118,114118,114118,114118,24608401,etanercept,tuberculosis,not found,negative,HR,1.7,0.6,4.6,etanercept,C0717758,T116|T121,cohort_kg,Tuberculosis,C0041296,T047,cohort_kg,OS,1,etanercept,etanercept,increased
Antineoplastic And Biologic Therapies,Thrombocytopenia And Platelet Disorders,Peer Interaction,30337,30337,30337,30337,15117843,abciximab,thrombocytopenia,increase,positive,OR,4.4,1.7,11.2,abciximab,C0288672,"T116, T121, T129",api,Thrombocytopenia,C0040034,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Race And Ethnicity,Peer Interaction,25829,25829,25829,25829,19665644,infliximab,good response according to European League Against Rheumatism criteria,increase,positive,RR,1.59,1.1,2.3,infliximab,C0666743,"T116, T121, T129",api,European (ethnic group),C0239307,T098,scispacy,RCT,1,infliximab,infliximab,increased
Antineoplastic And Biologic Therapies,Neuropsychiatric Status,Peer Interaction,7043,7043,7043,7043,33472855,tocilizumab,clinical status,not found,negative,OR,1.54,0.66,3.66,tocilizumab,C1609165,"T116, T121, T129",api,Clinical status,C0449440,T201,api,RCT,1,tocilizumab,tocilizumab,increased
Antineoplastic And Biologic Therapies,Multiple Sclerosis,Peer Interaction,117973,117973,117973,117973,30644981,natalizumab,conversion to secondary progressive multiple sclerosis,decrease,positive,HR,0.61,0.43,0.86,natalizumab,C1172734,T116|T121|T129,cohort_kg,"Multiple Sclerosis, Secondary Progressive",C0751965,T047,cohort_kg,OS,1,natalizumab,natalizumab,increased
Antineoplastic And Biologic Therapies,Immune-Mediated Disease,Peer Interaction,3684,3684,3684,3684,35961761,secukinumab,disease flare,decrease,positive,HR,0.28,0.13,0.63,secukinumab,C3179547,"T116, T121, T129",api,Autoimmune Diseases,C0004364,T047,api,RCT,1,secukinumab,secukinumab,increased
Antineoplastic And Biologic Therapies,Cardiovascular Disease,Peer Interaction,10226,10226,10226,10226,31117810,alirocumab,noncardiovascular death,not found,negative,HR,0.77,0.59,1.01,alirocumab,C3491162,"T116, T121, T129",api,Cardiovascular system,C0007226,T022,scispacy,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Biologic Therapies,Cardiovascular Disease,Peer Interaction,13789,13789,13789,13789,28927706,evolocumab,cardiovascular outcomes,decrease,positive,HR,0.83,0.75,0.93,evolocumab,C3529352,"T116, T121, T129",api,Cardiovascular system,C0007226,T022,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Cardiovascular Disease,Peer Interaction,13792,13792,13792,13792,28927706,evolocumab,cardiovascular outcomes,decrease,positive,HR,0.87,0.79,0.96,evolocumab,C3529352,"T116, T121, T129",api,Cardiovascular system,C0007226,T022,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Cardiovascular Disease,Peer Interaction,17303,17303,17303,17303,25773607,evolocumab,cardiovascular events,decrease,positive,HR,0.47,0.28,0.78,evolocumab,C3529352,"T116, T121, T129",api,Cardiovascular event,C1320716,T033,api,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Cardiovascular Disease,Peer Interaction,89133,89133,89133,89133,28245350,tocilizumab,cardiovascular events,not found,negative,HR,0.84,0.56,1.26,tocilizumab,C1609165,T116|T121|T129,cohort_kg,cardiovascular event,C1320716,T033,cohort_kg,OS,1,tocilizumab,tocilizumab,increased
Antineoplastic And Biologic Therapies,Gastrointestinal Disease,Peer Interaction,19044,19044,19044,19044,24637999,bevacizumab,GI adverse events,increase,positive,OR,2.15,1.05,4.4,bevacizumab,C0796392,"T116, T121, T129",api,gastroenterology (field),C0017163,T091,scispacy,RCT,1,bevacizumab,bevacizumab,increased
Antineoplastic And Biologic Therapies,Overall Health Status,Peer Interaction,7043,7043,7043,7043,33472855,tocilizumab,clinical status,not found,negative,OR,1.54,0.66,3.66,tocilizumab,C1609165,"T116, T121, T129",api,Clinical status,C0449440,T201,api,RCT,1,tocilizumab,tocilizumab,increased
Antineoplastic And Biologic Therapies,Malignant Neoplasm,Peer Interaction,89013,89013,89013,89013,28193515,infliximab,malignancy,not found,negative,SIR,1.69,0.46,4.32,infliximab,C0666743,T116|T121|T129,cohort_kg,malignant disease,C0442867,T047,cohort_kg,OS,1,infliximab,infliximab,increased
Antineoplastic And Biologic Therapies,Infection,Peer Interaction,78201,78201,78201,78201,22887849,infliximab,serious infections,decrease,positive,HR,0.49,0.29,0.83,infliximab,C0666743,T116|T121|T129,cohort_kg,Severe infection,C5139167,T047,cohort_kg,OS,1,infliximab,infliximab,increased
Antineoplastic And Biologic Therapies,Infection,Peer Interaction,93677,93677,93677,93677,29592917,tocilizumab,serious infection,increase,positive,HR,1.22,1.02,1.47,tocilizumab,C1609165,T116|T121|T129,cohort_kg,Severe infection,C5139167,T047,cohort_kg,OS,1,tocilizumab,tocilizumab,increased
Antineoplastic And Biologic Therapies,Infection,Peer Interaction,110096,110096,110096,110096,25989609,etanercept,medically significant infections,increase,positive,HR,2.13,1.22,3.74,etanercept,C0717758,T116|T121,cohort_kg,Clinical infection,C0275521,T047,cohort_kg,OS,1,etanercept,etanercept,increased
Antineoplastic And Biologic Therapies,Infection,Peer Interaction,111215,111215,111215,111215,26315675,etanercept,hospitalized infection,increase,positive,HR,1.24,1.07,1.45,etanercept,C0717758,T116|T121,cohort_kg,"Infections, Hospital",C0205721,T047,cohort_kg,OS,1,etanercept,etanercept,increased
Antineoplastic And Biologic Therapies,Infection,Peer Interaction,111216,111216,111216,111216,26315675,infliximab,hospitalized infection,increase,positive,HR,1.39,1.21,1.6,infliximab,C0666743,T116|T121|T129,cohort_kg,"Infections, Hospital",C0205721,T047,cohort_kg,OS,1,infliximab,infliximab,increased
Antineoplastic And Biologic Therapies,Infection,Peer Interaction,114107,114107,114107,114107,24608404,etanercept,hospitalised infection,decrease,positive,HR,0.83,0.72,0.96,etanercept,C0717758,T116|T121,cohort_kg,"Infections, Hospital",C0205721,T047,cohort_kg,OS,1,etanercept,etanercept,increased
Antineoplastic And Biologic Therapies,Infection,Peer Interaction,118066,118066,118066,118066,30679153,tocilizumab,composite serious infection,not found,negative,HR,1.05,0.95,1.16,tocilizumab,C1609165,T116|T121|T129,cohort_kg,Severe infection,C5139167,T047,cohort_kg,OS,1,tocilizumab,tocilizumab,increased
Antineoplastic And Biologic Therapies,Infection,Peer Interaction,118067,118067,118067,118067,30679153,tocilizumab,serious bacterial infection,increase,positive,HR,1.19,1.07,1.33,tocilizumab,C1609165,T116|T121|T129,cohort_kg,bacterial sepsis,C0684256,T047,cohort_kg,OS,1,tocilizumab,tocilizumab,increased
Antineoplastic And Biologic Therapies,Thrombosis And Thromboembolism,Peer Interaction,87357,87357,87357,87357,27639934,omalizumab,arterial thromboembolic events,not found,negative,HR,1.32,0.91,1.91,omalizumab,C0966225,T116|T121|T129,cohort_kg,Arterial thromboembolism,C3544094,T046,cohort_kg,OS,1,omalizumab,omalizumab,increased
Antineoplastic And Biologic Therapies,Cerebrovascular Disease,Peer Interaction,8896,8896,8896,8896,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Cerebrovascular Disease,Peer Interaction,8898,8898,8898,8898,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Cerebrovascular Disease,Peer Interaction,10102,10102,10102,10102,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.82,0.71,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Cerebrovascular Disease,Peer Interaction,10103,10103,10103,10103,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.85,0.77,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Cerebrovascular Disease,Peer Interaction,10104,10104,10104,10104,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",not found,negative,HR,0.89,0.76,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Cerebrovascular Disease,Peer Interaction,10636,10636,10636,10636,31707788,alirocumab,ischemic stroke,decrease,positive,HR,0.73,0.57,0.93,alirocumab,C3491162,"T116, T121, T129",api,Ischemic stroke,C0948008,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Biologic Therapies,Cerebrovascular Disease,Peer Interaction,12369,12369,12369,12369,29626068,evolocumab,major vascular events,decrease,positive,HR,0.8,0.71,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Cerebrovascular Disease,Peer Interaction,12370,12370,12370,12370,29626068,evolocumab,major vascular events,decrease,positive,HR,0.82,0.72,0.93,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Cerebrovascular Disease,Peer Interaction,12371,12371,12371,12371,29626068,evolocumab,major vascular events,decrease,positive,HR,0.79,0.69,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Cerebrovascular Disease,Peer Interaction,12372,12372,12372,12372,29626068,evolocumab,major vascular events,not found,negative,HR,0.95,0.85,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Cerebrovascular Disease,Peer Interaction,12373,12373,12373,12373,29626068,evolocumab,major vascular events,not found,negative,HR,0.92,0.84,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Cerebrovascular Disease,Peer Interaction,12374,12374,12374,12374,29626068,evolocumab,major vascular events,not found,negative,HR,0.93,0.85,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Cerebrovascular Disease,Peer Interaction,124840,124840,124840,124840,32781110,bevacizumab,acute cerebrovascular disease,not found,negative,HR,1.04,0.78,1.38,bevacizumab,C0796392,T116|T121|T129,cohort_kg,Acute cerebrovascular disease,C0810006,T047,cohort_kg,OS,1,bevacizumab,bevacizumab,increased
Antineoplastic And Biologic Therapies,Health Status And Severity Scoring Systems,Peer Interaction,22536,22536,22536,22536,21536936,omalizumab,asthma symptom score,decrease,positive,not found,-0.26,-0.42,-0.1,omalizumab,C0966225,"T116, T121, T129",api,Symptoms score,C3476546,T033,scispacy,RCT,1,omalizumab,omalizumab,increased
Antineoplastic And Biologic Therapies,Functional Limitation,Peer Interaction,11550,11550,11550,11550,29545067,natalizumab,sustained disability progression,not found,negative,OR,0.86,0.66,1.13,natalizumab,C1172734,"T116, T121, T129",api,Disability,C0231170,T033,scispacy,RCT,1,natalizumab,natalizumab,increased
Antineoplastic And Biologic Therapies,Functional Limitation,Peer Interaction,28521,28521,28521,28521,16510744,natalizumab,sustained progression of disability,decrease,positive,HR,0.58,0.43,0.77,natalizumab,C1172734,"T116, T121, T129",api,Disability,C0231170,T033,scispacy,RCT,1,natalizumab,natalizumab,increased
Antineoplastic And Biologic Therapies,General Clinical Status,Peer Interaction,7043,7043,7043,7043,33472855,tocilizumab,clinical status,not found,negative,OR,1.54,0.66,3.66,tocilizumab,C1609165,"T116, T121, T129",api,Clinical status,C0449440,T201,api,RCT,1,tocilizumab,tocilizumab,increased
Antineoplastic And Biologic Therapies,Falls And Fall Risk,Peer Interaction,17113,17113,17113,17113,26518090,omalizumab,fall asthma exacerbations,decrease,positive,OR,0.48,0.25,0.92,omalizumab,C0966225,"T116, T121, T129",api,Falls,C0085639,T033,scispacy,RCT,1,omalizumab,omalizumab,increased
Antineoplastic And Biologic Therapies,Falls And Fall Risk,Peer Interaction,17114,17114,17114,17114,26518090,omalizumab,fall asthma exacerbations,not found,negative,OR,0.73,0.33,1.64,omalizumab,C0966225,"T116, T121, T129",api,Falls,C0085639,T033,scispacy,RCT,1,omalizumab,omalizumab,increased
Antineoplastic And Biologic Therapies,Falls And Fall Risk,Peer Interaction,17119,17119,17119,17119,26518090,omalizumab,fall asthma exacerbations,decrease,positive,OR,0.12,0.02,0.64,omalizumab,C0966225,"T116, T121, T129",api,Falls,C0085639,T033,scispacy,RCT,1,omalizumab,omalizumab,increased
Antineoplastic And Biologic Therapies,Falls And Fall Risk,Peer Interaction,17120,17120,17120,17120,26518090,omalizumab,fall asthma exacerbations,decrease,positive,OR,0.05,0.002,0.98,omalizumab,C0966225,"T116, T121, T129",api,Falls,C0085639,T033,scispacy,RCT,1,omalizumab,omalizumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,7383,7383,7383,7383,34537830,evolocumab,cerebrovascular events,decrease,positive,HR,0.77,0.65,0.92,evolocumab,C3529352,"T116, T121, T129",api,Transient cerebrovascular events,C0852396,T047,api,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,8896,8896,8896,8896,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,8898,8898,8898,8898,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,9436,9436,9436,9436,31121022,alirocumab,myocardial infarction,decrease,positive,HR,0.85,0.77,0.95,alirocumab,C3491162,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,10102,10102,10102,10102,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.82,0.71,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,10103,10103,10103,10103,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.85,0.77,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,10104,10104,10104,10104,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",not found,negative,HR,0.89,0.76,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,10636,10636,10636,10636,31707788,alirocumab,ischemic stroke,decrease,positive,HR,0.73,0.57,0.93,alirocumab,C3491162,"T116, T121, T129",api,Ischemic stroke,C0948008,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,12369,12369,12369,12369,29626068,evolocumab,major vascular events,decrease,positive,HR,0.8,0.71,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,12370,12370,12370,12370,29626068,evolocumab,major vascular events,decrease,positive,HR,0.82,0.72,0.93,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,12371,12371,12371,12371,29626068,evolocumab,major vascular events,decrease,positive,HR,0.79,0.69,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,12372,12372,12372,12372,29626068,evolocumab,major vascular events,not found,negative,HR,0.95,0.85,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,12373,12373,12373,12373,29626068,evolocumab,major vascular events,not found,negative,HR,0.92,0.84,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,12374,12374,12374,12374,29626068,evolocumab,major vascular events,not found,negative,HR,0.93,0.85,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,17303,17303,17303,17303,25773607,evolocumab,cardiovascular events,decrease,positive,HR,0.47,0.28,0.78,evolocumab,C3529352,"T116, T121, T129",api,Cardiovascular event,C1320716,T033,api,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,31749,31749,31749,31749,12021219,abciximab,myocardial infarction,decrease,positive,RR,0.68,0.53,0.87,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,33469,33469,33469,33469,10341274,abciximab,myocardial infarction,decrease,positive,OR,0.23,0.12,0.49,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,33726,33726,33726,33726,10636365,abciximab,death or large myocardial infarction,decrease,positive,HR,0.46,0.32,0.67,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,scispacy,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,34349,34349,34349,34349,9164316,abciximab,myocardial infarction,decrease,positive,RR,0.29,0.1,0.84,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,34350,34350,34350,34350,9164316,abciximab,myocardial infarction,decrease,positive,RR,0.47,0.26,0.84,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,89133,89133,89133,89133,28245350,tocilizumab,cardiovascular events,not found,negative,HR,0.84,0.56,1.26,tocilizumab,C1609165,T116|T121|T129,cohort_kg,cardiovascular event,C1320716,T033,cohort_kg,OS,1,tocilizumab,tocilizumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke And Cardiovascular Events,Peer Interaction,124840,124840,124840,124840,32781110,bevacizumab,acute cerebrovascular disease,not found,negative,HR,1.04,0.78,1.38,bevacizumab,C0796392,T116|T121|T129,cohort_kg,Acute cerebrovascular disease,C0810006,T047,cohort_kg,OS,1,bevacizumab,bevacizumab,increased
Antineoplastic And Biologic Therapies,Hemorrhagic Stroke,Peer Interaction,8896,8896,8896,8896,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Hemorrhagic Stroke,Peer Interaction,8898,8898,8898,8898,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Hemorrhagic Stroke,Peer Interaction,10102,10102,10102,10102,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.82,0.71,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Hemorrhagic Stroke,Peer Interaction,10103,10103,10103,10103,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.85,0.77,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Hemorrhagic Stroke,Peer Interaction,10104,10104,10104,10104,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",not found,negative,HR,0.89,0.76,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Hemorrhagic Stroke,Peer Interaction,10636,10636,10636,10636,31707788,alirocumab,ischemic stroke,decrease,positive,HR,0.73,0.57,0.93,alirocumab,C3491162,"T116, T121, T129",api,Ischemic stroke,C0948008,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Biologic Therapies,Hemorrhagic Stroke,Peer Interaction,10649,10649,10649,10649,31707788,alirocumab,hemorrhagic stroke,not found,negative,HR,0.83,0.42,1.65,alirocumab,C3491162,"T116, T121, T129",api,Hemorrhagic Stroke,C5234922,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Biologic Therapies,Hemorrhagic Stroke,Peer Interaction,12369,12369,12369,12369,29626068,evolocumab,major vascular events,decrease,positive,HR,0.8,0.71,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Hemorrhagic Stroke,Peer Interaction,12370,12370,12370,12370,29626068,evolocumab,major vascular events,decrease,positive,HR,0.82,0.72,0.93,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Hemorrhagic Stroke,Peer Interaction,12371,12371,12371,12371,29626068,evolocumab,major vascular events,decrease,positive,HR,0.79,0.69,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Hemorrhagic Stroke,Peer Interaction,12372,12372,12372,12372,29626068,evolocumab,major vascular events,not found,negative,HR,0.95,0.85,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Hemorrhagic Stroke,Peer Interaction,12373,12373,12373,12373,29626068,evolocumab,major vascular events,not found,negative,HR,0.92,0.84,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Hemorrhagic Stroke,Peer Interaction,12374,12374,12374,12374,29626068,evolocumab,major vascular events,not found,negative,HR,0.93,0.85,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,8896,8896,8896,8896,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,8898,8898,8898,8898,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,9436,9436,9436,9436,31121022,alirocumab,myocardial infarction,decrease,positive,HR,0.85,0.77,0.95,alirocumab,C3491162,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,10102,10102,10102,10102,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.82,0.71,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,10103,10103,10103,10103,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.85,0.77,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,10104,10104,10104,10104,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",not found,negative,HR,0.89,0.76,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,10636,10636,10636,10636,31707788,alirocumab,ischemic stroke,decrease,positive,HR,0.73,0.57,0.93,alirocumab,C3491162,"T116, T121, T129",api,Ischemic stroke,C0948008,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,10649,10649,10649,10649,31707788,alirocumab,hemorrhagic stroke,not found,negative,HR,0.83,0.42,1.65,alirocumab,C3491162,"T116, T121, T129",api,Hemorrhagic Stroke,C5234922,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,12369,12369,12369,12369,29626068,evolocumab,major vascular events,decrease,positive,HR,0.8,0.71,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,12370,12370,12370,12370,29626068,evolocumab,major vascular events,decrease,positive,HR,0.82,0.72,0.93,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,12371,12371,12371,12371,29626068,evolocumab,major vascular events,decrease,positive,HR,0.79,0.69,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,12372,12372,12372,12372,29626068,evolocumab,major vascular events,not found,negative,HR,0.95,0.85,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,12373,12373,12373,12373,29626068,evolocumab,major vascular events,not found,negative,HR,0.92,0.84,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,12374,12374,12374,12374,29626068,evolocumab,major vascular events,not found,negative,HR,0.93,0.85,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,31749,31749,31749,31749,12021219,abciximab,myocardial infarction,decrease,positive,RR,0.68,0.53,0.87,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,33469,33469,33469,33469,10341274,abciximab,myocardial infarction,decrease,positive,OR,0.23,0.12,0.49,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,33726,33726,33726,33726,10636365,abciximab,death or large myocardial infarction,decrease,positive,HR,0.46,0.32,0.67,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,scispacy,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,34349,34349,34349,34349,9164316,abciximab,myocardial infarction,decrease,positive,RR,0.29,0.1,0.84,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,34350,34350,34350,34350,9164316,abciximab,myocardial infarction,decrease,positive,RR,0.47,0.26,0.84,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,84659,84659,84659,84659,26792814,etanercept,acute myocardial infarction,increase,positive,HR,1.3,1.0,1.8,etanercept,C0717758,T116|T121,cohort_kg,Acute myocardial infarction,C0155626,T047,cohort_kg,OS,1,etanercept,etanercept,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,84660,84660,84660,84660,26792814,infliximab,acute myocardial infarction,increase,positive,HR,1.3,1.0,1.6,infliximab,C0666743,T116|T121|T129,cohort_kg,Acute myocardial infarction,C0155626,T047,cohort_kg,OS,1,infliximab,infliximab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,124839,124839,124839,124839,32781110,bevacizumab,acute myocardial infarction,not found,negative,HR,0.96,0.74,1.25,bevacizumab,C0796392,T116|T121|T129,cohort_kg,Acute myocardial infarction,C0155626,T047,cohort_kg,OS,1,bevacizumab,bevacizumab,increased
Antineoplastic And Biologic Therapies,Ischemic Stroke,Peer Interaction,124840,124840,124840,124840,32781110,bevacizumab,acute cerebrovascular disease,not found,negative,HR,1.04,0.78,1.38,bevacizumab,C0796392,T116|T121|T129,cohort_kg,Acute cerebrovascular disease,C0810006,T047,cohort_kg,OS,1,bevacizumab,bevacizumab,increased
Antineoplastic And Biologic Therapies,Venous Thromboembolism,Peer Interaction,87357,87357,87357,87357,27639934,omalizumab,arterial thromboembolic events,not found,negative,HR,1.32,0.91,1.91,omalizumab,C0966225,T116|T121|T129,cohort_kg,Arterial thromboembolism,C3544094,T046,cohort_kg,OS,1,omalizumab,omalizumab,increased
Antineoplastic And Biologic Therapies,Viral Infections,Peer Interaction,21926,21926,21926,21926,21949007,tocilizumab,serious infections,increase,positive,RR,6.56,4.3,13.2,tocilizumab,C1609165,"T116, T121, T129",api,No serious viral infections,C5936290,T033,api,RCT,1,tocilizumab,tocilizumab,increased
Antineoplastic And Biologic Therapies,Viral Infections,Peer Interaction,110096,110096,110096,110096,25989609,etanercept,medically significant infections,increase,positive,HR,2.13,1.22,3.74,etanercept,C0717758,T116|T121,cohort_kg,Clinical infection,C0275521,T047,cohort_kg,OS,1,etanercept,etanercept,increased
Antineoplastic And Biologic Therapies,Arterial Structure,Peer Interaction,19470,19470,19470,19470,23870813,ranibizumab,arterial thrombotic event or hospital admission for heart failure,not found,negative,OR,1.69,0.8,3.57,ranibizumab,C1566537,"T116, T121, T129",api,Arteries,C0003842,T023,scispacy,RCT,1,ranibizumab,ranibizumab,increased
Antineoplastic And Biologic Therapies,Arterial Structure,Peer Interaction,30056,30056,30056,30056,15351163,abciximab,"combined incidence of death, recurrent myocardial infarction and target vessel re-vascularisation",not found,negative,RR,0.97,0.7,1.33,abciximab,C0288672,"T116, T121, T129",api,Blood Vessel,C0005847,T023,scispacy,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Arterial Structure,Peer Interaction,33620,33620,33620,33620,10423466,abciximab,repeated revascularization of the target vessel,not found,negative,HR,0.82,0.59,1.13,abciximab,C0288672,"T116, T121, T129",api,Blood Vessel,C0005847,T023,scispacy,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Arterial Structure,Peer Interaction,33621,33621,33621,33621,10423466,abciximab,repeated revascularization of the target vessel,increase,positive,HR,1.49,1.13,1.97,abciximab,C0288672,"T116, T121, T129",api,Blood Vessel,C0005847,T023,scispacy,RCT,1,abciximab,abciximab,increased
Antineoplastic And Biologic Therapies,Arterial Structure,Peer Interaction,33622,33622,33622,33622,10423466,abciximab,repeated revascularization of the target vessel,decrease,positive,HR,0.55,0.41,0.74,abciximab,C0288672,"T116, T121, T129",api,Blood Vessel,C0005847,T023,scispacy,RCT,1,abciximab,abciximab,increased
Malignant Neoplasm With Metastasis,Arthritis And Inflammatory Disorders,Peer Interaction,98360,98360,98360,98360,34397169,melanoma,rheumatic immune-related adverse events,increase,positive,OR,4.06,2.54,6.51,melanoma,C0025202,T191,cohort_kg,Immune-mediated/reactive arthropathies,C5225749,T047,cohort_kg,OS,1,melanoma,melanoma,increased
Iron Metabolism Disorders,Asthma And Obstructive Lung Disease,Peer Interaction,37042,37042,37042,37042,31380560,iron,asthma,not found,negative,OR,1.0,0.91,1.1,iron,C0302583,"T121, T123, T196",api,Asthma,C0004096,T047,api,MR,1,iron,iron,increased
Gastrointestinal Diseases,Asthma And Obstructive Lung Disease,Peer Interaction,37042,37042,37042,37042,31380560,iron,asthma,not found,negative,OR,1.0,0.91,1.1,iron,C0302583,"T121, T123, T196",api,Asthma,C0004096,T047,api,MR,1,iron,iron,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Activities Of Daily Living Limitation,Peer Interaction,114680,114680,114680,114680,24779559,hearing impairment,physical disability in activities of daily living,increase,positive,OR,1.4,1.1,1.9,hearing impairment,C1384666,T047,cohort_kg,Disability affecting daily living,C1446368,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Activities Of Daily Living Limitation,Peer Interaction,114681,114681,114681,114681,24779559,hearing impairment,physical disability in instrumental activities of daily living,increase,positive,OR,1.6,1.2,2.2,hearing impairment,C1384666,T047,cohort_kg,Impairment of activities of daily living,C4476938,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Activities Of Daily Living Limitation,Peer Interaction,114683,114683,114683,114683,24779559,hearing impairment,physical disability in lower extremity mobility,increase,positive,OR,1.4,1.1,1.7,hearing impairment,C1384666,T047,cohort_kg,Mobility Limitation,C1565249,T184,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Activities Of Daily Living Limitation,Peer Interaction,114686,114686,114686,114686,24779559,hearing impairment,walking limitation,increase,positive,OR,1.6,1.3,2.0,hearing impairment,C1384666,T047,cohort_kg,Limited Walking Ability,C2674459,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Dementia,Peer Interaction,87296,87296,87296,87296,27611845,hearing impairment,cognitive impairment,increase,positive,HR,1.9,1.11,3.26,hearing impairment,C1384666,T047,cohort_kg,Impaired cognition,C0338656,T048,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Dementia,Peer Interaction,96252,96252,96252,96252,33734430,hearing impairment,all-cause dementia,increase,positive,HR,1.16,1.04,1.3,hearing impairment,C1384666,T047,cohort_kg,Dementia,C0497327,T048,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Frailty And Physical Functional Status,Peer Interaction,88328,88328,88328,88328,27991672,hearing impairment,frailty,increase,positive,OR,1.66,1.37,2.01,hearing impairment,C1384666,T047,cohort_kg,Frailty,C0424594,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Frailty And Physical Functional Status,Peer Interaction,88329,88329,88329,88329,27991672,hearing impairment,prefrailty and frailty,increase,positive,OR,1.43,1.05,1.95,hearing impairment,C1384666,T047,cohort_kg,Frailty Syndrome,C4505081,T046,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Frailty And Physical Functional Status,Peer Interaction,103677,103677,103677,103677,36504135,hearing impairment,frailty,increase,positive,HR,1.31,1.12,1.74,hearing impairment,C1384666,T047,cohort_kg,Frailty,C0424594,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Employment Status And Work Disability,Peer Interaction,114685,114685,114685,114685,24779559,hearing impairment,work limitation,increase,positive,OR,1.4,1.0,1.9,hearing impairment,C1384666,T047,cohort_kg,I am limited in my work,C5212838,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Employment Status And Work Disability,Peer Interaction,114688,114688,114688,114688,24779559,hearing impairment,limitations in amount or type of work done,not found,negative,OR,1.2,1.0,1.6,hearing impairment,C1384666,T047,cohort_kg,I am limited in doing my work (include work at home),C4034816,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Dementia Including Alzheimer Disease,Peer Interaction,96252,96252,96252,96252,33734430,hearing impairment,all-cause dementia,increase,positive,HR,1.16,1.04,1.3,hearing impairment,C1384666,T047,cohort_kg,Dementia,C0497327,T048,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Frailty And Functional Status,Peer Interaction,88328,88328,88328,88328,27991672,hearing impairment,frailty,increase,positive,OR,1.66,1.37,2.01,hearing impairment,C1384666,T047,cohort_kg,Frailty,C0424594,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Frailty And Functional Status,Peer Interaction,88329,88329,88329,88329,27991672,hearing impairment,prefrailty and frailty,increase,positive,OR,1.43,1.05,1.95,hearing impairment,C1384666,T047,cohort_kg,Frailty Syndrome,C4505081,T046,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Frailty And Functional Status,Peer Interaction,103677,103677,103677,103677,36504135,hearing impairment,frailty,increase,positive,HR,1.31,1.12,1.74,hearing impairment,C1384666,T047,cohort_kg,Frailty,C0424594,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Functional Limitation,Peer Interaction,114680,114680,114680,114680,24779559,hearing impairment,physical disability in activities of daily living,increase,positive,OR,1.4,1.1,1.9,hearing impairment,C1384666,T047,cohort_kg,Disability affecting daily living,C1446368,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Functional Limitation,Peer Interaction,114681,114681,114681,114681,24779559,hearing impairment,physical disability in instrumental activities of daily living,increase,positive,OR,1.6,1.2,2.2,hearing impairment,C1384666,T047,cohort_kg,Impairment of activities of daily living,C4476938,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Functional Limitation,Peer Interaction,114683,114683,114683,114683,24779559,hearing impairment,physical disability in lower extremity mobility,increase,positive,OR,1.4,1.1,1.7,hearing impairment,C1384666,T047,cohort_kg,Mobility Limitation,C1565249,T184,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Functional Limitation,Peer Interaction,114684,114684,114684,114684,24779559,hearing impairment,physical disability in general physical activities,increase,positive,OR,1.3,1.1,1.6,hearing impairment,C1384666,T047,cohort_kg,Physical disability,C0520817,T046,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Functional Limitation,Peer Interaction,114686,114686,114686,114686,24779559,hearing impairment,walking limitation,increase,positive,OR,1.6,1.3,2.0,hearing impairment,C1384666,T047,cohort_kg,Limited Walking Ability,C2674459,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Employment And Work Disability,Peer Interaction,114685,114685,114685,114685,24779559,hearing impairment,work limitation,increase,positive,OR,1.4,1.0,1.9,hearing impairment,C1384666,T047,cohort_kg,I am limited in my work,C5212838,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Neurologic Disorders Including Epilepsy And Encephalopathy,Employment And Work Disability,Peer Interaction,114688,114688,114688,114688,24779559,hearing impairment,limitations in amount or type of work done,not found,negative,OR,1.2,1.0,1.6,hearing impairment,C1384666,T047,cohort_kg,I am limited in doing my work (include work at home),C4034816,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Health Literacy And Education,Diabetes Mellitus,Peer Interaction,62620,62620,62620,62620,18083794,reading comprehension,type 2 diabetes,decrease,positive,OR,0.58,0.44,0.77,reading comprehension,C0871214,T080,cohort_kg,Type 2 diabetes (Adult onset),C3842544,T047,cohort_kg,OS,1,reading comprehension,reading comprehension,increased
Blood Urea Nitrogen Level,Heart Failure,Peer Interaction,90660,90660,90660,90660,28633342,sodium,heart failure,increase,positive,HR,1.36,1.02,1.82,sodium,C0037473,T123|T196,cohort_kg,Heart failure,C0018801,T047,cohort_kg,OS,1,sodium,sodium,increased
Blood Urea Nitrogen Level,Coronary Artery Disease,Peer Interaction,68498,68498,68498,68498,20016010,sodium,cardiovascular disease,increase,positive,HR,1.19,1.01,1.4,sodium,C0037473,T123|T196,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,sodium,sodium,increased
Blood Urea Nitrogen Level,Coronary Artery Disease,Peer Interaction,90658,90658,90658,90658,28633342,sodium,coronary heart disease,increase,negative,HR,1.11,0.95,1.3,sodium,C0037473,T123|T196,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,sodium,sodium,increased
Blood Urea Nitrogen Level,Cardiovascular Disease,Peer Interaction,68498,68498,68498,68498,20016010,sodium,cardiovascular disease,increase,positive,HR,1.19,1.01,1.4,sodium,C0037473,T123|T196,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,sodium,sodium,increased
Blood Urea Nitrogen Level,Cardiovascular Disease,Peer Interaction,90658,90658,90658,90658,28633342,sodium,coronary heart disease,increase,negative,HR,1.11,0.95,1.3,sodium,C0037473,T123|T196,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,sodium,sodium,increased
Blood Urea Nitrogen Level,Malignant Neoplasm,Peer Interaction,68499,68499,68499,68499,20016010,sodium,total cancer,not found,negative,HR,1.04,0.93,1.16,sodium,C0037473,T123|T196,cohort_kg,Cancer:-:Pt:^Patient:-,C2707253,T201,cohort_kg,OS,1,sodium,sodium,increased
Blood Urea Nitrogen Level,Thrombosis And Thromboembolism,Peer Interaction,35266,35266,35266,35266,7700286,hydroxyurea,thrombosis,decrease,positive,RR,0.15,0.04,0.56,hydroxyurea,C0020402,"T109, T121",api,Thrombosis,C0040053,T046,api,RCT,1,hydroxyurea,hydroxyurea,increased
Blood Urea Nitrogen Level,Cerebrovascular Disease,Peer Interaction,68498,68498,68498,68498,20016010,sodium,cardiovascular disease,increase,positive,HR,1.19,1.01,1.4,sodium,C0037473,T123|T196,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,sodium,sodium,increased
Blood Urea Nitrogen Level,Ischemic Stroke And Cardiovascular Events,Peer Interaction,68498,68498,68498,68498,20016010,sodium,cardiovascular disease,increase,positive,HR,1.19,1.01,1.4,sodium,C0037473,T123|T196,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,sodium,sodium,increased
Blood Urea Nitrogen Level,Venous Thromboembolism,Peer Interaction,35266,35266,35266,35266,7700286,hydroxyurea,thrombosis,decrease,positive,RR,0.15,0.04,0.56,hydroxyurea,C0020402,"T109, T121",api,Thrombosis,C0040053,T046,api,RCT,1,hydroxyurea,hydroxyurea,increased
Cardiac Arrhythmias,Diabetes Mellitus,Peer Interaction,38033,38033,38033,38033,37022971,heart rate,type 2 diabetes,increase,positive,HR,1.2,1.09,1.33,heart rate,C0018810,T201,api,"Diabetes Mellitus, Non-Insulin-Dependent",C0011860,T047,api,MR,1,heart rate,heart rate,increased
Cardiac Arrhythmias,Diabetes Mellitus,Peer Interaction,38034,38034,38034,38034,37022971,heart rate,type 2 diabetes,increase,positive,HR,1.54,1.08,2.06,heart rate,C0018810,T201,api,"Diabetes Mellitus, Non-Insulin-Dependent",C0011860,T047,api,MR,1,heart rate,heart rate,increased
Cardiac Arrhythmias,Diabetes Mellitus,Peer Interaction,38035,38035,38035,38035,37022971,heart rate,type 2 diabetes,increase,positive,HR,1.15,1.01,1.31,heart rate,C0018810,T201,api,"Diabetes Mellitus, Non-Insulin-Dependent",C0011860,T047,api,MR,1,heart rate,heart rate,increased
Cardiac Arrhythmias,Diabetes Mellitus,Peer Interaction,52242,52242,52242,52242,12695289,heart rate,type 2 diabetes,increase,positive,RR,1.6,1.33,1.92,heart rate,C0018810,T201,cohort_kg,Type 2 diabetes (Adult onset),C3842544,T047,cohort_kg,OS,1,heart rate,heart rate,increased
Cardiac Arrhythmias,Diabetes Mellitus,Peer Interaction,123312,123312,123312,123312,32300048,heart rate,diabetes,increase,positive,HR,1.41,1.21,1.65,heart rate,C0018810,T201,cohort_kg,Diabetes,C0011847,T047,cohort_kg,OS,1,heart rate,heart rate,increased
Cardiac Arrhythmias,Heart Failure,Peer Interaction,23613,23613,23613,23613,20801495,heart rate,cardiovascular death or hospital admission for worsening heart failure,increase,positive,HR,2.34,1.84,2.98,heart rate,C0018810,T201,api,Heart failure,C0018801,T047,scispacy,RCT,1,heart rate,heart rate,increased
Cardiac Arrhythmias,Heart Failure,Peer Interaction,23614,23614,23614,23614,20801495,heart rate,cardiovascular death or hospital admission for worsening heart failure,decrease,positive,HR,0.95,0.85,1.06,heart rate,C0018810,T201,api,Heart failure,C0018801,T047,scispacy,RCT,1,heart rate,heart rate,increased
Dementia Including Alzheimer Disease,Activities Of Daily Living Limitation,Peer Interaction,114680,114680,114680,114680,24779559,hearing impairment,physical disability in activities of daily living,increase,positive,OR,1.4,1.1,1.9,hearing impairment,C1384666,T047,cohort_kg,Disability affecting daily living,C1446368,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Activities Of Daily Living Limitation,Peer Interaction,114681,114681,114681,114681,24779559,hearing impairment,physical disability in instrumental activities of daily living,increase,positive,OR,1.6,1.2,2.2,hearing impairment,C1384666,T047,cohort_kg,Impairment of activities of daily living,C4476938,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Activities Of Daily Living Limitation,Peer Interaction,114683,114683,114683,114683,24779559,hearing impairment,physical disability in lower extremity mobility,increase,positive,OR,1.4,1.1,1.7,hearing impairment,C1384666,T047,cohort_kg,Mobility Limitation,C1565249,T184,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Activities Of Daily Living Limitation,Peer Interaction,114686,114686,114686,114686,24779559,hearing impairment,walking limitation,increase,positive,OR,1.6,1.3,2.0,hearing impairment,C1384666,T047,cohort_kg,Limited Walking Ability,C2674459,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Dementia,Peer Interaction,87296,87296,87296,87296,27611845,hearing impairment,cognitive impairment,increase,positive,HR,1.9,1.11,3.26,hearing impairment,C1384666,T047,cohort_kg,Impaired cognition,C0338656,T048,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Dementia,Peer Interaction,96252,96252,96252,96252,33734430,hearing impairment,all-cause dementia,increase,positive,HR,1.16,1.04,1.3,hearing impairment,C1384666,T047,cohort_kg,Dementia,C0497327,T048,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Frailty And Physical Functional Status,Peer Interaction,88328,88328,88328,88328,27991672,hearing impairment,frailty,increase,positive,OR,1.66,1.37,2.01,hearing impairment,C1384666,T047,cohort_kg,Frailty,C0424594,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Frailty And Physical Functional Status,Peer Interaction,88329,88329,88329,88329,27991672,hearing impairment,prefrailty and frailty,increase,positive,OR,1.43,1.05,1.95,hearing impairment,C1384666,T047,cohort_kg,Frailty Syndrome,C4505081,T046,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Frailty And Physical Functional Status,Peer Interaction,103677,103677,103677,103677,36504135,hearing impairment,frailty,increase,positive,HR,1.31,1.12,1.74,hearing impairment,C1384666,T047,cohort_kg,Frailty,C0424594,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Employment Status And Work Disability,Peer Interaction,114685,114685,114685,114685,24779559,hearing impairment,work limitation,increase,positive,OR,1.4,1.0,1.9,hearing impairment,C1384666,T047,cohort_kg,I am limited in my work,C5212838,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Employment Status And Work Disability,Peer Interaction,114688,114688,114688,114688,24779559,hearing impairment,limitations in amount or type of work done,not found,negative,OR,1.2,1.0,1.6,hearing impairment,C1384666,T047,cohort_kg,I am limited in doing my work (include work at home),C4034816,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Frailty And Functional Status,Peer Interaction,88328,88328,88328,88328,27991672,hearing impairment,frailty,increase,positive,OR,1.66,1.37,2.01,hearing impairment,C1384666,T047,cohort_kg,Frailty,C0424594,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Frailty And Functional Status,Peer Interaction,88329,88329,88329,88329,27991672,hearing impairment,prefrailty and frailty,increase,positive,OR,1.43,1.05,1.95,hearing impairment,C1384666,T047,cohort_kg,Frailty Syndrome,C4505081,T046,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Frailty And Functional Status,Peer Interaction,103677,103677,103677,103677,36504135,hearing impairment,frailty,increase,positive,HR,1.31,1.12,1.74,hearing impairment,C1384666,T047,cohort_kg,Frailty,C0424594,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Functional Limitation,Peer Interaction,114680,114680,114680,114680,24779559,hearing impairment,physical disability in activities of daily living,increase,positive,OR,1.4,1.1,1.9,hearing impairment,C1384666,T047,cohort_kg,Disability affecting daily living,C1446368,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Functional Limitation,Peer Interaction,114681,114681,114681,114681,24779559,hearing impairment,physical disability in instrumental activities of daily living,increase,positive,OR,1.6,1.2,2.2,hearing impairment,C1384666,T047,cohort_kg,Impairment of activities of daily living,C4476938,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Functional Limitation,Peer Interaction,114683,114683,114683,114683,24779559,hearing impairment,physical disability in lower extremity mobility,increase,positive,OR,1.4,1.1,1.7,hearing impairment,C1384666,T047,cohort_kg,Mobility Limitation,C1565249,T184,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Functional Limitation,Peer Interaction,114684,114684,114684,114684,24779559,hearing impairment,physical disability in general physical activities,increase,positive,OR,1.3,1.1,1.6,hearing impairment,C1384666,T047,cohort_kg,Physical disability,C0520817,T046,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Functional Limitation,Peer Interaction,114686,114686,114686,114686,24779559,hearing impairment,walking limitation,increase,positive,OR,1.6,1.3,2.0,hearing impairment,C1384666,T047,cohort_kg,Limited Walking Ability,C2674459,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Employment And Work Disability,Peer Interaction,114685,114685,114685,114685,24779559,hearing impairment,work limitation,increase,positive,OR,1.4,1.0,1.9,hearing impairment,C1384666,T047,cohort_kg,I am limited in my work,C5212838,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Dementia Including Alzheimer Disease,Employment And Work Disability,Peer Interaction,114688,114688,114688,114688,24779559,hearing impairment,limitations in amount or type of work done,not found,negative,OR,1.2,1.0,1.6,hearing impairment,C1384666,T047,cohort_kg,I am limited in doing my work (include work at home),C4034816,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Antiviral Medications,Coronary Artery Disease,Peer Interaction,23451,23451,23451,23451,21427402,abacavir,myocardial infarction,not found,negative,HR,0.7,0.2,2.4,abacavir,C0663655,"T114, T121",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abacavir,abacavir,increased
Antiviral Medications,Coronary Artery Disease,Peer Interaction,23454,23454,23454,23454,21427402,abacavir,myocardial infarction,not found,negative,HR,0.6,0.3,1.4,abacavir,C0663655,"T114, T121",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abacavir,abacavir,increased
Antiviral Medications,Coronary Artery Disease,Peer Interaction,108631,108631,108631,108631,25595744,HIV,myocardial infarction,not found,negative,IRR,1.01,0.41,2.54,HIV,C0019682,T005,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,HIV,HIV,increased
Antiviral Medications,Coronary Artery Disease,Peer Interaction,108632,108632,108632,108632,25595744,HIV,myocardial infarction,increase,positive,IRR,1.78,0.75,4.24,HIV,C0019682,T005,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,HIV,HIV,increased
Antiviral Medications,Coronary Artery Disease,Peer Interaction,121823,121823,121823,121823,31828320,atazanavir,myocardial infarction,not found,negative,OR,1.54,0.87,2.73,atazanavir,C1145759,T109|T121,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,atazanavir,atazanavir,increased
Antiviral Medications,Psychiatric Disorders,Peer Interaction,122316,122316,122316,122316,31996920,oseltamivir,neuropsychiatric events,not found,negative,HR,0.98,0.96,1.01,oseltamivir,C0874161,T109|T121,cohort_kg,One or more neuropsychiatric symptoms,C3534763,T033,cohort_kg,OS,1,oseltamivir,oseltamivir,increased
Antiviral Medications,Quality Of Life,Peer Interaction,79713,79713,79713,79713,23254417,HIV,life expectancy,decrease,positive,life-years lost,5.1,1.6,8.5,HIV,C0019682,T005,cohort_kg,Life Expectancy,C0023671,T102,cohort_kg,OS,1,HIV,HIV,increased
Antiviral Medications,Tuberculosis,Peer Interaction,59893,59893,59893,59893,17199408,HIV,culture-positive tuberculosis,increase,positive,incidence rate ratio,18.8,10.3,34.5,HIV,C0019682,T005,cohort_kg,tuberculosis culture,C0851253,T060,cohort_kg,OS,1,HIV,HIV,increased
Antiviral Medications,Tuberculosis,Peer Interaction,59894,59894,59894,59894,17199408,HIV,culture-positive tuberculosis,not found,negative,odds ratio,1.7,0.5,6.8,HIV,C0019682,T005,cohort_kg,tuberculosis culture,C0851253,T060,cohort_kg,OS,1,HIV,HIV,increased
Antiviral Medications,Neuropsychiatric Status,Peer Interaction,122316,122316,122316,122316,31996920,oseltamivir,neuropsychiatric events,not found,negative,HR,0.98,0.96,1.01,oseltamivir,C0874161,T109|T121,cohort_kg,One or more neuropsychiatric symptoms,C3534763,T033,cohort_kg,OS,1,oseltamivir,oseltamivir,increased
Antiviral Medications,Multiple Sclerosis,Peer Interaction,126675,126675,126675,126675,38098141,HIV,multiple sclerosis,decrease,positive,SIR,0.53,0.32,0.9,HIV,C0019682,T005,cohort_kg,Multiple Sclerosis,C0026769,T047,cohort_kg,OS,1,HIV,HIV,increased
Antiviral Medications,Ischemic Stroke And Cardiovascular Events,Peer Interaction,23451,23451,23451,23451,21427402,abacavir,myocardial infarction,not found,negative,HR,0.7,0.2,2.4,abacavir,C0663655,"T114, T121",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abacavir,abacavir,increased
Antiviral Medications,Ischemic Stroke And Cardiovascular Events,Peer Interaction,23454,23454,23454,23454,21427402,abacavir,myocardial infarction,not found,negative,HR,0.6,0.3,1.4,abacavir,C0663655,"T114, T121",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abacavir,abacavir,increased
Antiviral Medications,Ischemic Stroke And Cardiovascular Events,Peer Interaction,108631,108631,108631,108631,25595744,HIV,myocardial infarction,not found,negative,IRR,1.01,0.41,2.54,HIV,C0019682,T005,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,HIV,HIV,increased
Antiviral Medications,Ischemic Stroke And Cardiovascular Events,Peer Interaction,108632,108632,108632,108632,25595744,HIV,myocardial infarction,increase,positive,IRR,1.78,0.75,4.24,HIV,C0019682,T005,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,HIV,HIV,increased
Antiviral Medications,Ischemic Stroke And Cardiovascular Events,Peer Interaction,121823,121823,121823,121823,31828320,atazanavir,myocardial infarction,not found,negative,OR,1.54,0.87,2.73,atazanavir,C1145759,T109|T121,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,atazanavir,atazanavir,increased
Antiviral Medications,Ischemic Stroke,Peer Interaction,23451,23451,23451,23451,21427402,abacavir,myocardial infarction,not found,negative,HR,0.7,0.2,2.4,abacavir,C0663655,"T114, T121",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abacavir,abacavir,increased
Antiviral Medications,Ischemic Stroke,Peer Interaction,23454,23454,23454,23454,21427402,abacavir,myocardial infarction,not found,negative,HR,0.6,0.3,1.4,abacavir,C0663655,"T114, T121",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abacavir,abacavir,increased
Antiviral Medications,Ischemic Stroke,Peer Interaction,108631,108631,108631,108631,25595744,HIV,myocardial infarction,not found,negative,IRR,1.01,0.41,2.54,HIV,C0019682,T005,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,HIV,HIV,increased
Antiviral Medications,Ischemic Stroke,Peer Interaction,108632,108632,108632,108632,25595744,HIV,myocardial infarction,increase,positive,IRR,1.78,0.75,4.24,HIV,C0019682,T005,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,HIV,HIV,increased
Antiviral Medications,Ischemic Stroke,Peer Interaction,121823,121823,121823,121823,31828320,atazanavir,myocardial infarction,not found,negative,OR,1.54,0.87,2.73,atazanavir,C1145759,T109|T121,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,atazanavir,atazanavir,increased
Antiviral Medications,Viral Infections,Peer Interaction,33397,33397,33397,33397,10536125,oseltamivir,culture-proved influenza,decrease,positive,RR,0.13,0.04,0.35,oseltamivir,C0874161,"T109, T121",api,Influenza,C0021400,T047,scispacy,RCT,1,oseltamivir,oseltamivir,increased
Immunosuppression And Immunomodulatory Therapy,Adverse Drug Reactions,Peer Interaction,90141,90141,90141,90141,28487395,rituximab,any adverse event,decrease,positive,HR,0.27,0.16,0.44,rituximab,C0393022,T116|T121|T129,cohort_kg,Adverse event,C0877248,T046,cohort_kg,OS,1,rituximab,rituximab,increased
Immunosuppression And Immunomodulatory Therapy,Dermatitis,Peer Interaction,17735,17735,17735,17735,25372085,rituximab,major relapse,decrease,positive,HR,6.61,1.56,27.96,rituximab,C0393022,"T116, T121, T129",api,"Dermatitis (chronic or chronically relapsing, major feature)",C1864160,T033,api,RCT,1,rituximab,rituximab,increased
Immunosuppression And Immunomodulatory Therapy,Arthritis And Inflammatory Disorders,Peer Interaction,10503,10503,10503,10503,30504445,rituximab,arthritis,decrease,positive,HR,0.45,0.154,1.322,rituximab,C0393022,"T116, T121, T129",api,Arthritis,C0003864,T047,api,RCT,1,rituximab,rituximab,increased
Immunosuppression And Immunomodulatory Therapy,Risk Factors And Risk Assessment,Peer Interaction,88105,88105,88105,88105,27899372,rituximab,malignancy risk,not found,negative,SIR,0.67,0.08,2.43,rituximab,C0393022,T116|T121|T129,cohort_kg,Cancer Risk,C0596244,T081,cohort_kg,OS,1,rituximab,rituximab,increased
Immunosuppression And Immunomodulatory Therapy,Risk Factors And Risk Assessment,Peer Interaction,88107,88107,88107,88107,27899372,rituximab,malignancy risk,decrease,positive,SIR,0.22,0.03,0.86,rituximab,C0393022,T116|T121|T129,cohort_kg,Cancer Risk,C0596244,T081,cohort_kg,OS,1,rituximab,rituximab,increased
Immunosuppression And Immunomodulatory Therapy,Infection,Peer Interaction,6764,6764,6764,6764,34097368,rituximab,number of disease flares,decrease,positive,RR,0.12,0.05,0.29,rituximab,C0393022,"T116, T121, T129",api,Disease,C0012634,T047,scispacy,RCT,1,rituximab,rituximab,increased
Immunosuppression And Immunomodulatory Therapy,Infection,Peer Interaction,111217,111217,111217,111217,26315675,rituximab,hospitalized infection,increase,positive,HR,1.36,1.21,1.53,rituximab,C0393022,T116|T121|T129,cohort_kg,"Infections, Hospital",C0205721,T047,cohort_kg,OS,1,rituximab,rituximab,increased
Immunosuppression And Immunomodulatory Therapy,Infection,Peer Interaction,119440,119440,119440,119440,31108503,rituximab,hospitalized infection,increase,positive,RR,8.9,5.7,13.52,rituximab,C0393022,T116|T121|T129,cohort_kg,"Infections, Hospital",C0205721,T047,cohort_kg,OS,1,rituximab,rituximab,increased
Race And Ethnicity,Diabetes Mellitus,Peer Interaction,103771,103771,103771,103771,36534444,Black race,progressively worsening glycemic control and obesity,increase,positive,RRR,3.0,1.3,6.8,Black race,,,cohort_kg,obesity in diabetes,C2945676,T033,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Obesity And Body Mass Index,Peer Interaction,103771,103771,103771,103771,36534444,Black race,progressively worsening glycemic control and obesity,increase,positive,RRR,3.0,1.3,6.8,Black race,,,cohort_kg,obesity in diabetes,C2945676,T033,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Heart Failure,Peer Interaction,100166,100166,100166,100166,35086658,Black race,heart failure,increase,positive,HR,1.65,1.07,2.53,Black race,,,cohort_kg,Heart failure,C0018801,T047,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Heart Failure,Peer Interaction,100167,100167,100167,100167,35086658,Black race,heart failure with reduced ejection fraction,increase,positive,HR,2.55,1.46,4.44,Black race,,,cohort_kg,Heart failure with reduced ejection fraction,C3839346,T047,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Obesity,Peer Interaction,103771,103771,103771,103771,36534444,Black race,progressively worsening glycemic control and obesity,increase,positive,RRR,3.0,1.3,6.8,Black race,,,cohort_kg,obesity in diabetes,C2945676,T033,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Obesity And Glycemic Control,Peer Interaction,103770,103770,103770,103770,36534444,Black race,worsening glycemic control and concurrent BMI z-score decrease,increase,positive,RRR,3.0,1.3,6.8,Black race,,,cohort_kg,worsening glycemic control and concurrent BMI z-score decrease,,,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Obesity And Glycemic Control,Peer Interaction,103771,103771,103771,103771,36534444,Black race,progressively worsening glycemic control and obesity,increase,positive,RRR,3.0,1.3,6.8,Black race,,,cohort_kg,obesity in diabetes,C2945676,T033,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Remote Monitoring And Telehealth Services,Peer Interaction,97891,97891,97891,97891,34245753,Black race,completion of any type of telemedicine encounter,increase,positive,OR,1.97,1.33,2.94,Black race,,,cohort_kg,Telemedicine Visit,C5419157,T058,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Coronary Artery Disease,Peer Interaction,106442,106442,106442,106442,37579311,Black race,cardiovascular disease mortality,increase,positive,HR,1.54,1.34,1.77,Black race,,,cohort_kg,cardiovascular morbidity,C1301700,T047,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Coronary Artery Disease,Peer Interaction,106443,106443,106443,106443,37579311,Black race,cardiovascular disease mortality,not found,negative,HR,1.04,0.9,1.21,Black race,,,cohort_kg,cardiovascular morbidity,C1301700,T047,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Cardiovascular Disease And Hemodynamic Support,Peer Interaction,106442,106442,106442,106442,37579311,Black race,cardiovascular disease mortality,increase,positive,HR,1.54,1.34,1.77,Black race,,,cohort_kg,cardiovascular morbidity,C1301700,T047,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Cardiovascular Disease And Hemodynamic Support,Peer Interaction,106443,106443,106443,106443,37579311,Black race,cardiovascular disease mortality,not found,negative,HR,1.04,0.9,1.21,Black race,,,cohort_kg,cardiovascular morbidity,C1301700,T047,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Kidney Disease And Renal Replacement Therapy,Peer Interaction,101600,101600,101600,101600,35667006,Black race,kidney failure with replacement therapy,increase,positive,HR,2.8,1.6,4.9,Black race,,,cohort_kg,Renal Replacement Therapy,C0206074,T061,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Kidney Disease And Renal Replacement Therapy,Peer Interaction,101601,101601,101601,101601,35667006,Black race,kidney failure with replacement therapy,not found,negative,HR,1.3,0.8,2.1,Black race,,,cohort_kg,Renal Replacement Therapy,C0206074,T061,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Kidney Disease And Renal Replacement Therapy,Peer Interaction,126105,126105,126105,126105,33186136,Black race,requiring renal replacement therapy,increase,positive,OR,1.8,1.0,3.1,Black race,,,cohort_kg,Renal Replacement Therapy,C0206074,T061,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Inflammatory Disorders,Peer Interaction,129492,129492,129492,129492,39551068,Black race,colitis,decrease,positive,HR,0.46,0.27,0.76,Black race,,,cohort_kg,Colitis,C0009319,T047,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Immunosuppression And Immunomodulatory Therapy,Peer Interaction,129490,129490,129490,129490,39551068,Black race,immune-related adverse events requiring treatment with systemic steroids,decrease,positive,HR,0.61,0.46,0.81,Black race,,,cohort_kg,Adverse effects in the therapeutic use of immunosuppressive agents,C0496526,T037,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Immune-Mediated Disease,Peer Interaction,129489,129489,129489,129489,39551068,Black race,all-grade immune-related adverse events,decrease,positive,HR,0.75,0.62,0.9,Black race,,,cohort_kg,Immune Related Adverse Event,C5670017,T033,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Cardiovascular Disease,Peer Interaction,106442,106442,106442,106442,37579311,Black race,cardiovascular disease mortality,increase,positive,HR,1.54,1.34,1.77,Black race,,,cohort_kg,cardiovascular morbidity,C1301700,T047,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Cardiovascular Disease,Peer Interaction,106443,106443,106443,106443,37579311,Black race,cardiovascular disease mortality,not found,negative,HR,1.04,0.9,1.21,Black race,,,cohort_kg,cardiovascular morbidity,C1301700,T047,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Healthcare Access,Peer Interaction,103311,103311,103311,103311,36322057,Black race,mental health care utilization,increase,positive,RR,1.64,1.23,2.19,Black race,,,cohort_kg,mental health access,C3244252,T170,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Cerebrovascular Disease,Peer Interaction,106442,106442,106442,106442,37579311,Black race,cardiovascular disease mortality,increase,positive,HR,1.54,1.34,1.77,Black race,,,cohort_kg,cardiovascular morbidity,C1301700,T047,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Cerebrovascular Disease,Peer Interaction,106443,106443,106443,106443,37579311,Black race,cardiovascular disease mortality,not found,negative,HR,1.04,0.9,1.21,Black race,,,cohort_kg,cardiovascular morbidity,C1301700,T047,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Transplantation And Renal Replacement Therapy,Peer Interaction,101600,101600,101600,101600,35667006,Black race,kidney failure with replacement therapy,increase,positive,HR,2.8,1.6,4.9,Black race,,,cohort_kg,Renal Replacement Therapy,C0206074,T061,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Transplantation And Renal Replacement Therapy,Peer Interaction,101601,101601,101601,101601,35667006,Black race,kidney failure with replacement therapy,not found,negative,HR,1.3,0.8,2.1,Black race,,,cohort_kg,Renal Replacement Therapy,C0206074,T061,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Transplantation And Renal Replacement Therapy,Peer Interaction,126105,126105,126105,126105,33186136,Black race,requiring renal replacement therapy,increase,positive,OR,1.8,1.0,3.1,Black race,,,cohort_kg,Renal Replacement Therapy,C0206074,T061,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Ischemic Stroke And Cardiovascular Events,Peer Interaction,106442,106442,106442,106442,37579311,Black race,cardiovascular disease mortality,increase,positive,HR,1.54,1.34,1.77,Black race,,,cohort_kg,cardiovascular morbidity,C1301700,T047,cohort_kg,OS,1,Black race,race,increased
Race And Ethnicity,Ischemic Stroke And Cardiovascular Events,Peer Interaction,106443,106443,106443,106443,37579311,Black race,cardiovascular disease mortality,not found,negative,HR,1.04,0.9,1.21,Black race,,,cohort_kg,cardiovascular morbidity,C1301700,T047,cohort_kg,OS,1,Black race,race,increased
Hematologic Disease,Asthma And Obstructive Lung Disease,Peer Interaction,37042,37042,37042,37042,31380560,iron,asthma,not found,negative,OR,1.0,0.91,1.1,iron,C0302583,"T121, T123, T196",api,Asthma,C0004096,T047,api,MR,1,iron,iron,increased
Gastrointestinal Disease,Gastroesophageal Reflux Disease,Peer Interaction,110985,110985,110985,110985,26255560,Clostridium difficile infection,gastroesophageal reflux disease,increase,positive,RR,1.9,1.4,2.6,Clostridium difficile infection,C0343386,T047,cohort_kg,Gastroesophageal reflux disease,C0017168,T047,cohort_kg,OS,1,Clostridium difficile infection,clostridium difficile infection,increased
Gastrointestinal Disease,Arthritis And Inflammatory Disorders,Peer Interaction,85850,85850,85850,85850,27182697,Clostridium difficile infection,reactive arthritis,increase,positive,OR,7.1,1.6,31.7,Clostridium difficile infection,C0343386,T047,cohort_kg,"Arthritis, Reactive",C0085435,T047,cohort_kg,OS,1,Clostridium difficile infection,clostridium difficile infection,increased
Physical Activity Level,Diabetes Mellitus,Peer Interaction,129204,129204,129204,129204,39324186,regular physical activity,diabetes,decrease,positive,HR,0.54,0.48,0.6,regular physical activity,C0815170,T056,cohort_kg,Diabetes,C0011847,T047,cohort_kg,OS,1,regular physical activity,physical activity,increased
Physical Activity Level,Hypertension,Peer Interaction,129202,129202,129202,129202,39324186,regular physical activity,hypertension,decrease,positive,HR,0.72,0.68,0.77,regular physical activity,C0815170,T056,cohort_kg,Hypertension (variable),C3280772,T033,cohort_kg,OS,1,regular physical activity,physical activity,increased
Physical Activity Level,Obesity And Body Mass Index,Peer Interaction,129206,129206,129206,129206,39324186,regular physical activity,obesity,decrease,positive,HR,0.44,0.4,0.5,regular physical activity,C0815170,T056,cohort_kg,Obesity,C0028754,T047,cohort_kg,OS,1,regular physical activity,physical activity,increased
Physical Activity Level,Obesity,Peer Interaction,129206,129206,129206,129206,39324186,regular physical activity,obesity,decrease,positive,HR,0.44,0.4,0.5,regular physical activity,C0815170,T056,cohort_kg,Obesity,C0028754,T047,cohort_kg,OS,1,regular physical activity,physical activity,increased
Physical Activity Level,Obesity And Glycemic Control,Peer Interaction,129206,129206,129206,129206,39324186,regular physical activity,obesity,decrease,positive,HR,0.44,0.4,0.5,regular physical activity,C0815170,T056,cohort_kg,Obesity,C0028754,T047,cohort_kg,OS,1,regular physical activity,physical activity,increased
Physical Activity Level,Dementia,Peer Interaction,84247,84247,84247,84247,16108937,activity level,cognitive impairment,decrease,positive,OR,0.32,0.12,0.84,activity level,C0683317,T033,cohort_kg,Impaired cognition,C0338656,T048,cohort_kg,OS,1,activity level,activity level,increased
Physical Activity Level,Dementia,Peer Interaction,100494,100494,100494,100494,35192690,regular physical activity,all-cause dementia,decrease,positive,HR,0.82,0.75,0.9,regular physical activity,C0815170,T056,cohort_kg,Dementia,C0497327,T048,cohort_kg,OS,1,regular physical activity,physical activity,increased
Physical Activity Level,Dementia,Peer Interaction,100495,100495,100495,100495,35192690,regular physical activity,Alzheimer disease,decrease,positive,HR,0.85,0.77,0.95,regular physical activity,C0815170,T056,cohort_kg,Alzheimer's Disease,C0002395,T047,cohort_kg,OS,1,regular physical activity,physical activity,increased
Physical Activity Level,Dementia,Peer Interaction,100496,100496,100496,100496,35192690,regular physical activity,vascular dementia,decrease,positive,HR,0.78,0.61,0.99,regular physical activity,C0815170,T056,cohort_kg,"Dementia, Vascular",C0011269,T047,cohort_kg,OS,1,regular physical activity,physical activity,increased
Physical Activity Level,Dementia Including Alzheimer Disease,Peer Interaction,100494,100494,100494,100494,35192690,regular physical activity,all-cause dementia,decrease,positive,HR,0.82,0.75,0.9,regular physical activity,C0815170,T056,cohort_kg,Dementia,C0497327,T048,cohort_kg,OS,1,regular physical activity,physical activity,increased
Physical Activity Level,Dementia Including Alzheimer Disease,Peer Interaction,100495,100495,100495,100495,35192690,regular physical activity,Alzheimer disease,decrease,positive,HR,0.85,0.77,0.95,regular physical activity,C0815170,T056,cohort_kg,Alzheimer's Disease,C0002395,T047,cohort_kg,OS,1,regular physical activity,physical activity,increased
Physical Activity Level,Dementia Including Alzheimer Disease,Peer Interaction,100496,100496,100496,100496,35192690,regular physical activity,vascular dementia,decrease,positive,HR,0.78,0.61,0.99,regular physical activity,C0815170,T056,cohort_kg,"Dementia, Vascular",C0011269,T047,cohort_kg,OS,1,regular physical activity,physical activity,increased
Physical Activity Level,Cerebrovascular Disease,Peer Interaction,100496,100496,100496,100496,35192690,regular physical activity,vascular dementia,decrease,positive,HR,0.78,0.61,0.99,regular physical activity,C0815170,T056,cohort_kg,"Dementia, Vascular",C0011269,T047,cohort_kg,OS,1,regular physical activity,physical activity,increased
Medication Use,Stroke Or Transient Ischemic Attack,Peer Interaction,30955,30955,30955,30955,14643116,ximelagatran,stroke or systemic embolism,decrease,positive,RR,0.71,0.48,1.065,ximelagatran,C0966370,"T109, T121",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,ximelagatran,ximelagatran,increased
Medication Use,Thrombosis And Thromboembolism,Peer Interaction,29235,29235,29235,29235,16203879,ximelagatran,venous thromboembolism,decrease,positive,RR,0.705,0.625,0.795,ximelagatran,C0966370,"T109, T121",api,Venous Thromboembolism,C1861172,T047,api,RCT,1,ximelagatran,ximelagatran,increased
Medication Use,Thrombosis And Thromboembolism,Peer Interaction,58482,58482,58482,58482,16778256,argatroban,thrombotic composite risk,decrease,positive,HR,0.33,0.2,0.54,argatroban,C0048470,T116|T121,cohort_kg,Risk for venous thromboembolism,C3496592,T033,cohort_kg,OS,1,argatroban,argatroban,increased
Medication Use,Thrombosis And Thromboembolism,Peer Interaction,58483,58483,58483,58483,16778256,argatroban,thrombotic composite risk in HIT with thrombosis,decrease,positive,HR,0.39,0.25,0.62,argatroban,C0048470,T116|T121,cohort_kg,One or more high risk factors for thromboembolism or more than one moderate risk factor for thromboembolism,C3534738,T033,cohort_kg,OS,1,argatroban,argatroban,increased
Medication Use,Cerebrovascular Disease,Peer Interaction,30955,30955,30955,30955,14643116,ximelagatran,stroke or systemic embolism,decrease,positive,RR,0.71,0.48,1.065,ximelagatran,C0966370,"T109, T121",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,ximelagatran,ximelagatran,increased
Medication Use,Ischemic Stroke And Cardiovascular Events,Peer Interaction,30955,30955,30955,30955,14643116,ximelagatran,stroke or systemic embolism,decrease,positive,RR,0.71,0.48,1.065,ximelagatran,C0966370,"T109, T121",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,ximelagatran,ximelagatran,increased
Medication Use,Hemorrhagic Stroke,Peer Interaction,30955,30955,30955,30955,14643116,ximelagatran,stroke or systemic embolism,decrease,positive,RR,0.71,0.48,1.065,ximelagatran,C0966370,"T109, T121",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,ximelagatran,ximelagatran,increased
Medication Use,Ischemic Stroke,Peer Interaction,30955,30955,30955,30955,14643116,ximelagatran,stroke or systemic embolism,decrease,positive,RR,0.71,0.48,1.065,ximelagatran,C0966370,"T109, T121",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,ximelagatran,ximelagatran,increased
Medication Use,Venous Thromboembolism,Peer Interaction,29235,29235,29235,29235,16203879,ximelagatran,venous thromboembolism,decrease,positive,RR,0.705,0.625,0.795,ximelagatran,C0966370,"T109, T121",api,Venous Thromboembolism,C1861172,T047,api,RCT,1,ximelagatran,ximelagatran,increased
Medication Use,Venous Thromboembolism,Peer Interaction,58482,58482,58482,58482,16778256,argatroban,thrombotic composite risk,decrease,positive,HR,0.33,0.2,0.54,argatroban,C0048470,T116|T121,cohort_kg,Risk for venous thromboembolism,C3496592,T033,cohort_kg,OS,1,argatroban,argatroban,increased
Pregnancy-Related Infections And Complications,Diabetes Mellitus,Peer Interaction,25605,25605,25605,25605,19066370,selenium,type 2 diabetes mellitus,not found,negative,RR,1.07,0.94,1.22,selenium,C0036581,"T121, T123, T196",api,"Diabetes Mellitus, Non-Insulin-Dependent",C0011860,T047,api,RCT,1,selenium,selenium,increased
Pregnancy-Related Infections And Complications,Diabetes Mellitus,Peer Interaction,25915,25915,25915,25915,19491386,vitamin E,type 2 diabetes,not found,negative,RR,1.13,0.99,1.29,vitamin E,C0042874,"T109, T121, T127",api,"Diabetes Mellitus, Non-Insulin-Dependent",C0011860,T047,api,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Diabetes Mellitus,Peer Interaction,53929,53929,53929,53929,14747214,vitamin E,type 2 diabetes,decrease,positive,RR,0.69,0.51,0.94,vitamin E,C0042874,T109|T121|T127,cohort_kg,Type 2 diabetes (Adult onset),C3842544,T047,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Stroke Or Transient Ischemic Attack,Peer Interaction,26414,26414,26414,26414,18997197,vitamin E,hemorrhagic stroke,increase,positive,HR,1.74,1.04,2.91,vitamin E,C0042874,"T109, T121, T127",api,Hemorrhagic Stroke,C5234922,T047,api,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Stroke Or Transient Ischemic Attack,Peer Interaction,46114,46114,46114,46114,10383366,vitamin E,ischemic stroke,not found,negative,relative risk,1.18,0.77,1.82,vitamin E,C0042874,T109|T121|T127,cohort_kg,Ischemic stroke,C0948008,T047,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Chronic Kidney Disease,Peer Interaction,23480,23480,23480,23480,21257986,vitamin E,chronic lung disease,decrease,positive,HR,0.9,0.81,0.99,vitamin E,C0042874,"T109, T121, T127",api,Chronic lung disease,C0746102,T047,api,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Coronary Artery Disease,Peer Interaction,29628,29628,29628,29628,15998891,vitamin E,myocardial infarction,not found,negative,RR,1.01,0.82,1.23,vitamin E,C0042874,"T109, T121, T127",api,Myocardial Infarction,C0027051,T047,api,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Coronary Artery Disease,Peer Interaction,34815,34815,34815,34815,8594266,alpha tocopherol,angina pectoris,not found,negative,RR,0.97,0.85,1.1,alpha tocopherol,C0969677,"T109, T121, T127",api,Angina Pectoris,C0002962,T184,api,RCT,1,alpha tocopherol,alpha tocopherol,increased
Pregnancy-Related Infections And Complications,Coronary Artery Disease,Peer Interaction,34816,34816,34816,34816,8594266,alpha tocopherol,angina pectoris,decrease,positive,RR,0.91,0.83,0.99,alpha tocopherol,C0969677,"T109, T121, T127",api,Angina Pectoris,C0002962,T184,api,RCT,1,alpha tocopherol,alpha tocopherol,increased
Pregnancy-Related Infections And Complications,Coronary Artery Disease,Peer Interaction,42081,42081,42081,42081,8479464,vitamin E,coronary heart disease,decrease,positive,relative risk,0.64,0.49,0.83,vitamin E,C0042874,T109|T121|T127,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Coronary Artery Disease,Peer Interaction,55949,55949,55949,55949,15585762,vitamin E,coronary heart disease,not found,negative,RR,0.84,0.71,1.0,vitamin E,C0042874,T109|T121|T127,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Coronary Artery Disease,Peer Interaction,91942,91942,91942,91942,29064788,selenium,coronary heart disease,decrease,positive,OR,0.67,0.52,0.85,selenium,C0036581,T121|T123|T196,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,selenium,selenium,increased
Pregnancy-Related Infections And Complications,Malignant Neoplasm With Metastasis,Peer Interaction,29631,29631,29631,29631,15998891,vitamin E,total invasive cancer,not found,negative,RR,1.01,0.94,1.08,vitamin E,C0042874,"T109, T121, T127",api,Invasive Malignant Neoplasm,C0677898,T191,scispacy,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Dementia,Peer Interaction,29521,29521,29521,29521,15829527,vitamin E,Alzheimer's disease,not found,negative,HR,1.02,0.74,1.41,vitamin E,C0042874,"T109, T121, T127",api,Alzheimer's Disease,C0002395,T047,api,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Dementia,Peer Interaction,47992,47992,47992,47992,11037017,selenium,cognitive decline,increase,positive,OR,1.58,1.08,2.31,selenium,C0036581,T121|T123|T196,cohort_kg,Cognitive deterioration,C0854193,T048,cohort_kg,OS,1,selenium,selenium,increased
Pregnancy-Related Infections And Complications,Dementia,Peer Interaction,50722,50722,50722,50722,12076218,vitamin E,Alzheimer disease,decrease,positive,RR,0.82,0.66,1.0,vitamin E,C0042874,T109|T121|T127,cohort_kg,Alzheimer's Disease,C0002395,T047,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Dementia,Peer Interaction,56323,56323,56323,56323,15699242,vitamin E,Alzheimer disease,decrease,positive,relative risk,0.74,0.62,0.88,vitamin E,C0042874,T109|T121|T127,cohort_kg,Alzheimer's Disease,C0002395,T047,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Dementia,Peer Interaction,62480,62480,62480,62480,18047492,vitamin E,dementia,not found,negative,HR,0.98,0.77,1.25,vitamin E,C0042874,T109|T121|T127,cohort_kg,Dementia,C0497327,T048,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Dementia,Peer Interaction,62481,62481,62481,62481,18047492,vitamin E,Alzheimer's disease,not found,negative,HR,1.04,0.78,1.39,vitamin E,C0042874,T109|T121|T127,cohort_kg,Alzheimer's Disease,C0002395,T047,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Chronic Respiratory Disease,Peer Interaction,23480,23480,23480,23480,21257986,vitamin E,chronic lung disease,decrease,positive,HR,0.9,0.81,0.99,vitamin E,C0042874,"T109, T121, T127",api,Chronic lung disease,C0746102,T047,api,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Dementia Including Alzheimer Disease,Peer Interaction,29521,29521,29521,29521,15829527,vitamin E,Alzheimer's disease,not found,negative,HR,1.02,0.74,1.41,vitamin E,C0042874,"T109, T121, T127",api,Alzheimer's Disease,C0002395,T047,api,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Dementia Including Alzheimer Disease,Peer Interaction,50722,50722,50722,50722,12076218,vitamin E,Alzheimer disease,decrease,positive,RR,0.82,0.66,1.0,vitamin E,C0042874,T109|T121|T127,cohort_kg,Alzheimer's Disease,C0002395,T047,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Dementia Including Alzheimer Disease,Peer Interaction,56323,56323,56323,56323,15699242,vitamin E,Alzheimer disease,decrease,positive,relative risk,0.74,0.62,0.88,vitamin E,C0042874,T109|T121|T127,cohort_kg,Alzheimer's Disease,C0002395,T047,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Dementia Including Alzheimer Disease,Peer Interaction,62480,62480,62480,62480,18047492,vitamin E,dementia,not found,negative,HR,0.98,0.77,1.25,vitamin E,C0042874,T109|T121|T127,cohort_kg,Dementia,C0497327,T048,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Dementia Including Alzheimer Disease,Peer Interaction,62481,62481,62481,62481,18047492,vitamin E,Alzheimer's disease,not found,negative,HR,1.04,0.78,1.39,vitamin E,C0042874,T109|T121|T127,cohort_kg,Alzheimer's Disease,C0002395,T047,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Cardiovascular Disease,Peer Interaction,34784,34784,34784,34784,8622332,vitamin E,cardiovascular death and non-fatal myocardial infarction,decrease,positive,RR,0.53,0.34,0.83,vitamin E,C0042874,"T109, T121, T127",api,Cardiovascular system,C0007226,T022,scispacy,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Cardiovascular Disease,Peer Interaction,42081,42081,42081,42081,8479464,vitamin E,coronary heart disease,decrease,positive,relative risk,0.64,0.49,0.83,vitamin E,C0042874,T109|T121|T127,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Cardiovascular Disease,Peer Interaction,48926,48926,48926,48926,11380744,vitamin E,cardiovascular events,decrease,positive,RR,0.16,0.04,0.55,vitamin E,C0042874,T109|T121|T127,cohort_kg,cardiovascular event,C1320716,T033,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Cardiovascular Disease,Peer Interaction,55949,55949,55949,55949,15585762,vitamin E,coronary heart disease,not found,negative,RR,0.84,0.71,1.0,vitamin E,C0042874,T109|T121|T127,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Cardiovascular Disease,Peer Interaction,91942,91942,91942,91942,29064788,selenium,coronary heart disease,decrease,positive,OR,0.67,0.52,0.85,selenium,C0036581,T121|T123|T196,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,selenium,selenium,increased
Pregnancy-Related Infections And Complications,Malignant Neoplasm,Peer Interaction,29631,29631,29631,29631,15998891,vitamin E,total invasive cancer,not found,negative,RR,1.01,0.94,1.08,vitamin E,C0042874,"T109, T121, T127",api,Invasive Malignant Neoplasm,C0677898,T191,scispacy,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Malignant Neoplasm,Peer Interaction,29632,29632,29632,29632,15998891,vitamin E,breast cancer,not found,negative,RR,1.0,0.9,1.12,vitamin E,C0042874,"T109, T121, T127",api,Malignant neoplasm of breast,C0006142,T191,api,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Infection,Peer Interaction,22633,22633,22633,22633,21415104,selenium,new infections,not found,negative,OR,0.81,0.57,1.15,selenium,C0036581,"T121, T123, T196",api,New infection,C0439633,T079,api,RCT,1,selenium,selenium,increased
Pregnancy-Related Infections And Complications,Infection,Peer Interaction,22634,22634,22634,22634,21415104,selenium,new infections,decrease,positive,OR,0.53,0.3,0.93,selenium,C0036581,"T121, T123, T196",api,New infection,C0439633,T079,api,RCT,1,selenium,selenium,increased
Pregnancy-Related Infections And Complications,Infection,Peer Interaction,30717,30717,30717,30717,15315997,vitamin E,respiratory tract infections,decrease,positive,RR,0.88,0.76,1.0,vitamin E,C0042874,"T109, T121, T127",api,Respiratory Tract Infections,C0035243,T047,api,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Cerebrovascular Disease,Peer Interaction,46114,46114,46114,46114,10383366,vitamin E,ischemic stroke,not found,negative,relative risk,1.18,0.77,1.82,vitamin E,C0042874,T109|T121|T127,cohort_kg,Ischemic stroke,C0948008,T047,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Ischemic Stroke And Cardiovascular Events,Peer Interaction,29628,29628,29628,29628,15998891,vitamin E,myocardial infarction,not found,negative,RR,1.01,0.82,1.23,vitamin E,C0042874,"T109, T121, T127",api,Myocardial Infarction,C0027051,T047,api,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Ischemic Stroke And Cardiovascular Events,Peer Interaction,34815,34815,34815,34815,8594266,alpha tocopherol,angina pectoris,not found,negative,RR,0.97,0.85,1.1,alpha tocopherol,C0969677,"T109, T121, T127",api,Angina Pectoris,C0002962,T184,api,RCT,1,alpha tocopherol,alpha tocopherol,increased
Pregnancy-Related Infections And Complications,Ischemic Stroke And Cardiovascular Events,Peer Interaction,34816,34816,34816,34816,8594266,alpha tocopherol,angina pectoris,decrease,positive,RR,0.91,0.83,0.99,alpha tocopherol,C0969677,"T109, T121, T127",api,Angina Pectoris,C0002962,T184,api,RCT,1,alpha tocopherol,alpha tocopherol,increased
Pregnancy-Related Infections And Complications,Ischemic Stroke And Cardiovascular Events,Peer Interaction,46114,46114,46114,46114,10383366,vitamin E,ischemic stroke,not found,negative,relative risk,1.18,0.77,1.82,vitamin E,C0042874,T109|T121|T127,cohort_kg,Ischemic stroke,C0948008,T047,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Ischemic Stroke And Cardiovascular Events,Peer Interaction,48926,48926,48926,48926,11380744,vitamin E,cardiovascular events,decrease,positive,RR,0.16,0.04,0.55,vitamin E,C0042874,T109|T121|T127,cohort_kg,cardiovascular event,C1320716,T033,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Hemorrhagic Stroke,Peer Interaction,26414,26414,26414,26414,18997197,vitamin E,hemorrhagic stroke,increase,positive,HR,1.74,1.04,2.91,vitamin E,C0042874,"T109, T121, T127",api,Hemorrhagic Stroke,C5234922,T047,api,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Hemorrhagic Stroke,Peer Interaction,46114,46114,46114,46114,10383366,vitamin E,ischemic stroke,not found,negative,relative risk,1.18,0.77,1.82,vitamin E,C0042874,T109|T121|T127,cohort_kg,Ischemic stroke,C0948008,T047,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Ischemic Stroke,Peer Interaction,26414,26414,26414,26414,18997197,vitamin E,hemorrhagic stroke,increase,positive,HR,1.74,1.04,2.91,vitamin E,C0042874,"T109, T121, T127",api,Hemorrhagic Stroke,C5234922,T047,api,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Ischemic Stroke,Peer Interaction,29628,29628,29628,29628,15998891,vitamin E,myocardial infarction,not found,negative,RR,1.01,0.82,1.23,vitamin E,C0042874,"T109, T121, T127",api,Myocardial Infarction,C0027051,T047,api,RCT,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Ischemic Stroke,Peer Interaction,46114,46114,46114,46114,10383366,vitamin E,ischemic stroke,not found,negative,relative risk,1.18,0.77,1.82,vitamin E,C0042874,T109|T121|T127,cohort_kg,Ischemic stroke,C0948008,T047,cohort_kg,OS,1,vitamin E,vitamin,increased
Pregnancy-Related Infections And Complications,Viral Infections,Peer Interaction,30717,30717,30717,30717,15315997,vitamin E,respiratory tract infections,decrease,positive,RR,0.88,0.76,1.0,vitamin E,C0042874,"T109, T121, T127",api,Respiratory Tract Infections,C0035243,T047,api,RCT,1,vitamin E,vitamin,increased
Malignant Neoplasm,Arthritis And Inflammatory Disorders,Peer Interaction,98360,98360,98360,98360,34397169,melanoma,rheumatic immune-related adverse events,increase,positive,OR,4.06,2.54,6.51,melanoma,C0025202,T191,cohort_kg,Immune-mediated/reactive arthropathies,C5225749,T047,cohort_kg,OS,1,melanoma,melanoma,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Activities Of Daily Living Limitation,Peer Interaction,114680,114680,114680,114680,24779559,hearing impairment,physical disability in activities of daily living,increase,positive,OR,1.4,1.1,1.9,hearing impairment,C1384666,T047,cohort_kg,Disability affecting daily living,C1446368,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Activities Of Daily Living Limitation,Peer Interaction,114681,114681,114681,114681,24779559,hearing impairment,physical disability in instrumental activities of daily living,increase,positive,OR,1.6,1.2,2.2,hearing impairment,C1384666,T047,cohort_kg,Impairment of activities of daily living,C4476938,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Activities Of Daily Living Limitation,Peer Interaction,114683,114683,114683,114683,24779559,hearing impairment,physical disability in lower extremity mobility,increase,positive,OR,1.4,1.1,1.7,hearing impairment,C1384666,T047,cohort_kg,Mobility Limitation,C1565249,T184,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Activities Of Daily Living Limitation,Peer Interaction,114686,114686,114686,114686,24779559,hearing impairment,walking limitation,increase,positive,OR,1.6,1.3,2.0,hearing impairment,C1384666,T047,cohort_kg,Limited Walking Ability,C2674459,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Dementia,Peer Interaction,87296,87296,87296,87296,27611845,hearing impairment,cognitive impairment,increase,positive,HR,1.9,1.11,3.26,hearing impairment,C1384666,T047,cohort_kg,Impaired cognition,C0338656,T048,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Dementia,Peer Interaction,96252,96252,96252,96252,33734430,hearing impairment,all-cause dementia,increase,positive,HR,1.16,1.04,1.3,hearing impairment,C1384666,T047,cohort_kg,Dementia,C0497327,T048,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Frailty And Physical Functional Status,Peer Interaction,88328,88328,88328,88328,27991672,hearing impairment,frailty,increase,positive,OR,1.66,1.37,2.01,hearing impairment,C1384666,T047,cohort_kg,Frailty,C0424594,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Frailty And Physical Functional Status,Peer Interaction,88329,88329,88329,88329,27991672,hearing impairment,prefrailty and frailty,increase,positive,OR,1.43,1.05,1.95,hearing impairment,C1384666,T047,cohort_kg,Frailty Syndrome,C4505081,T046,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Frailty And Physical Functional Status,Peer Interaction,103677,103677,103677,103677,36504135,hearing impairment,frailty,increase,positive,HR,1.31,1.12,1.74,hearing impairment,C1384666,T047,cohort_kg,Frailty,C0424594,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Employment Status And Work Disability,Peer Interaction,114685,114685,114685,114685,24779559,hearing impairment,work limitation,increase,positive,OR,1.4,1.0,1.9,hearing impairment,C1384666,T047,cohort_kg,I am limited in my work,C5212838,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Employment Status And Work Disability,Peer Interaction,114688,114688,114688,114688,24779559,hearing impairment,limitations in amount or type of work done,not found,negative,OR,1.2,1.0,1.6,hearing impairment,C1384666,T047,cohort_kg,I am limited in doing my work (include work at home),C4034816,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Dementia Including Alzheimer Disease,Peer Interaction,96252,96252,96252,96252,33734430,hearing impairment,all-cause dementia,increase,positive,HR,1.16,1.04,1.3,hearing impairment,C1384666,T047,cohort_kg,Dementia,C0497327,T048,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Frailty And Functional Status,Peer Interaction,88328,88328,88328,88328,27991672,hearing impairment,frailty,increase,positive,OR,1.66,1.37,2.01,hearing impairment,C1384666,T047,cohort_kg,Frailty,C0424594,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Frailty And Functional Status,Peer Interaction,88329,88329,88329,88329,27991672,hearing impairment,prefrailty and frailty,increase,positive,OR,1.43,1.05,1.95,hearing impairment,C1384666,T047,cohort_kg,Frailty Syndrome,C4505081,T046,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Frailty And Functional Status,Peer Interaction,103677,103677,103677,103677,36504135,hearing impairment,frailty,increase,positive,HR,1.31,1.12,1.74,hearing impairment,C1384666,T047,cohort_kg,Frailty,C0424594,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Functional Limitation,Peer Interaction,114680,114680,114680,114680,24779559,hearing impairment,physical disability in activities of daily living,increase,positive,OR,1.4,1.1,1.9,hearing impairment,C1384666,T047,cohort_kg,Disability affecting daily living,C1446368,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Functional Limitation,Peer Interaction,114681,114681,114681,114681,24779559,hearing impairment,physical disability in instrumental activities of daily living,increase,positive,OR,1.6,1.2,2.2,hearing impairment,C1384666,T047,cohort_kg,Impairment of activities of daily living,C4476938,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Functional Limitation,Peer Interaction,114683,114683,114683,114683,24779559,hearing impairment,physical disability in lower extremity mobility,increase,positive,OR,1.4,1.1,1.7,hearing impairment,C1384666,T047,cohort_kg,Mobility Limitation,C1565249,T184,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Functional Limitation,Peer Interaction,114684,114684,114684,114684,24779559,hearing impairment,physical disability in general physical activities,increase,positive,OR,1.3,1.1,1.6,hearing impairment,C1384666,T047,cohort_kg,Physical disability,C0520817,T046,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Functional Limitation,Peer Interaction,114686,114686,114686,114686,24779559,hearing impairment,walking limitation,increase,positive,OR,1.6,1.3,2.0,hearing impairment,C1384666,T047,cohort_kg,Limited Walking Ability,C2674459,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Employment And Work Disability,Peer Interaction,114685,114685,114685,114685,24779559,hearing impairment,work limitation,increase,positive,OR,1.4,1.0,1.9,hearing impairment,C1384666,T047,cohort_kg,I am limited in my work,C5212838,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Hyperglycemia And Hyperosmolar Hyperglycemic State,Employment And Work Disability,Peer Interaction,114688,114688,114688,114688,24779559,hearing impairment,limitations in amount or type of work done,not found,negative,OR,1.2,1.0,1.6,hearing impairment,C1384666,T047,cohort_kg,I am limited in doing my work (include work at home),C4034816,T033,cohort_kg,OS,1,hearing impairment,hearing impairment,increased
Antineoplastic And Immunotherapy Treatments,Diabetes Mellitus,Peer Interaction,1358,1358,1358,1358,39913634,alirocumab,new-onset type 2 diabetes,not found,negative,OR,0.998,0.86,1.158,alirocumab,C3491162,"T116, T121, T129",api,"Diabetes Mellitus, Non-Insulin-Dependent",C0011860,T047,scispacy,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Immunotherapy Treatments,Heart Failure,Peer Interaction,7081,7081,7081,7081,33332779,tocilizumab,clinical failure,decrease,positive,HR,0.55,0.33,0.93,tocilizumab,C1609165,"T116, T121, T129",api,Clinical Failure,C3640841,T033,api,RCT,1,tocilizumab,tocilizumab,increased
Antineoplastic And Immunotherapy Treatments,Heart Failure,Peer Interaction,21580,21580,21580,21580,22578446,bevacizumab,arteriothrombotic event or heart failure,decrease,positive,OR,0.23,0.05,1.07,bevacizumab,C0796392,"T116, T121, T129",api,Heart failure,C0018801,T047,scispacy,RCT,1,bevacizumab,bevacizumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke Or Transient Ischemic Attack,Peer Interaction,7383,7383,7383,7383,34537830,evolocumab,cerebrovascular events,decrease,positive,HR,0.77,0.65,0.92,evolocumab,C3529352,"T116, T121, T129",api,Transient cerebrovascular events,C0852396,T047,api,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke Or Transient Ischemic Attack,Peer Interaction,8896,8896,8896,8896,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke Or Transient Ischemic Attack,Peer Interaction,8898,8898,8898,8898,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke Or Transient Ischemic Attack,Peer Interaction,10102,10102,10102,10102,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.82,0.71,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke Or Transient Ischemic Attack,Peer Interaction,10103,10103,10103,10103,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.85,0.77,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke Or Transient Ischemic Attack,Peer Interaction,10104,10104,10104,10104,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",not found,negative,HR,0.89,0.76,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke Or Transient Ischemic Attack,Peer Interaction,10636,10636,10636,10636,31707788,alirocumab,ischemic stroke,decrease,positive,HR,0.73,0.57,0.93,alirocumab,C3491162,"T116, T121, T129",api,Ischemic stroke,C0948008,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke Or Transient Ischemic Attack,Peer Interaction,10649,10649,10649,10649,31707788,alirocumab,hemorrhagic stroke,not found,negative,HR,0.83,0.42,1.65,alirocumab,C3491162,"T116, T121, T129",api,Hemorrhagic Stroke,C5234922,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke Or Transient Ischemic Attack,Peer Interaction,12369,12369,12369,12369,29626068,evolocumab,major vascular events,decrease,positive,HR,0.8,0.71,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke Or Transient Ischemic Attack,Peer Interaction,12370,12370,12370,12370,29626068,evolocumab,major vascular events,decrease,positive,HR,0.82,0.72,0.93,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke Or Transient Ischemic Attack,Peer Interaction,12371,12371,12371,12371,29626068,evolocumab,major vascular events,decrease,positive,HR,0.79,0.69,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke Or Transient Ischemic Attack,Peer Interaction,12372,12372,12372,12372,29626068,evolocumab,major vascular events,not found,negative,HR,0.95,0.85,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke Or Transient Ischemic Attack,Peer Interaction,12373,12373,12373,12373,29626068,evolocumab,major vascular events,not found,negative,HR,0.92,0.84,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke Or Transient Ischemic Attack,Peer Interaction,12374,12374,12374,12374,29626068,evolocumab,major vascular events,not found,negative,HR,0.93,0.85,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Stroke Or Transient Ischemic Attack,Peer Interaction,124840,124840,124840,124840,32781110,bevacizumab,acute cerebrovascular disease,not found,negative,HR,1.04,0.78,1.38,bevacizumab,C0796392,T116|T121|T129,cohort_kg,Acute cerebrovascular disease,C0810006,T047,cohort_kg,OS,1,bevacizumab,bevacizumab,increased
Antineoplastic And Immunotherapy Treatments,Arteritis And Arteriosclerosis Disorders,Peer Interaction,11282,11282,11282,11282,30403574,alirocumab,"composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization",decrease,positive,HR,0.85,0.78,0.93,alirocumab,C3491162,"T116, T121, T129",api,Coronary Arteriosclerosis,C0010054,T047,scispacy,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Immunotherapy Treatments,Coronary Stent Status And Complications,Peer Interaction,8901,8901,8901,8901,31707849,evolocumab,major coronary events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Coronary artery stent (device),C0687568,T074,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Coronary Stent Status And Complications,Peer Interaction,8902,8902,8902,8902,31707849,evolocumab,major coronary events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Coronary artery stent (device),C0687568,T074,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Coronary Artery Disease,Peer Interaction,9436,9436,9436,9436,31121022,alirocumab,myocardial infarction,decrease,positive,HR,0.85,0.77,0.95,alirocumab,C3491162,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Immunotherapy Treatments,Coronary Artery Disease,Peer Interaction,11282,11282,11282,11282,30403574,alirocumab,"composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization",decrease,positive,HR,0.85,0.78,0.93,alirocumab,C3491162,"T116, T121, T129",api,Coronary Arteriosclerosis,C0010054,T047,scispacy,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Immunotherapy Treatments,Coronary Artery Disease,Peer Interaction,31749,31749,31749,31749,12021219,abciximab,myocardial infarction,decrease,positive,RR,0.68,0.53,0.87,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Coronary Artery Disease,Peer Interaction,33469,33469,33469,33469,10341274,abciximab,myocardial infarction,decrease,positive,OR,0.23,0.12,0.49,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Coronary Artery Disease,Peer Interaction,33726,33726,33726,33726,10636365,abciximab,death or large myocardial infarction,decrease,positive,HR,0.46,0.32,0.67,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,scispacy,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Coronary Artery Disease,Peer Interaction,34349,34349,34349,34349,9164316,abciximab,myocardial infarction,decrease,positive,RR,0.29,0.1,0.84,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Coronary Artery Disease,Peer Interaction,34350,34350,34350,34350,9164316,abciximab,myocardial infarction,decrease,positive,RR,0.47,0.26,0.84,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Malignant Neoplasm With Metastasis,Peer Interaction,89013,89013,89013,89013,28193515,infliximab,malignancy,not found,negative,SIR,1.69,0.46,4.32,infliximab,C0666743,T116|T121|T129,cohort_kg,malignant disease,C0442867,T047,cohort_kg,OS,1,infliximab,infliximab,increased
Antineoplastic And Immunotherapy Treatments,Gastrointestinal Diseases,Peer Interaction,19044,19044,19044,19044,24637999,bevacizumab,GI adverse events,increase,positive,OR,2.15,1.05,4.4,bevacizumab,C0796392,"T116, T121, T129",api,gastroenterology (field),C0017163,T091,scispacy,RCT,1,bevacizumab,bevacizumab,increased
Antineoplastic And Immunotherapy Treatments,Clinical Monitoring And Surveillance,Peer Interaction,7043,7043,7043,7043,33472855,tocilizumab,clinical status,not found,negative,OR,1.54,0.66,3.66,tocilizumab,C1609165,"T116, T121, T129",api,Clinical status,C0449440,T201,api,RCT,1,tocilizumab,tocilizumab,increased
Antineoplastic And Immunotherapy Treatments,General Health Status,Peer Interaction,7043,7043,7043,7043,33472855,tocilizumab,clinical status,not found,negative,OR,1.54,0.66,3.66,tocilizumab,C1609165,"T116, T121, T129",api,Clinical status,C0449440,T201,api,RCT,1,tocilizumab,tocilizumab,increased
Antineoplastic And Immunotherapy Treatments,Quality Of Life,Peer Interaction,19968,19968,19968,19968,23821759,bevacizumab,survival,decrease,positive,HR,0.52,0.29,0.94,bevacizumab,C0796392,"T116, T121, T129",api,survival aspects,C0220921,T169,api,RCT,1,bevacizumab,bevacizumab,increased
Antineoplastic And Immunotherapy Treatments,Quality Of Life,Peer Interaction,19969,19969,19969,19969,23821759,bevacizumab,survival,not found,negative,HR,1.03,0.84,1.27,bevacizumab,C0796392,"T116, T121, T129",api,survival aspects,C0220921,T169,api,RCT,1,bevacizumab,bevacizumab,increased
Antineoplastic And Immunotherapy Treatments,Quality Of Life,Peer Interaction,28824,28824,28824,28824,16481637,etanercept,asthma-related quality-of-life score,increase,positive,not found,0.85,0.16,1.54,etanercept,C0717758,"T116, T121",api,Perceived quality of life,C0518214,T033,scispacy,RCT,1,etanercept,etanercept,increased
Antineoplastic And Immunotherapy Treatments,Health-Related Quality Of Life,Peer Interaction,28824,28824,28824,28824,16481637,etanercept,asthma-related quality-of-life score,increase,positive,not found,0.85,0.16,1.54,etanercept,C0717758,"T116, T121",api,Perceived quality of life,C0518214,T033,scispacy,RCT,1,etanercept,etanercept,increased
Antineoplastic And Immunotherapy Treatments,Liver Disease,Peer Interaction,80397,80397,80397,80397,23419359,infliximab,drug-induced liver injury,increase,positive,incidence rate,675.0,184.0,718.0,infliximab,C0666743,T116|T121|T129,cohort_kg,Drug-Induced Liver Disease,C0860207,T047,cohort_kg,OS,1,infliximab,infliximab,increased
Antineoplastic And Immunotherapy Treatments,Inflammatory Disorder,Peer Interaction,3684,3684,3684,3684,35961761,secukinumab,disease flare,decrease,positive,HR,0.28,0.13,0.63,secukinumab,C3179547,"T116, T121, T129",api,Autoimmune Diseases,C0004364,T047,api,RCT,1,secukinumab,secukinumab,increased
Antineoplastic And Immunotherapy Treatments,Functional Dependence,Peer Interaction,11550,11550,11550,11550,29545067,natalizumab,sustained disability progression,not found,negative,OR,0.86,0.66,1.13,natalizumab,C1172734,"T116, T121, T129",api,Disability,C0231170,T033,scispacy,RCT,1,natalizumab,natalizumab,increased
Antineoplastic And Immunotherapy Treatments,Functional Dependence,Peer Interaction,28521,28521,28521,28521,16510744,natalizumab,sustained progression of disability,decrease,positive,HR,0.58,0.43,0.77,natalizumab,C1172734,"T116, T121, T129",api,Disability,C0231170,T033,scispacy,RCT,1,natalizumab,natalizumab,increased
Antineoplastic And Immunotherapy Treatments,Medication Use And Adherence,Peer Interaction,115798,115798,115798,115798,29981385,etanercept,adherence,increase,positive,OR,1.77,1.63,1.92,etanercept,C0717758,T116|T121,cohort_kg,Adherence (attribute),C1510802,T169,cohort_kg,OS,1,etanercept,etanercept,increased
Antineoplastic And Immunotherapy Treatments,Medication Use And Adherence,Peer Interaction,115799,115799,115799,115799,29981385,ustekinumab,adherence,increase,positive,OR,2.54,2.24,2.87,ustekinumab,C1608841,T116|T121|T129,cohort_kg,Adherence (attribute),C1510802,T169,cohort_kg,OS,1,ustekinumab,ustekinumab,increased
Antineoplastic And Immunotherapy Treatments,Depression,Peer Interaction,10801,10801,10801,10801,31066887,infliximab,depressive symptoms,not found,negative,RR,1.09,0.8,1.5,infliximab,C0666743,"T116, T121, T129",api,Depressive Symptoms,C0086132,T048,api,RCT,1,infliximab,infliximab,increased
Antineoplastic And Immunotherapy Treatments,Allergic And Hypersensitivity Disorders,Peer Interaction,3684,3684,3684,3684,35961761,secukinumab,disease flare,decrease,positive,HR,0.28,0.13,0.63,secukinumab,C3179547,"T116, T121, T129",api,Autoimmune Diseases,C0004364,T047,api,RCT,1,secukinumab,secukinumab,increased
Antineoplastic And Immunotherapy Treatments,Tuberculosis,Peer Interaction,76952,76952,76952,76952,22523429,etanercept,nontuberculous mycobacterial disease,increase,positive,rate,35.0,1.0,69.0,etanercept,C0717758,T116|T121,cohort_kg,Nontuberculous mycobacterial infections,C5543174,T047,cohort_kg,OS,1,etanercept,etanercept,increased
Antineoplastic And Immunotherapy Treatments,Tuberculosis,Peer Interaction,76953,76953,76953,76953,22523429,etanercept,tuberculosis,increase,positive,rate,17.0,0.0,41.0,etanercept,C0717758,T116|T121,cohort_kg,Tuberculosis,C0041296,T047,cohort_kg,OS,1,etanercept,etanercept,increased
Antineoplastic And Immunotherapy Treatments,Tuberculosis,Peer Interaction,76954,76954,76954,76954,22523429,infliximab,nontuberculous mycobacterial disease,increase,positive,rate,116.0,30.0,203.0,infliximab,C0666743,T116|T121|T129,cohort_kg,Nontuberculous mycobacterial infections,C5543174,T047,cohort_kg,OS,1,infliximab,infliximab,increased
Antineoplastic And Immunotherapy Treatments,Tuberculosis,Peer Interaction,76955,76955,76955,76955,22523429,infliximab,tuberculosis,increase,positive,rate,83.0,10.0,156.0,infliximab,C0666743,T116|T121|T129,cohort_kg,Tuberculosis,C0041296,T047,cohort_kg,OS,1,infliximab,infliximab,increased
Antineoplastic And Immunotherapy Treatments,Tuberculosis,Peer Interaction,114117,114117,114117,114117,24608401,infliximab,tuberculosis,not found,negative,HR,2.7,0.7,10.9,infliximab,C0666743,T116|T121|T129,cohort_kg,Tuberculosis,C0041296,T047,cohort_kg,OS,1,infliximab,infliximab,increased
Antineoplastic And Immunotherapy Treatments,Tuberculosis,Peer Interaction,114118,114118,114118,114118,24608401,etanercept,tuberculosis,not found,negative,HR,1.7,0.6,4.6,etanercept,C0717758,T116|T121,cohort_kg,Tuberculosis,C0041296,T047,cohort_kg,OS,1,etanercept,etanercept,increased
Antineoplastic And Immunotherapy Treatments,Thrombocytopenia And Platelet Disorders,Peer Interaction,30337,30337,30337,30337,15117843,abciximab,thrombocytopenia,increase,positive,OR,4.4,1.7,11.2,abciximab,C0288672,"T116, T121, T129",api,Thrombocytopenia,C0040034,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Race And Ethnicity,Peer Interaction,25829,25829,25829,25829,19665644,infliximab,good response according to European League Against Rheumatism criteria,increase,positive,RR,1.59,1.1,2.3,infliximab,C0666743,"T116, T121, T129",api,European (ethnic group),C0239307,T098,scispacy,RCT,1,infliximab,infliximab,increased
Antineoplastic And Immunotherapy Treatments,Neuropsychiatric Status,Peer Interaction,7043,7043,7043,7043,33472855,tocilizumab,clinical status,not found,negative,OR,1.54,0.66,3.66,tocilizumab,C1609165,"T116, T121, T129",api,Clinical status,C0449440,T201,api,RCT,1,tocilizumab,tocilizumab,increased
Antineoplastic And Immunotherapy Treatments,Multiple Sclerosis,Peer Interaction,117973,117973,117973,117973,30644981,natalizumab,conversion to secondary progressive multiple sclerosis,decrease,positive,HR,0.61,0.43,0.86,natalizumab,C1172734,T116|T121|T129,cohort_kg,"Multiple Sclerosis, Secondary Progressive",C0751965,T047,cohort_kg,OS,1,natalizumab,natalizumab,increased
Antineoplastic And Immunotherapy Treatments,Immune-Mediated Disease,Peer Interaction,3684,3684,3684,3684,35961761,secukinumab,disease flare,decrease,positive,HR,0.28,0.13,0.63,secukinumab,C3179547,"T116, T121, T129",api,Autoimmune Diseases,C0004364,T047,api,RCT,1,secukinumab,secukinumab,increased
Antineoplastic And Immunotherapy Treatments,Cardiovascular Disease,Peer Interaction,10226,10226,10226,10226,31117810,alirocumab,noncardiovascular death,not found,negative,HR,0.77,0.59,1.01,alirocumab,C3491162,"T116, T121, T129",api,Cardiovascular system,C0007226,T022,scispacy,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Immunotherapy Treatments,Cardiovascular Disease,Peer Interaction,13789,13789,13789,13789,28927706,evolocumab,cardiovascular outcomes,decrease,positive,HR,0.83,0.75,0.93,evolocumab,C3529352,"T116, T121, T129",api,Cardiovascular system,C0007226,T022,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Cardiovascular Disease,Peer Interaction,13792,13792,13792,13792,28927706,evolocumab,cardiovascular outcomes,decrease,positive,HR,0.87,0.79,0.96,evolocumab,C3529352,"T116, T121, T129",api,Cardiovascular system,C0007226,T022,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Cardiovascular Disease,Peer Interaction,17303,17303,17303,17303,25773607,evolocumab,cardiovascular events,decrease,positive,HR,0.47,0.28,0.78,evolocumab,C3529352,"T116, T121, T129",api,Cardiovascular event,C1320716,T033,api,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Cardiovascular Disease,Peer Interaction,89133,89133,89133,89133,28245350,tocilizumab,cardiovascular events,not found,negative,HR,0.84,0.56,1.26,tocilizumab,C1609165,T116|T121|T129,cohort_kg,cardiovascular event,C1320716,T033,cohort_kg,OS,1,tocilizumab,tocilizumab,increased
Antineoplastic And Immunotherapy Treatments,Gastrointestinal Disease,Peer Interaction,19044,19044,19044,19044,24637999,bevacizumab,GI adverse events,increase,positive,OR,2.15,1.05,4.4,bevacizumab,C0796392,"T116, T121, T129",api,gastroenterology (field),C0017163,T091,scispacy,RCT,1,bevacizumab,bevacizumab,increased
Antineoplastic And Immunotherapy Treatments,Overall Health Status,Peer Interaction,7043,7043,7043,7043,33472855,tocilizumab,clinical status,not found,negative,OR,1.54,0.66,3.66,tocilizumab,C1609165,"T116, T121, T129",api,Clinical status,C0449440,T201,api,RCT,1,tocilizumab,tocilizumab,increased
Antineoplastic And Immunotherapy Treatments,Malignant Neoplasm,Peer Interaction,89013,89013,89013,89013,28193515,infliximab,malignancy,not found,negative,SIR,1.69,0.46,4.32,infliximab,C0666743,T116|T121|T129,cohort_kg,malignant disease,C0442867,T047,cohort_kg,OS,1,infliximab,infliximab,increased
Antineoplastic And Immunotherapy Treatments,Infection,Peer Interaction,78201,78201,78201,78201,22887849,infliximab,serious infections,decrease,positive,HR,0.49,0.29,0.83,infliximab,C0666743,T116|T121|T129,cohort_kg,Severe infection,C5139167,T047,cohort_kg,OS,1,infliximab,infliximab,increased
Antineoplastic And Immunotherapy Treatments,Infection,Peer Interaction,93677,93677,93677,93677,29592917,tocilizumab,serious infection,increase,positive,HR,1.22,1.02,1.47,tocilizumab,C1609165,T116|T121|T129,cohort_kg,Severe infection,C5139167,T047,cohort_kg,OS,1,tocilizumab,tocilizumab,increased
Antineoplastic And Immunotherapy Treatments,Infection,Peer Interaction,110096,110096,110096,110096,25989609,etanercept,medically significant infections,increase,positive,HR,2.13,1.22,3.74,etanercept,C0717758,T116|T121,cohort_kg,Clinical infection,C0275521,T047,cohort_kg,OS,1,etanercept,etanercept,increased
Antineoplastic And Immunotherapy Treatments,Infection,Peer Interaction,111215,111215,111215,111215,26315675,etanercept,hospitalized infection,increase,positive,HR,1.24,1.07,1.45,etanercept,C0717758,T116|T121,cohort_kg,"Infections, Hospital",C0205721,T047,cohort_kg,OS,1,etanercept,etanercept,increased
Antineoplastic And Immunotherapy Treatments,Infection,Peer Interaction,111216,111216,111216,111216,26315675,infliximab,hospitalized infection,increase,positive,HR,1.39,1.21,1.6,infliximab,C0666743,T116|T121|T129,cohort_kg,"Infections, Hospital",C0205721,T047,cohort_kg,OS,1,infliximab,infliximab,increased
Antineoplastic And Immunotherapy Treatments,Infection,Peer Interaction,114107,114107,114107,114107,24608404,etanercept,hospitalised infection,decrease,positive,HR,0.83,0.72,0.96,etanercept,C0717758,T116|T121,cohort_kg,"Infections, Hospital",C0205721,T047,cohort_kg,OS,1,etanercept,etanercept,increased
Antineoplastic And Immunotherapy Treatments,Infection,Peer Interaction,118066,118066,118066,118066,30679153,tocilizumab,composite serious infection,not found,negative,HR,1.05,0.95,1.16,tocilizumab,C1609165,T116|T121|T129,cohort_kg,Severe infection,C5139167,T047,cohort_kg,OS,1,tocilizumab,tocilizumab,increased
Antineoplastic And Immunotherapy Treatments,Infection,Peer Interaction,118067,118067,118067,118067,30679153,tocilizumab,serious bacterial infection,increase,positive,HR,1.19,1.07,1.33,tocilizumab,C1609165,T116|T121|T129,cohort_kg,bacterial sepsis,C0684256,T047,cohort_kg,OS,1,tocilizumab,tocilizumab,increased
Antineoplastic And Immunotherapy Treatments,Thrombosis And Thromboembolism,Peer Interaction,87357,87357,87357,87357,27639934,omalizumab,arterial thromboembolic events,not found,negative,HR,1.32,0.91,1.91,omalizumab,C0966225,T116|T121|T129,cohort_kg,Arterial thromboembolism,C3544094,T046,cohort_kg,OS,1,omalizumab,omalizumab,increased
Antineoplastic And Immunotherapy Treatments,Cerebrovascular Disease,Peer Interaction,8896,8896,8896,8896,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Cerebrovascular Disease,Peer Interaction,8898,8898,8898,8898,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Cerebrovascular Disease,Peer Interaction,10102,10102,10102,10102,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.82,0.71,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Cerebrovascular Disease,Peer Interaction,10103,10103,10103,10103,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.85,0.77,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Cerebrovascular Disease,Peer Interaction,10104,10104,10104,10104,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",not found,negative,HR,0.89,0.76,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Cerebrovascular Disease,Peer Interaction,10636,10636,10636,10636,31707788,alirocumab,ischemic stroke,decrease,positive,HR,0.73,0.57,0.93,alirocumab,C3491162,"T116, T121, T129",api,Ischemic stroke,C0948008,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Immunotherapy Treatments,Cerebrovascular Disease,Peer Interaction,12369,12369,12369,12369,29626068,evolocumab,major vascular events,decrease,positive,HR,0.8,0.71,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Cerebrovascular Disease,Peer Interaction,12370,12370,12370,12370,29626068,evolocumab,major vascular events,decrease,positive,HR,0.82,0.72,0.93,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Cerebrovascular Disease,Peer Interaction,12371,12371,12371,12371,29626068,evolocumab,major vascular events,decrease,positive,HR,0.79,0.69,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Cerebrovascular Disease,Peer Interaction,12372,12372,12372,12372,29626068,evolocumab,major vascular events,not found,negative,HR,0.95,0.85,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Cerebrovascular Disease,Peer Interaction,12373,12373,12373,12373,29626068,evolocumab,major vascular events,not found,negative,HR,0.92,0.84,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Cerebrovascular Disease,Peer Interaction,12374,12374,12374,12374,29626068,evolocumab,major vascular events,not found,negative,HR,0.93,0.85,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Cerebrovascular Disease,Peer Interaction,124840,124840,124840,124840,32781110,bevacizumab,acute cerebrovascular disease,not found,negative,HR,1.04,0.78,1.38,bevacizumab,C0796392,T116|T121|T129,cohort_kg,Acute cerebrovascular disease,C0810006,T047,cohort_kg,OS,1,bevacizumab,bevacizumab,increased
Antineoplastic And Immunotherapy Treatments,Health Status And Severity Scoring Systems,Peer Interaction,22536,22536,22536,22536,21536936,omalizumab,asthma symptom score,decrease,positive,not found,-0.26,-0.42,-0.1,omalizumab,C0966225,"T116, T121, T129",api,Symptoms score,C3476546,T033,scispacy,RCT,1,omalizumab,omalizumab,increased
Antineoplastic And Immunotherapy Treatments,Functional Limitation,Peer Interaction,11550,11550,11550,11550,29545067,natalizumab,sustained disability progression,not found,negative,OR,0.86,0.66,1.13,natalizumab,C1172734,"T116, T121, T129",api,Disability,C0231170,T033,scispacy,RCT,1,natalizumab,natalizumab,increased
Antineoplastic And Immunotherapy Treatments,Functional Limitation,Peer Interaction,28521,28521,28521,28521,16510744,natalizumab,sustained progression of disability,decrease,positive,HR,0.58,0.43,0.77,natalizumab,C1172734,"T116, T121, T129",api,Disability,C0231170,T033,scispacy,RCT,1,natalizumab,natalizumab,increased
Antineoplastic And Immunotherapy Treatments,General Clinical Status,Peer Interaction,7043,7043,7043,7043,33472855,tocilizumab,clinical status,not found,negative,OR,1.54,0.66,3.66,tocilizumab,C1609165,"T116, T121, T129",api,Clinical status,C0449440,T201,api,RCT,1,tocilizumab,tocilizumab,increased
Antineoplastic And Immunotherapy Treatments,Falls And Fall Risk,Peer Interaction,17113,17113,17113,17113,26518090,omalizumab,fall asthma exacerbations,decrease,positive,OR,0.48,0.25,0.92,omalizumab,C0966225,"T116, T121, T129",api,Falls,C0085639,T033,scispacy,RCT,1,omalizumab,omalizumab,increased
Antineoplastic And Immunotherapy Treatments,Falls And Fall Risk,Peer Interaction,17114,17114,17114,17114,26518090,omalizumab,fall asthma exacerbations,not found,negative,OR,0.73,0.33,1.64,omalizumab,C0966225,"T116, T121, T129",api,Falls,C0085639,T033,scispacy,RCT,1,omalizumab,omalizumab,increased
Antineoplastic And Immunotherapy Treatments,Falls And Fall Risk,Peer Interaction,17119,17119,17119,17119,26518090,omalizumab,fall asthma exacerbations,decrease,positive,OR,0.12,0.02,0.64,omalizumab,C0966225,"T116, T121, T129",api,Falls,C0085639,T033,scispacy,RCT,1,omalizumab,omalizumab,increased
Antineoplastic And Immunotherapy Treatments,Falls And Fall Risk,Peer Interaction,17120,17120,17120,17120,26518090,omalizumab,fall asthma exacerbations,decrease,positive,OR,0.05,0.002,0.98,omalizumab,C0966225,"T116, T121, T129",api,Falls,C0085639,T033,scispacy,RCT,1,omalizumab,omalizumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,7383,7383,7383,7383,34537830,evolocumab,cerebrovascular events,decrease,positive,HR,0.77,0.65,0.92,evolocumab,C3529352,"T116, T121, T129",api,Transient cerebrovascular events,C0852396,T047,api,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,8896,8896,8896,8896,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,8898,8898,8898,8898,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,9436,9436,9436,9436,31121022,alirocumab,myocardial infarction,decrease,positive,HR,0.85,0.77,0.95,alirocumab,C3491162,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,10102,10102,10102,10102,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.82,0.71,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,10103,10103,10103,10103,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.85,0.77,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,10104,10104,10104,10104,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",not found,negative,HR,0.89,0.76,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,10636,10636,10636,10636,31707788,alirocumab,ischemic stroke,decrease,positive,HR,0.73,0.57,0.93,alirocumab,C3491162,"T116, T121, T129",api,Ischemic stroke,C0948008,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,12369,12369,12369,12369,29626068,evolocumab,major vascular events,decrease,positive,HR,0.8,0.71,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,12370,12370,12370,12370,29626068,evolocumab,major vascular events,decrease,positive,HR,0.82,0.72,0.93,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,12371,12371,12371,12371,29626068,evolocumab,major vascular events,decrease,positive,HR,0.79,0.69,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,12372,12372,12372,12372,29626068,evolocumab,major vascular events,not found,negative,HR,0.95,0.85,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,12373,12373,12373,12373,29626068,evolocumab,major vascular events,not found,negative,HR,0.92,0.84,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,12374,12374,12374,12374,29626068,evolocumab,major vascular events,not found,negative,HR,0.93,0.85,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,17303,17303,17303,17303,25773607,evolocumab,cardiovascular events,decrease,positive,HR,0.47,0.28,0.78,evolocumab,C3529352,"T116, T121, T129",api,Cardiovascular event,C1320716,T033,api,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,31749,31749,31749,31749,12021219,abciximab,myocardial infarction,decrease,positive,RR,0.68,0.53,0.87,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,33469,33469,33469,33469,10341274,abciximab,myocardial infarction,decrease,positive,OR,0.23,0.12,0.49,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,33726,33726,33726,33726,10636365,abciximab,death or large myocardial infarction,decrease,positive,HR,0.46,0.32,0.67,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,scispacy,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,34349,34349,34349,34349,9164316,abciximab,myocardial infarction,decrease,positive,RR,0.29,0.1,0.84,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,34350,34350,34350,34350,9164316,abciximab,myocardial infarction,decrease,positive,RR,0.47,0.26,0.84,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,89133,89133,89133,89133,28245350,tocilizumab,cardiovascular events,not found,negative,HR,0.84,0.56,1.26,tocilizumab,C1609165,T116|T121|T129,cohort_kg,cardiovascular event,C1320716,T033,cohort_kg,OS,1,tocilizumab,tocilizumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke And Cardiovascular Events,Peer Interaction,124840,124840,124840,124840,32781110,bevacizumab,acute cerebrovascular disease,not found,negative,HR,1.04,0.78,1.38,bevacizumab,C0796392,T116|T121|T129,cohort_kg,Acute cerebrovascular disease,C0810006,T047,cohort_kg,OS,1,bevacizumab,bevacizumab,increased
Antineoplastic And Immunotherapy Treatments,Hemorrhagic Stroke,Peer Interaction,8896,8896,8896,8896,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Hemorrhagic Stroke,Peer Interaction,8898,8898,8898,8898,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Hemorrhagic Stroke,Peer Interaction,10102,10102,10102,10102,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.82,0.71,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Hemorrhagic Stroke,Peer Interaction,10103,10103,10103,10103,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.85,0.77,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Hemorrhagic Stroke,Peer Interaction,10104,10104,10104,10104,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",not found,negative,HR,0.89,0.76,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Hemorrhagic Stroke,Peer Interaction,10636,10636,10636,10636,31707788,alirocumab,ischemic stroke,decrease,positive,HR,0.73,0.57,0.93,alirocumab,C3491162,"T116, T121, T129",api,Ischemic stroke,C0948008,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Immunotherapy Treatments,Hemorrhagic Stroke,Peer Interaction,10649,10649,10649,10649,31707788,alirocumab,hemorrhagic stroke,not found,negative,HR,0.83,0.42,1.65,alirocumab,C3491162,"T116, T121, T129",api,Hemorrhagic Stroke,C5234922,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Immunotherapy Treatments,Hemorrhagic Stroke,Peer Interaction,12369,12369,12369,12369,29626068,evolocumab,major vascular events,decrease,positive,HR,0.8,0.71,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Hemorrhagic Stroke,Peer Interaction,12370,12370,12370,12370,29626068,evolocumab,major vascular events,decrease,positive,HR,0.82,0.72,0.93,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Hemorrhagic Stroke,Peer Interaction,12371,12371,12371,12371,29626068,evolocumab,major vascular events,decrease,positive,HR,0.79,0.69,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Hemorrhagic Stroke,Peer Interaction,12372,12372,12372,12372,29626068,evolocumab,major vascular events,not found,negative,HR,0.95,0.85,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Hemorrhagic Stroke,Peer Interaction,12373,12373,12373,12373,29626068,evolocumab,major vascular events,not found,negative,HR,0.92,0.84,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Hemorrhagic Stroke,Peer Interaction,12374,12374,12374,12374,29626068,evolocumab,major vascular events,not found,negative,HR,0.93,0.85,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,8896,8896,8896,8896,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,8898,8898,8898,8898,31707849,evolocumab,major vascular events,decrease,positive,HR,0.85,0.79,0.92,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,9436,9436,9436,9436,31121022,alirocumab,myocardial infarction,decrease,positive,HR,0.85,0.77,0.95,alirocumab,C3491162,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,10102,10102,10102,10102,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.82,0.71,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,10103,10103,10103,10103,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",decrease,positive,HR,0.85,0.77,0.94,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,10104,10104,10104,10104,31196453,evolocumab,"cardiovascular death, myocardial infarction, or stroke",not found,negative,HR,0.89,0.76,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,10636,10636,10636,10636,31707788,alirocumab,ischemic stroke,decrease,positive,HR,0.73,0.57,0.93,alirocumab,C3491162,"T116, T121, T129",api,Ischemic stroke,C0948008,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,10649,10649,10649,10649,31707788,alirocumab,hemorrhagic stroke,not found,negative,HR,0.83,0.42,1.65,alirocumab,C3491162,"T116, T121, T129",api,Hemorrhagic Stroke,C5234922,T047,api,RCT,1,alirocumab,alirocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,12369,12369,12369,12369,29626068,evolocumab,major vascular events,decrease,positive,HR,0.8,0.71,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,12370,12370,12370,12370,29626068,evolocumab,major vascular events,decrease,positive,HR,0.82,0.72,0.93,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,12371,12371,12371,12371,29626068,evolocumab,major vascular events,decrease,positive,HR,0.79,0.69,0.91,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,12372,12372,12372,12372,29626068,evolocumab,major vascular events,not found,negative,HR,0.95,0.85,1.05,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,12373,12373,12373,12373,29626068,evolocumab,major vascular events,not found,negative,HR,0.92,0.84,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,12374,12374,12374,12374,29626068,evolocumab,major vascular events,not found,negative,HR,0.93,0.85,1.02,evolocumab,C3529352,"T116, T121, T129",api,Cerebrovascular accident,C0038454,T047,scispacy,RCT,1,evolocumab,evolocumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,31749,31749,31749,31749,12021219,abciximab,myocardial infarction,decrease,positive,RR,0.68,0.53,0.87,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,33469,33469,33469,33469,10341274,abciximab,myocardial infarction,decrease,positive,OR,0.23,0.12,0.49,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,33726,33726,33726,33726,10636365,abciximab,death or large myocardial infarction,decrease,positive,HR,0.46,0.32,0.67,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,scispacy,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,34349,34349,34349,34349,9164316,abciximab,myocardial infarction,decrease,positive,RR,0.29,0.1,0.84,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,34350,34350,34350,34350,9164316,abciximab,myocardial infarction,decrease,positive,RR,0.47,0.26,0.84,abciximab,C0288672,"T116, T121, T129",api,Myocardial Infarction,C0027051,T047,api,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,84659,84659,84659,84659,26792814,etanercept,acute myocardial infarction,increase,positive,HR,1.3,1.0,1.8,etanercept,C0717758,T116|T121,cohort_kg,Acute myocardial infarction,C0155626,T047,cohort_kg,OS,1,etanercept,etanercept,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,84660,84660,84660,84660,26792814,infliximab,acute myocardial infarction,increase,positive,HR,1.3,1.0,1.6,infliximab,C0666743,T116|T121|T129,cohort_kg,Acute myocardial infarction,C0155626,T047,cohort_kg,OS,1,infliximab,infliximab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,124839,124839,124839,124839,32781110,bevacizumab,acute myocardial infarction,not found,negative,HR,0.96,0.74,1.25,bevacizumab,C0796392,T116|T121|T129,cohort_kg,Acute myocardial infarction,C0155626,T047,cohort_kg,OS,1,bevacizumab,bevacizumab,increased
Antineoplastic And Immunotherapy Treatments,Ischemic Stroke,Peer Interaction,124840,124840,124840,124840,32781110,bevacizumab,acute cerebrovascular disease,not found,negative,HR,1.04,0.78,1.38,bevacizumab,C0796392,T116|T121|T129,cohort_kg,Acute cerebrovascular disease,C0810006,T047,cohort_kg,OS,1,bevacizumab,bevacizumab,increased
Antineoplastic And Immunotherapy Treatments,Venous Thromboembolism,Peer Interaction,87357,87357,87357,87357,27639934,omalizumab,arterial thromboembolic events,not found,negative,HR,1.32,0.91,1.91,omalizumab,C0966225,T116|T121|T129,cohort_kg,Arterial thromboembolism,C3544094,T046,cohort_kg,OS,1,omalizumab,omalizumab,increased
Antineoplastic And Immunotherapy Treatments,Viral Infections,Peer Interaction,21926,21926,21926,21926,21949007,tocilizumab,serious infections,increase,positive,RR,6.56,4.3,13.2,tocilizumab,C1609165,"T116, T121, T129",api,No serious viral infections,C5936290,T033,api,RCT,1,tocilizumab,tocilizumab,increased
Antineoplastic And Immunotherapy Treatments,Viral Infections,Peer Interaction,110096,110096,110096,110096,25989609,etanercept,medically significant infections,increase,positive,HR,2.13,1.22,3.74,etanercept,C0717758,T116|T121,cohort_kg,Clinical infection,C0275521,T047,cohort_kg,OS,1,etanercept,etanercept,increased
Antineoplastic And Immunotherapy Treatments,Arterial Structure,Peer Interaction,19470,19470,19470,19470,23870813,ranibizumab,arterial thrombotic event or hospital admission for heart failure,not found,negative,OR,1.69,0.8,3.57,ranibizumab,C1566537,"T116, T121, T129",api,Arteries,C0003842,T023,scispacy,RCT,1,ranibizumab,ranibizumab,increased
Antineoplastic And Immunotherapy Treatments,Arterial Structure,Peer Interaction,30056,30056,30056,30056,15351163,abciximab,"combined incidence of death, recurrent myocardial infarction and target vessel re-vascularisation",not found,negative,RR,0.97,0.7,1.33,abciximab,C0288672,"T116, T121, T129",api,Blood Vessel,C0005847,T023,scispacy,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Arterial Structure,Peer Interaction,33620,33620,33620,33620,10423466,abciximab,repeated revascularization of the target vessel,not found,negative,HR,0.82,0.59,1.13,abciximab,C0288672,"T116, T121, T129",api,Blood Vessel,C0005847,T023,scispacy,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Arterial Structure,Peer Interaction,33621,33621,33621,33621,10423466,abciximab,repeated revascularization of the target vessel,increase,positive,HR,1.49,1.13,1.97,abciximab,C0288672,"T116, T121, T129",api,Blood Vessel,C0005847,T023,scispacy,RCT,1,abciximab,abciximab,increased
Antineoplastic And Immunotherapy Treatments,Arterial Structure,Peer Interaction,33622,33622,33622,33622,10423466,abciximab,repeated revascularization of the target vessel,decrease,positive,HR,0.55,0.41,0.74,abciximab,C0288672,"T116, T121, T129",api,Blood Vessel,C0005847,T023,scispacy,RCT,1,abciximab,abciximab,increased
Dietary Intake And Eating Behaviors,Obesity And Body Mass Index,Peer Interaction,112531,112531,112531,112531,26718416,protein intake,overweight or obesity,not found,negative,OR,1.1,0.99,1.22,protein intake,C0489617,T081,cohort_kg,Overweight or obese,C4479421,T033,cohort_kg,OS,1,protein intake,protein,increased
Dietary Intake And Eating Behaviors,Obesity,Peer Interaction,112531,112531,112531,112531,26718416,protein intake,overweight or obesity,not found,negative,OR,1.1,0.99,1.22,protein intake,C0489617,T081,cohort_kg,Overweight or obese,C4479421,T033,cohort_kg,OS,1,protein intake,protein,increased
Dietary Intake And Eating Behaviors,Obesity And Glycemic Control,Peer Interaction,112531,112531,112531,112531,26718416,protein intake,overweight or obesity,not found,negative,OR,1.1,0.99,1.22,protein intake,C0489617,T081,cohort_kg,Overweight or obese,C4479421,T033,cohort_kg,OS,1,protein intake,protein,increased
Dietary Intake And Eating Behaviors,Activities Of Daily Living Limitation,Peer Interaction,89320,89320,89320,89320,28306154,protein intake,mobility limitation,increase,positive,RR,1.86,1.41,2.44,protein intake,C0489617,T081,cohort_kg,Mobility Limitation,C1565249,T184,cohort_kg,OS,1,protein intake,protein,increased
Dietary Intake And Eating Behaviors,Functional Limitation,Peer Interaction,89320,89320,89320,89320,28306154,protein intake,mobility limitation,increase,positive,RR,1.86,1.41,2.44,protein intake,C0489617,T081,cohort_kg,Mobility Limitation,C1565249,T184,cohort_kg,OS,1,protein intake,protein,increased
Health Literacy,Diabetes Mellitus,Peer Interaction,62620,62620,62620,62620,18083794,reading comprehension,type 2 diabetes,decrease,positive,OR,0.58,0.44,0.77,reading comprehension,C0871214,T080,cohort_kg,Type 2 diabetes (Adult onset),C3842544,T047,cohort_kg,OS,1,reading comprehension,reading comprehension,increased
Abnormal Biomarker Levels,Diabetes Mellitus,Peer Interaction,86798,86798,86798,86798,27466075,prolactin,type 2 diabetes,decrease,positive,HR,0.48,0.26,0.9,prolactin,C0033371,T116|T121|T125,cohort_kg,Type 2 diabetes (Adult onset),C3842544,T047,cohort_kg,OS,1,prolactin,prolactin,increased
Abnormal Biomarker Levels,Diabetes Mellitus,Peer Interaction,101585,101585,101585,101585,35666146,prolactin,future type 2 diabetes,decrease,positive,OR,2.48,0.81,7.58,prolactin,C0033371,T116|T121|T125,cohort_kg,Increased risk of type 2 diabetes,C5195213,T033,cohort_kg,OS,1,prolactin,prolactin,increased
Abnormal Biomarker Levels,Diabetes Mellitus,Peer Interaction,107431,107431,107431,107431,25202819,parathyroid hormone,gestational diabetes mellitus,increase,positive,OR,1.82,1.09,3.02,parathyroid hormone,C0030520,T116|T121|T125,cohort_kg,Gestational Diabetes,C0085207,T047,cohort_kg,OS,1,parathyroid hormone,parathyroid hormone,increased
Abnormal Biomarker Levels,Heart Failure,Peer Interaction,51307,51307,51307,51307,12397047,parathyroid hormone,congestive heart failure,increase,positive,OR,2.0,1.3,2.9,parathyroid hormone,C0030520,T116|T121|T125,cohort_kg,Congestive heart failure,C0018802,T047,cohort_kg,OS,1,parathyroid hormone,parathyroid hormone,increased
Abnormal Biomarker Levels,Heart Failure,Peer Interaction,113513,113513,113513,113513,24423292,parathyroid hormone,heart failure,not found,negative,HR,1.21,0.99,1.48,parathyroid hormone,C0030520,T116|T121|T125,cohort_kg,Heart failure,C0018801,T047,cohort_kg,OS,1,parathyroid hormone,parathyroid hormone,increased
Abnormal Biomarker Levels,Coronary Artery Disease,Peer Interaction,51306,51306,51306,51306,12397047,parathyroid hormone,myocardial infarction,increase,positive,OR,1.6,1.1,2.3,parathyroid hormone,C0030520,T116|T121|T125,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,parathyroid hormone,parathyroid hormone,increased
Abnormal Biomarker Levels,Inflammatory Disorder,Peer Interaction,47744,47744,47744,47744,10966252,procalcitonin,sepsis,increase,positive,median,16.8,0.9,351.2,procalcitonin,C0072027,T116|T123,cohort_kg,Sepsis,C0243026,T047,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Inflammatory Disorder,Peer Interaction,49342,49342,49342,49342,11500339,procalcitonin,sepsis,increase,positive,AUC,0.92,0.85,1.0,procalcitonin,C0072027,T116|T123,cohort_kg,Sepsis,C0243026,T047,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Inflammatory Disorder,Peer Interaction,52538,52538,52538,52538,12794413,procalcitonin,infection,increase,positive,area under the receiver operating characteristic curve,0.756,0.675,0.836,procalcitonin,C0072027,T116|T123,cohort_kg,Infection,C3714514,T046,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Inflammatory Disorder,Peer Interaction,52540,52540,52540,52540,12794413,procalcitonin,sepsis,increase,positive,area under the receiver operating characteristic curve,0.925,0.899,0.952,procalcitonin,C0072027,T116|T123,cohort_kg,Sepsis,C0243026,T047,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Inflammatory Disorder,Peer Interaction,72129,72129,72129,72129,21283000,procalcitonin,infection,increase,positive,odds ratio,1.0094,1.0005,1.0184,procalcitonin,C0072027,T116|T123,cohort_kg,Infection,C3714514,T046,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Inflammatory Disorders,Peer Interaction,47744,47744,47744,47744,10966252,procalcitonin,sepsis,increase,positive,median,16.8,0.9,351.2,procalcitonin,C0072027,T116|T123,cohort_kg,Sepsis,C0243026,T047,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Inflammatory Disorders,Peer Interaction,49342,49342,49342,49342,11500339,procalcitonin,sepsis,increase,positive,AUC,0.92,0.85,1.0,procalcitonin,C0072027,T116|T123,cohort_kg,Sepsis,C0243026,T047,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Inflammatory Disorders,Peer Interaction,52538,52538,52538,52538,12794413,procalcitonin,infection,increase,positive,area under the receiver operating characteristic curve,0.756,0.675,0.836,procalcitonin,C0072027,T116|T123,cohort_kg,Infection,C3714514,T046,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Inflammatory Disorders,Peer Interaction,52540,52540,52540,52540,12794413,procalcitonin,sepsis,increase,positive,area under the receiver operating characteristic curve,0.925,0.899,0.952,procalcitonin,C0072027,T116|T123,cohort_kg,Sepsis,C0243026,T047,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Inflammatory Disorders,Peer Interaction,72129,72129,72129,72129,21283000,procalcitonin,infection,increase,positive,odds ratio,1.0094,1.0005,1.0184,procalcitonin,C0072027,T116|T123,cohort_kg,Infection,C3714514,T046,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Immune Dysregulation And Systemic Inflammatory Response,Peer Interaction,47747,47747,47747,47747,10966252,procalcitonin,systemic inflammatory response syndrome,increase,positive,median,3.0,0.7,29.5,procalcitonin,C0072027,T116|T123,cohort_kg,Systemic Inflammatory Response Syndrome,C0242966,T047,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Infection,Peer Interaction,47744,47744,47744,47744,10966252,procalcitonin,sepsis,increase,positive,median,16.8,0.9,351.2,procalcitonin,C0072027,T116|T123,cohort_kg,Sepsis,C0243026,T047,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Infection,Peer Interaction,49342,49342,49342,49342,11500339,procalcitonin,sepsis,increase,positive,AUC,0.92,0.85,1.0,procalcitonin,C0072027,T116|T123,cohort_kg,Sepsis,C0243026,T047,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Infection,Peer Interaction,52538,52538,52538,52538,12794413,procalcitonin,infection,increase,positive,area under the receiver operating characteristic curve,0.756,0.675,0.836,procalcitonin,C0072027,T116|T123,cohort_kg,Infection,C3714514,T046,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Infection,Peer Interaction,52540,52540,52540,52540,12794413,procalcitonin,sepsis,increase,positive,area under the receiver operating characteristic curve,0.925,0.899,0.952,procalcitonin,C0072027,T116|T123,cohort_kg,Sepsis,C0243026,T047,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Infection,Peer Interaction,72129,72129,72129,72129,21283000,procalcitonin,infection,increase,positive,odds ratio,1.0094,1.0005,1.0184,procalcitonin,C0072027,T116|T123,cohort_kg,Infection,C3714514,T046,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Infection,Peer Interaction,79067,79067,79067,79067,23109682,procalcitonin,invasive bacterial infections,increase,positive,odds ratio,21.69,7.93,59.28,procalcitonin,C0072027,T116|T123,cohort_kg,Invasive infections,C5436123,T047,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Infection,Peer Interaction,79069,79069,79069,79069,23109682,procalcitonin,invasive bacterial infections,decrease,positive,negative likelihood ratio,0.25,0.12,0.55,procalcitonin,C0072027,T116|T123,cohort_kg,Invasive infections,C5436123,T047,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Ischemic Stroke And Cardiovascular Events,Peer Interaction,51306,51306,51306,51306,12397047,parathyroid hormone,myocardial infarction,increase,positive,OR,1.6,1.1,2.3,parathyroid hormone,C0030520,T116|T121|T125,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,parathyroid hormone,parathyroid hormone,increased
Abnormal Biomarker Levels,Ischemic Stroke,Peer Interaction,51306,51306,51306,51306,12397047,parathyroid hormone,myocardial infarction,increase,positive,OR,1.6,1.1,2.3,parathyroid hormone,C0030520,T116|T121|T125,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,parathyroid hormone,parathyroid hormone,increased
Abnormal Biomarker Levels,Viral Infections,Peer Interaction,52538,52538,52538,52538,12794413,procalcitonin,infection,increase,positive,area under the receiver operating characteristic curve,0.756,0.675,0.836,procalcitonin,C0072027,T116|T123,cohort_kg,Infection,C3714514,T046,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
Abnormal Biomarker Levels,Viral Infections,Peer Interaction,72129,72129,72129,72129,21283000,procalcitonin,infection,increase,positive,odds ratio,1.0094,1.0005,1.0184,procalcitonin,C0072027,T116|T123,cohort_kg,Infection,C3714514,T046,cohort_kg,OS,1,procalcitonin,procalcitonin,increased
C-Reactive Protein Level,Diabetes Mellitus,Peer Interaction,32573,32573,32573,32573,11466099,C-reactive protein,type 2 diabetes mellitus,increase,positive,RR,15.7,6.5,37.9,C-reactive protein,C0006560,"T116, T129",api,"Diabetes Mellitus, Non-Insulin-Dependent",C0011860,T047,api,RCT,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Diabetes Mellitus,Peer Interaction,32575,32575,32575,32575,11466099,C-reactive protein,type 2 diabetes mellitus,increase,positive,RR,4.2,1.5,12.0,C-reactive protein,C0006560,"T116, T129",api,"Diabetes Mellitus, Non-Insulin-Dependent",C0011860,T047,api,RCT,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Diabetes Mellitus,Peer Interaction,36644,36644,36644,36644,18700811,C-reactive protein,type 2 diabetes,increase,positive,HR,1.39,1.29,1.51,C-reactive protein,C0006560,"T116, T129",api,"Diabetes Mellitus, Non-Insulin-Dependent",C0011860,T047,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Diabetes Mellitus,Peer Interaction,60649,60649,60649,60649,17392546,C-reactive protein,type 2 diabetes,increase,positive,HR,7.6,4.43,13.04,C-reactive protein,C0006560,T116|T129,cohort_kg,Type 2 diabetes (Adult onset),C3842544,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Hypertension,Peer Interaction,53628,53628,53628,53628,14665655,C-reactive protein,hypertension,increase,positive,RR,1.25,1.14,1.4,C-reactive protein,C0006560,T116|T129,cohort_kg,Hypertension (variable),C3280772,T033,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Obesity And Body Mass Index,Peer Interaction,36756,36756,36756,36756,19584180,C-reactive protein,body mass index,increase,positive,not found,1.22,0.18,2.25,C-reactive protein,C0006560,"T116, T129",api,Body mass index,C1305855,T201,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Obesity And Body Mass Index,Peer Interaction,36758,36758,36758,36758,19584180,C-reactive protein,body mass index,increase,positive,not found,0.98,0.32,1.63,C-reactive protein,C0006560,"T116, T129",api,Body mass index,C1305855,T201,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Heart Failure,Peer Interaction,2715,2715,2715,2715,39159269,C-reactive protein measurement,clinical failure,not found,negative,OR,0.41,0.09,1.83,C-reactive protein measurement,C0201657,T059,api,Clinical Failure,C3640841,T033,api,RCT,1,C-reactive protein measurement,c-reactive protein,increased
C-Reactive Protein Level,Heart Failure,Peer Interaction,53347,53347,53347,53347,14568895,C-reactive protein,congestive heart failure,increase,positive,RR,1.48,1.23,1.78,C-reactive protein,C0006560,T116|T129,cohort_kg,Congestive heart failure,C0018802,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Heart Failure,Peer Interaction,57804,57804,57804,57804,16516078,C-reactive protein,heart failure,increase,positive,HR,1.1,0.5,2.3,C-reactive protein,C0006560,T116|T129,cohort_kg,Heart failure,C0018801,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Heart Failure,Peer Interaction,63581,63581,63581,63581,18452784,C-reactive protein,congestive heart failure,increase,positive,HR,1.38,1.01,1.86,C-reactive protein,C0006560,T116|T129,cohort_kg,Congestive heart failure,C0018802,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Heart Failure,Peer Interaction,69751,69751,69751,69751,20447537,C-reactive protein,heart failure,not found,negative,HR,1.09,0.99,1.24,C-reactive protein,C0006560,T116|T129,cohort_kg,Heart failure,C0018801,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Heart Failure,Peer Interaction,71532,71532,71532,71532,21070922,C-reactive protein,heart failure,increase,positive,HR,1.57,1.28,1.94,C-reactive protein,C0006560,T116|T129,cohort_kg,Heart failure,C0018801,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Heart Failure,Peer Interaction,106243,106243,106243,106243,37495278,C-reactive protein,incident heart failure,increase,positive,HR,2.22,1.76,2.79,C-reactive protein,C0006560,T116|T129,cohort_kg,acute heart failure,C0264714,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Heart Failure,Peer Interaction,106244,106244,106244,106244,37495278,C-reactive protein,incident heart failure with reduced ejection fraction,increase,positive,HR,1.09,1.04,1.14,C-reactive protein,C0006560,T116|T129,cohort_kg,Heart failure with reduced ejection fraction,C3839346,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Heart Failure,Peer Interaction,106245,106245,106245,106245,37495278,C-reactive protein,incident heart failure with preserved ejection fraction,increase,positive,HR,1.12,1.07,1.18,C-reactive protein,C0006560,T116|T129,cohort_kg,Physical Examination Findings of New or Worsening Heart Failure,C3897927,T033,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Obesity,Peer Interaction,36756,36756,36756,36756,19584180,C-reactive protein,body mass index,increase,positive,not found,1.22,0.18,2.25,C-reactive protein,C0006560,"T116, T129",api,Body mass index,C1305855,T201,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Obesity,Peer Interaction,36757,36757,36757,36757,19584180,C-reactive protein,fat mass,increase,positive,not found,2.67,0.65,4.68,C-reactive protein,C0006560,"T116, T129",api,Fat Mass,C4764117,T081,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Obesity,Peer Interaction,36758,36758,36758,36758,19584180,C-reactive protein,body mass index,increase,positive,not found,0.98,0.32,1.63,C-reactive protein,C0006560,"T116, T129",api,Body mass index,C1305855,T201,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Obesity,Peer Interaction,36759,36759,36759,36759,19584180,C-reactive protein,fat mass,increase,positive,not found,2.07,0.79,3.34,C-reactive protein,C0006560,"T116, T129",api,Fat Mass,C4764117,T081,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Atrial Fibrillation,Peer Interaction,36717,36717,36717,36717,20797493,C-reactive protein,atrial fibrillation,increase,positive,OR,1.77,1.22,2.55,C-reactive protein,C0006560,"T116, T129",api,Atrial Fibrillation,C0004238,T047,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Atrial Fibrillation,Peer Interaction,36718,36718,36718,36718,20797493,C-reactive protein,atrial fibrillation,increase,positive,OR,2.19,1.54,3.1,C-reactive protein,C0006560,"T116, T129",api,Atrial Fibrillation,C0004238,T047,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Atrial Fibrillation,Peer Interaction,36719,36719,36719,36719,20797493,C-reactive protein,atrial fibrillation,increase,positive,OR,1.63,1.21,2.2,C-reactive protein,C0006560,"T116, T129",api,Atrial Fibrillation,C0004238,T047,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Atrial Fibrillation,Peer Interaction,36720,36720,36720,36720,20797493,C-reactive protein,atrial fibrillation,increase,positive,OR,1.47,1.02,2.13,C-reactive protein,C0006560,"T116, T129",api,Atrial Fibrillation,C0004238,T047,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Atrial Fibrillation,Peer Interaction,53492,53492,53492,53492,14623805,C-reactive protein,atrial fibrillation,increase,positive,OR,1.8,1.2,2.5,C-reactive protein,C0006560,T116|T129,cohort_kg,Atrial Fibrillation,C0004238,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Atrial Fibrillation,Peer Interaction,68636,68636,68636,68636,20048208,C-reactive protein,atrial fibrillation,increase,positive,HR,1.25,1.07,1.45,C-reactive protein,C0006560,T116|T129,cohort_kg,Atrial Fibrillation,C0004238,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Atrial Fibrillation,Peer Interaction,70776,70776,70776,70776,20797493,C-reactive protein,atrial fibrillation,increase,positive,odds ratio,2.19,1.54,3.1,C-reactive protein,C0006560,T116|T129,cohort_kg,Atrial Fibrillation,C0004238,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Atrial Fibrillation,Peer Interaction,71535,71535,71535,71535,21070922,C-reactive protein,atrial fibrillation,increase,positive,HR,1.18,1.03,1.34,C-reactive protein,C0006560,T116|T129,cohort_kg,Atrial Fibrillation,C0004238,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Stroke Or Transient Ischemic Attack,Peer Interaction,49109,49109,49109,49109,11425769,C-reactive protein,acute coronary events,increase,positive,odds ratio,5.9,2.0,17.9,C-reactive protein,C0006560,T116|T129,cohort_kg,Acute Coronary Syndrome,C0948089,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Stroke Or Transient Ischemic Attack,Peer Interaction,52588,52588,52588,52588,12821545,C-reactive protein,ischemic stroke,increase,positive,HR,1.19,0.92,1.53,C-reactive protein,C0006560,T116|T129,cohort_kg,Ischemic stroke,C0948008,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Stroke Or Transient Ischemic Attack,Peer Interaction,52589,52589,52589,52589,12821545,C-reactive protein,ischemic stroke,not found,negative,HR,1.05,0.81,1.37,C-reactive protein,C0006560,T116|T129,cohort_kg,Ischemic stroke,C0948008,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Atrial Fibrillation And Flutter,Peer Interaction,36717,36717,36717,36717,20797493,C-reactive protein,atrial fibrillation,increase,positive,OR,1.77,1.22,2.55,C-reactive protein,C0006560,"T116, T129",api,Atrial Fibrillation,C0004238,T047,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Atrial Fibrillation And Flutter,Peer Interaction,36718,36718,36718,36718,20797493,C-reactive protein,atrial fibrillation,increase,positive,OR,2.19,1.54,3.1,C-reactive protein,C0006560,"T116, T129",api,Atrial Fibrillation,C0004238,T047,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Atrial Fibrillation And Flutter,Peer Interaction,36719,36719,36719,36719,20797493,C-reactive protein,atrial fibrillation,increase,positive,OR,1.63,1.21,2.2,C-reactive protein,C0006560,"T116, T129",api,Atrial Fibrillation,C0004238,T047,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Atrial Fibrillation And Flutter,Peer Interaction,36720,36720,36720,36720,20797493,C-reactive protein,atrial fibrillation,increase,positive,OR,1.47,1.02,2.13,C-reactive protein,C0006560,"T116, T129",api,Atrial Fibrillation,C0004238,T047,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Atrial Fibrillation And Flutter,Peer Interaction,53492,53492,53492,53492,14623805,C-reactive protein,atrial fibrillation,increase,positive,OR,1.8,1.2,2.5,C-reactive protein,C0006560,T116|T129,cohort_kg,Atrial Fibrillation,C0004238,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Atrial Fibrillation And Flutter,Peer Interaction,68636,68636,68636,68636,20048208,C-reactive protein,atrial fibrillation,increase,positive,HR,1.25,1.07,1.45,C-reactive protein,C0006560,T116|T129,cohort_kg,Atrial Fibrillation,C0004238,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Atrial Fibrillation And Flutter,Peer Interaction,70776,70776,70776,70776,20797493,C-reactive protein,atrial fibrillation,increase,positive,odds ratio,2.19,1.54,3.1,C-reactive protein,C0006560,T116|T129,cohort_kg,Atrial Fibrillation,C0004238,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Atrial Fibrillation And Flutter,Peer Interaction,71535,71535,71535,71535,21070922,C-reactive protein,atrial fibrillation,increase,positive,HR,1.18,1.03,1.34,C-reactive protein,C0006560,T116|T129,cohort_kg,Atrial Fibrillation,C0004238,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Arteritis And Arteriosclerosis Disorders,Peer Interaction,27938,27938,27938,27938,17283264,C-reactive protein,"combined end point (definite or suspected death from coronary heart disease, nonfatal myocardial infarction, and fatal or nonfatal stroke)",increase,positive,HR,1.48,1.26,1.74,C-reactive protein,C0006560,"T116, T129",api,Coronary Arteriosclerosis,C0010054,T047,scispacy,RCT,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Arteritis And Arteriosclerosis Disorders,Peer Interaction,27943,27943,27943,27943,17283264,C-reactive protein,"combined end point (definite or suspected death from coronary heart disease, nonfatal myocardial infarction, and fatal or nonfatal stroke)",increase,positive,HR,1.36,1.15,1.61,C-reactive protein,C0006560,"T116, T129",api,Coronary Arteriosclerosis,C0010054,T047,scispacy,RCT,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Mental Health Conditions,Peer Interaction,128940,128940,128940,128940,39167384,C-reactive protein,any psychiatric disorder,increase,positive,HR,1.02,1.0,1.04,C-reactive protein,C0006560,T116|T129,cohort_kg,"Psychiatric Disorders, CTCAE",C4555206,T033,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,27938,27938,27938,27938,17283264,C-reactive protein,"combined end point (definite or suspected death from coronary heart disease, nonfatal myocardial infarction, and fatal or nonfatal stroke)",increase,positive,HR,1.48,1.26,1.74,C-reactive protein,C0006560,"T116, T129",api,Coronary Arteriosclerosis,C0010054,T047,scispacy,RCT,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,27943,27943,27943,27943,17283264,C-reactive protein,"combined end point (definite or suspected death from coronary heart disease, nonfatal myocardial infarction, and fatal or nonfatal stroke)",increase,positive,HR,1.36,1.15,1.61,C-reactive protein,C0006560,"T116, T129",api,Coronary Arteriosclerosis,C0010054,T047,scispacy,RCT,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,33648,33648,33648,33648,9892589,C-reactive protein,coronary heart disease,increase,positive,HRR,1.67,1.29,2.17,C-reactive protein,C0006560,"T116, T129",api,Coronary heart disease,C0010068,T047,api,RCT,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,33649,33649,33649,33649,9892589,C-reactive protein,coronary heart disease,increase,positive,HRR,1.6,1.23,2.08,C-reactive protein,C0006560,"T116, T129",api,Coronary heart disease,C0010068,T047,api,RCT,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,33650,33650,33650,33650,9892589,C-reactive protein,coronary heart disease,increase,positive,HRR,1.5,1.14,1.97,C-reactive protein,C0006560,"T116, T129",api,Coronary heart disease,C0010068,T047,api,RCT,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,37323,37323,37323,37323,27327646,C-reactive protein,coronary artery disease,decrease,positive,OR,0.88,0.84,0.94,C-reactive protein,C0006560,"T116, T129",api,Coronary Artery Disease,C1956346,T047,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,42780,42780,42780,42780,8797513,C-reactive protein,coronary heart disease death,increase,positive,RR,4.3,1.74,10.8,C-reactive protein,C0006560,T116|T129,cohort_kg,Decedent's cause of death due to coronary heart disease,C2924292,T033,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,49109,49109,49109,49109,11425769,C-reactive protein,acute coronary events,increase,positive,odds ratio,5.9,2.0,17.9,C-reactive protein,C0006560,T116|T129,cohort_kg,Acute Coronary Syndrome,C0948089,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,50975,50975,50975,50975,12190368,C-reactive protein,incident coronary heart disease,increase,positive,OR,2.3,1.4,3.7,C-reactive protein,C0006560,T116|T129,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,51218,51218,51218,51218,12370215,C-reactive protein,cardiovascular disease,increase,positive,relative risk,5.91,2.65,13.15,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,54380,54380,54380,54380,15070788,C-reactive protein,coronary heart disease,increase,positive,odds ratio,1.45,1.25,1.68,C-reactive protein,C0006560,T116|T129,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,55987,55987,55987,55987,15602020,C-reactive protein,coronary heart disease,increase,positive,RR,1.79,1.27,2.51,C-reactive protein,C0006560,T116|T129,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,58224,58224,58224,58224,16682383,C-reactive protein,coronary heart disease,increase,positive,HR,1.9,1.5,2.4,C-reactive protein,C0006560,T116|T129,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,60724,60724,60724,60724,17404162,C-reactive protein,cardiovascular disease,increase,positive,HR,1.78,1.3,2.45,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,66396,66396,66396,66396,19363058,C-reactive protein,cardiovascular disease,increase,positive,AUC,0.805,0.795,0.815,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,73574,73574,73574,73574,21700090,C-reactive protein,cardiovascular disease,increase,positive,HR,1.22,1.1,1.34,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,73575,73575,73575,73575,21700090,C-reactive protein,cardiovascular disease,not found,negative,HR,1.0,0.86,1.38,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,75621,75621,75621,75621,22210562,C-reactive protein,cardiovascular disease mortality,increase,positive,HR,1.53,1.43,1.64,C-reactive protein,C0006560,T116|T129,cohort_kg,cardiovascular morbidity,C1301700,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,83829,83829,83829,83829,15983245,C-reactive protein,myocardial infarction,increase,positive,odds ratio,2.2,1.3,3.6,C-reactive protein,C0006560,T116|T129,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,84301,84301,84301,84301,16126719,C-reactive protein,coronary heart disease,increase,positive,HR,1.03,1.0,1.06,C-reactive protein,C0006560,T116|T129,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Coronary Artery Disease,Peer Interaction,84302,84302,84302,84302,16126719,C-reactive protein,coronary heart disease,not found,negative,HR,1.55,0.89,2.69,C-reactive protein,C0006560,T116|T129,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Psychiatric Disorders,Peer Interaction,128940,128940,128940,128940,39167384,C-reactive protein,any psychiatric disorder,increase,positive,HR,1.02,1.0,1.04,C-reactive protein,C0006560,T116|T129,cohort_kg,"Psychiatric Disorders, CTCAE",C4555206,T033,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Malignant Neoplasm With Metastasis,Peer Interaction,36619,36619,36619,36619,20056955,C-reactive protein,cancer,increase,positive,HR,1.09,1.03,1.14,C-reactive protein,C0006560,"T116, T129",api,Malignant Neoplasms,C0006826,T191,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Gastrointestinal Diseases,Peer Interaction,37343,37343,37343,37343,27327646,C-reactive protein,inflammatory bowel disease,decrease,positive,OR,0.85,0.74,0.98,C-reactive protein,C0006560,"T116, T129",api,Inflammatory Bowel Diseases,C0021390,T047,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Immune System Disorders And Immunodeficiency,Peer Interaction,22782,22782,22782,22782,21592994,C-reactive protein,immune reconstitution inflammatory syndrome,increase,positive,OR,8.7,2.2,34.8,C-reactive protein,C0006560,"T116, T129",api,Immune Reconstitution Inflammatory Syndrome,C1619738,T047,api,RCT,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Immune System Disorders And Immunodeficiency,Peer Interaction,22789,22789,22789,22789,21592994,C-reactive protein,AIDS or death,increase,positive,OR,4.6,2.0,10.3,C-reactive protein,C0006560,"T116, T129",api,Acquired Immunodeficiency Syndrome,C0001175,T047,scispacy,RCT,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Activities Of Daily Living Limitation,Peer Interaction,58999,58999,58999,58999,16936150,C-reactive protein,persistent functional limitation,increase,positive,HR,1.7,1.2,2.3,C-reactive protein,C0006560,T116|T129,cohort_kg,Persistent or Significant Disability or Incapacity,C2347488,T032,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Inflammatory Disorder,Peer Interaction,37343,37343,37343,37343,27327646,C-reactive protein,inflammatory bowel disease,decrease,positive,OR,0.85,0.74,0.98,C-reactive protein,C0006560,"T116, T129",api,Inflammatory Bowel Diseases,C0021390,T047,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Inflammatory Disorder,Peer Interaction,52539,52539,52539,52539,12794413,C-reactive protein,infection,not found,negative,area under the receiver operating characteristic curve,0.58,0.488,0.672,C-reactive protein,C0006560,T116|T129,cohort_kg,Infection,C3714514,T046,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Inflammatory Disorder,Peer Interaction,52541,52541,52541,52541,12794413,C-reactive protein,sepsis,increase,positive,area under the receiver operating characteristic curve,0.677,0.622,0.733,C-reactive protein,C0006560,T116|T129,cohort_kg,Sepsis,C0243026,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease And Hemodynamic Support,Peer Interaction,75621,75621,75621,75621,22210562,C-reactive protein,cardiovascular disease mortality,increase,positive,HR,1.53,1.43,1.64,C-reactive protein,C0006560,T116|T129,cohort_kg,cardiovascular morbidity,C1301700,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Inflammatory Disorders,Peer Interaction,37343,37343,37343,37343,27327646,C-reactive protein,inflammatory bowel disease,decrease,positive,OR,0.85,0.74,0.98,C-reactive protein,C0006560,"T116, T129",api,Inflammatory Bowel Diseases,C0021390,T047,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Inflammatory Disorders,Peer Interaction,52539,52539,52539,52539,12794413,C-reactive protein,infection,not found,negative,area under the receiver operating characteristic curve,0.58,0.488,0.672,C-reactive protein,C0006560,T116|T129,cohort_kg,Infection,C3714514,T046,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Inflammatory Disorders,Peer Interaction,52541,52541,52541,52541,12794413,C-reactive protein,sepsis,increase,positive,area under the receiver operating characteristic curve,0.677,0.622,0.733,C-reactive protein,C0006560,T116|T129,cohort_kg,Sepsis,C0243026,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Immunosuppression And Immunomodulatory Therapy,Peer Interaction,22782,22782,22782,22782,21592994,C-reactive protein,immune reconstitution inflammatory syndrome,increase,positive,OR,8.7,2.2,34.8,C-reactive protein,C0006560,"T116, T129",api,Immune Reconstitution Inflammatory Syndrome,C1619738,T047,api,RCT,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease,Peer Interaction,33648,33648,33648,33648,9892589,C-reactive protein,coronary heart disease,increase,positive,HRR,1.67,1.29,2.17,C-reactive protein,C0006560,"T116, T129",api,Coronary heart disease,C0010068,T047,api,RCT,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease,Peer Interaction,33649,33649,33649,33649,9892589,C-reactive protein,coronary heart disease,increase,positive,HRR,1.6,1.23,2.08,C-reactive protein,C0006560,"T116, T129",api,Coronary heart disease,C0010068,T047,api,RCT,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease,Peer Interaction,33650,33650,33650,33650,9892589,C-reactive protein,coronary heart disease,increase,positive,HRR,1.5,1.14,1.97,C-reactive protein,C0006560,"T116, T129",api,Coronary heart disease,C0010068,T047,api,RCT,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease,Peer Interaction,37323,37323,37323,37323,27327646,C-reactive protein,coronary artery disease,decrease,positive,OR,0.88,0.84,0.94,C-reactive protein,C0006560,"T116, T129",api,Coronary Artery Disease,C1956346,T047,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease,Peer Interaction,50975,50975,50975,50975,12190368,C-reactive protein,incident coronary heart disease,increase,positive,OR,2.3,1.4,3.7,C-reactive protein,C0006560,T116|T129,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease,Peer Interaction,51218,51218,51218,51218,12370215,C-reactive protein,cardiovascular disease,increase,positive,relative risk,5.91,2.65,13.15,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease,Peer Interaction,54293,54293,54293,54293,15047644,C-reactive protein,cardiovascular events,increase,positive,relative risk,1.51,1.29,5.32,C-reactive protein,C0006560,T116|T129,cohort_kg,cardiovascular event,C1320716,T033,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease,Peer Interaction,54380,54380,54380,54380,15070788,C-reactive protein,coronary heart disease,increase,positive,odds ratio,1.45,1.25,1.68,C-reactive protein,C0006560,T116|T129,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease,Peer Interaction,55054,55054,55054,55054,15262834,C-reactive protein,cardiovascular disease events,increase,positive,HR,1.9,1.2,2.9,C-reactive protein,C0006560,T116|T129,cohort_kg,cardiovascular event,C1320716,T033,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease,Peer Interaction,55987,55987,55987,55987,15602020,C-reactive protein,coronary heart disease,increase,positive,RR,1.79,1.27,2.51,C-reactive protein,C0006560,T116|T129,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease,Peer Interaction,58224,58224,58224,58224,16682383,C-reactive protein,coronary heart disease,increase,positive,HR,1.9,1.5,2.4,C-reactive protein,C0006560,T116|T129,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease,Peer Interaction,60724,60724,60724,60724,17404162,C-reactive protein,cardiovascular disease,increase,positive,HR,1.78,1.3,2.45,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease,Peer Interaction,66396,66396,66396,66396,19363058,C-reactive protein,cardiovascular disease,increase,positive,AUC,0.805,0.795,0.815,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease,Peer Interaction,73574,73574,73574,73574,21700090,C-reactive protein,cardiovascular disease,increase,positive,HR,1.22,1.1,1.34,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease,Peer Interaction,73575,73575,73575,73575,21700090,C-reactive protein,cardiovascular disease,not found,negative,HR,1.0,0.86,1.38,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease,Peer Interaction,75621,75621,75621,75621,22210562,C-reactive protein,cardiovascular disease mortality,increase,positive,HR,1.53,1.43,1.64,C-reactive protein,C0006560,T116|T129,cohort_kg,cardiovascular morbidity,C1301700,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease,Peer Interaction,84301,84301,84301,84301,16126719,C-reactive protein,coronary heart disease,increase,positive,HR,1.03,1.0,1.06,C-reactive protein,C0006560,T116|T129,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cardiovascular Disease,Peer Interaction,84302,84302,84302,84302,16126719,C-reactive protein,coronary heart disease,not found,negative,HR,1.55,0.89,2.69,C-reactive protein,C0006560,T116|T129,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Gastrointestinal Disease,Peer Interaction,37343,37343,37343,37343,27327646,C-reactive protein,inflammatory bowel disease,decrease,positive,OR,0.85,0.74,0.98,C-reactive protein,C0006560,"T116, T129",api,Inflammatory Bowel Diseases,C0021390,T047,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Malignant Neoplasm,Peer Interaction,27600,27600,27600,27600,17551149,C-reactive protein,breast cancer,not found,negative,HR,0.9,0.71,1.16,C-reactive protein,C0006560,"T116, T129",api,Malignant neoplasm of breast,C0006142,T191,api,RCT,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Malignant Neoplasm,Peer Interaction,36619,36619,36619,36619,20056955,C-reactive protein,cancer,increase,positive,HR,1.09,1.03,1.14,C-reactive protein,C0006560,"T116, T129",api,Malignant Neoplasms,C0006826,T191,api,MR,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Immune Dysregulation And Systemic Inflammatory Response,Peer Interaction,22782,22782,22782,22782,21592994,C-reactive protein,immune reconstitution inflammatory syndrome,increase,positive,OR,8.7,2.2,34.8,C-reactive protein,C0006560,"T116, T129",api,Immune Reconstitution Inflammatory Syndrome,C1619738,T047,api,RCT,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Infection,Peer Interaction,49812,49812,49812,49812,11731648,C-reactive protein,serious bacterial infection,increase,positive,Beta,0.76,0.64,0.89,C-reactive protein,C0006560,T116|T129,cohort_kg,bacterial sepsis,C0684256,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Infection,Peer Interaction,52539,52539,52539,52539,12794413,C-reactive protein,infection,not found,negative,area under the receiver operating characteristic curve,0.58,0.488,0.672,C-reactive protein,C0006560,T116|T129,cohort_kg,Infection,C3714514,T046,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Infection,Peer Interaction,52541,52541,52541,52541,12794413,C-reactive protein,sepsis,increase,positive,area under the receiver operating characteristic curve,0.677,0.622,0.733,C-reactive protein,C0006560,T116|T129,cohort_kg,Sepsis,C0243026,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Infection,Peer Interaction,79068,79068,79068,79068,23109682,C-reactive protein,invasive bacterial infections,increase,positive,positive likelihood ratio,3.45,2.2,5.42,C-reactive protein,C0006560,T116|T129,cohort_kg,Invasive infections,C5436123,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Infection,Peer Interaction,79070,79070,79070,79070,23109682,C-reactive protein,invasive bacterial infections,decrease,positive,negative likelihood ratio,0.41,0.22,0.76,C-reactive protein,C0006560,T116|T129,cohort_kg,Invasive infections,C5436123,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cerebrovascular Disease,Peer Interaction,51218,51218,51218,51218,12370215,C-reactive protein,cardiovascular disease,increase,positive,relative risk,5.91,2.65,13.15,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cerebrovascular Disease,Peer Interaction,52588,52588,52588,52588,12821545,C-reactive protein,ischemic stroke,increase,positive,HR,1.19,0.92,1.53,C-reactive protein,C0006560,T116|T129,cohort_kg,Ischemic stroke,C0948008,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cerebrovascular Disease,Peer Interaction,52589,52589,52589,52589,12821545,C-reactive protein,ischemic stroke,not found,negative,HR,1.05,0.81,1.37,C-reactive protein,C0006560,T116|T129,cohort_kg,Ischemic stroke,C0948008,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cerebrovascular Disease,Peer Interaction,60724,60724,60724,60724,17404162,C-reactive protein,cardiovascular disease,increase,positive,HR,1.78,1.3,2.45,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cerebrovascular Disease,Peer Interaction,66396,66396,66396,66396,19363058,C-reactive protein,cardiovascular disease,increase,positive,AUC,0.805,0.795,0.815,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cerebrovascular Disease,Peer Interaction,73574,73574,73574,73574,21700090,C-reactive protein,cardiovascular disease,increase,positive,HR,1.22,1.1,1.34,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cerebrovascular Disease,Peer Interaction,73575,73575,73575,73575,21700090,C-reactive protein,cardiovascular disease,not found,negative,HR,1.0,0.86,1.38,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Cerebrovascular Disease,Peer Interaction,75621,75621,75621,75621,22210562,C-reactive protein,cardiovascular disease mortality,increase,positive,HR,1.53,1.43,1.64,C-reactive protein,C0006560,T116|T129,cohort_kg,cardiovascular morbidity,C1301700,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Functional Limitation,Peer Interaction,58999,58999,58999,58999,16936150,C-reactive protein,persistent functional limitation,increase,positive,HR,1.7,1.2,2.3,C-reactive protein,C0006560,T116|T129,cohort_kg,Persistent or Significant Disability or Incapacity,C2347488,T032,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Ischemic Stroke And Cardiovascular Events,Peer Interaction,49109,49109,49109,49109,11425769,C-reactive protein,acute coronary events,increase,positive,odds ratio,5.9,2.0,17.9,C-reactive protein,C0006560,T116|T129,cohort_kg,Acute Coronary Syndrome,C0948089,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Ischemic Stroke And Cardiovascular Events,Peer Interaction,51218,51218,51218,51218,12370215,C-reactive protein,cardiovascular disease,increase,positive,relative risk,5.91,2.65,13.15,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Ischemic Stroke And Cardiovascular Events,Peer Interaction,52588,52588,52588,52588,12821545,C-reactive protein,ischemic stroke,increase,positive,HR,1.19,0.92,1.53,C-reactive protein,C0006560,T116|T129,cohort_kg,Ischemic stroke,C0948008,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Ischemic Stroke And Cardiovascular Events,Peer Interaction,52589,52589,52589,52589,12821545,C-reactive protein,ischemic stroke,not found,negative,HR,1.05,0.81,1.37,C-reactive protein,C0006560,T116|T129,cohort_kg,Ischemic stroke,C0948008,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Ischemic Stroke And Cardiovascular Events,Peer Interaction,54293,54293,54293,54293,15047644,C-reactive protein,cardiovascular events,increase,positive,relative risk,1.51,1.29,5.32,C-reactive protein,C0006560,T116|T129,cohort_kg,cardiovascular event,C1320716,T033,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Ischemic Stroke And Cardiovascular Events,Peer Interaction,55054,55054,55054,55054,15262834,C-reactive protein,cardiovascular disease events,increase,positive,HR,1.9,1.2,2.9,C-reactive protein,C0006560,T116|T129,cohort_kg,cardiovascular event,C1320716,T033,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Ischemic Stroke And Cardiovascular Events,Peer Interaction,60724,60724,60724,60724,17404162,C-reactive protein,cardiovascular disease,increase,positive,HR,1.78,1.3,2.45,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Ischemic Stroke And Cardiovascular Events,Peer Interaction,66396,66396,66396,66396,19363058,C-reactive protein,cardiovascular disease,increase,positive,AUC,0.805,0.795,0.815,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Ischemic Stroke And Cardiovascular Events,Peer Interaction,73574,73574,73574,73574,21700090,C-reactive protein,cardiovascular disease,increase,positive,HR,1.22,1.1,1.34,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Ischemic Stroke And Cardiovascular Events,Peer Interaction,73575,73575,73575,73575,21700090,C-reactive protein,cardiovascular disease,not found,negative,HR,1.0,0.86,1.38,C-reactive protein,C0006560,T116|T129,cohort_kg,Cardiovascular Diseases,C0007222,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Ischemic Stroke And Cardiovascular Events,Peer Interaction,75621,75621,75621,75621,22210562,C-reactive protein,cardiovascular disease mortality,increase,positive,HR,1.53,1.43,1.64,C-reactive protein,C0006560,T116|T129,cohort_kg,cardiovascular morbidity,C1301700,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Ischemic Stroke And Cardiovascular Events,Peer Interaction,83829,83829,83829,83829,15983245,C-reactive protein,myocardial infarction,increase,positive,odds ratio,2.2,1.3,3.6,C-reactive protein,C0006560,T116|T129,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Hemorrhagic Stroke,Peer Interaction,52588,52588,52588,52588,12821545,C-reactive protein,ischemic stroke,increase,positive,HR,1.19,0.92,1.53,C-reactive protein,C0006560,T116|T129,cohort_kg,Ischemic stroke,C0948008,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Hemorrhagic Stroke,Peer Interaction,52589,52589,52589,52589,12821545,C-reactive protein,ischemic stroke,not found,negative,HR,1.05,0.81,1.37,C-reactive protein,C0006560,T116|T129,cohort_kg,Ischemic stroke,C0948008,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Ischemic Stroke,Peer Interaction,49109,49109,49109,49109,11425769,C-reactive protein,acute coronary events,increase,positive,odds ratio,5.9,2.0,17.9,C-reactive protein,C0006560,T116|T129,cohort_kg,Acute Coronary Syndrome,C0948089,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Ischemic Stroke,Peer Interaction,52588,52588,52588,52588,12821545,C-reactive protein,ischemic stroke,increase,positive,HR,1.19,0.92,1.53,C-reactive protein,C0006560,T116|T129,cohort_kg,Ischemic stroke,C0948008,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Ischemic Stroke,Peer Interaction,52589,52589,52589,52589,12821545,C-reactive protein,ischemic stroke,not found,negative,HR,1.05,0.81,1.37,C-reactive protein,C0006560,T116|T129,cohort_kg,Ischemic stroke,C0948008,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Ischemic Stroke,Peer Interaction,83829,83829,83829,83829,15983245,C-reactive protein,myocardial infarction,increase,positive,odds ratio,2.2,1.3,3.6,C-reactive protein,C0006560,T116|T129,cohort_kg,Myocardial Infarction,C0027051,T047,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
C-Reactive Protein Level,Viral Infections,Peer Interaction,52539,52539,52539,52539,12794413,C-reactive protein,infection,not found,negative,area under the receiver operating characteristic curve,0.58,0.488,0.672,C-reactive protein,C0006560,T116|T129,cohort_kg,Infection,C3714514,T046,cohort_kg,OS,1,C-reactive protein,c-reactive protein,increased
Family Medical History,Coronary Artery Disease,Peer Interaction,52052,52052,52052,52052,12628945,number of children,coronary heart disease,increase,positive,odds ratio,1.3,1.17,1.44,Number of Children in Household,C1518468,T081,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,number of children,children,increased
Family Medical History,Cardiovascular Disease,Peer Interaction,52052,52052,52052,52052,12628945,number of children,coronary heart disease,increase,positive,odds ratio,1.3,1.17,1.44,Number of Children in Household,C1518468,T081,cohort_kg,Coronary heart disease,C0010068,T047,cohort_kg,OS,1,number of children,children,increased
